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Progressive retinal ganglion cell (RGC) degeneration in glaucoma, the leading cause 
of permanent vision loss, is commonly caused by elevated intraocular pressure (IOP). 
Neuroprotective treatments complementing current IOP-reducing therapies could 
improve glaucoma management (Chapters 1, 3). IOP elevations induce glial reactivity 
(Chapter 4) and dysregulate RGC calcium (Chapters 2-3, 5-7), contributing to RGC 
degeneration (Chapters 5, 7), but it is unknown how glaucomatous forces perturb RGC 
and glial Ca2+ homeostasis. We discovered that mouse RGCs and Müller glia respond to 
osmotic pressure and tensile stretch with a cytosolic Ca2+ elevation that is primarily 
mediated by opening of the mechanosensitive cation channel transient receptor potential 
vanilloid 4 (TRPV4; Chapters 5-7). We therefore hypothesized that TRPV4 activation by 
glaucomatous forces drives RGC excitotoxicity. Consistent with this, intraocular 
injection of a selective TRPV4 agonist (GSK1016790A) induced mouse RGC loss 
(Chapter 7). This was prevented by systemic administration of a selective TRPV4 
antagonist (HC-067047). Sustained exposure to glaucomatous mechanical strain caused 
RGC apoptosis, which was rescued by Ca2+ chelation or pharmacological/genetic TRPV4 
antagonism, indicating that Ca2+ influx via TRPV4 is required for mechanical 
excitotoxicity (Chapter 7). Furthermore, RGCs and Müller glia swell during the 
progression of glaucoma and other blinding conditions, indicating the presence of 
aberrant osmotic gradients and loss of volume control. We found that RGC and Müller
  
iv 
cell swelling is exacerbated by TRPV4-dependent Ca2+ influx. Swelling differentially 
activated TRPV4 in neurons and glia, the later of which required phospholipase A2-
dependent production of 5,6-EET, an endogenous TRPV4 agonist. The water channel 
aquaporin 4 (AQP4) facilitated water entry, which enhanced glial TRPV4 activation 
(Chapter 6). Finally, we found that TRPV4 antagonism in mouse and primate glaucoma 
models lowered IOP to normal levels, potentially by promoting fluid drainage from the 
eye via the trabecular meshwork (TM). Although IOP elevation for eight weeks caused 
mouse RGC loss, this was prevented by daily treatment with a TRPV4 antagonist 
(Chapter 7). TRPV4 inhibition, therefore, simultaneously lowers IOP and increases RGC 
resilience. This, together with our finding that TRPV4 is expressed in human RGCs, 
Müller glia and TM cells (Chapters 6, 7), makes TRPV4 an attractive therapeutic target 
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This frontispiece illustrates retinal ganglion cells, which are vulnerable to intraocular 
pressure in glaucoma, expressing the force-sensitive and calcium-permeable ion channel 
Transient Receptor Potential Vanilloid 4 (TRPV4), a phenomenon that may explain how 
intraocular forces dysregulate calcium in retinal ganglion cells and cause their 
degeneration. The concentric arrangement symbolizes the appearance of pressure 
phosphenes, which may be generated through mechanical activation of TRPV4. This 
image is a collage of TRPV4-immunofluoresence (green) in retinal ganglion cells (red 















“The eye obviously has fire within, for when the eye is struck fire flashes out.” 
 
— Alcmaeon of Croton, 5th century B.C., On the history of deformation phosphenes and 
the idea of internal light generated in the eye for the purpose of vision (Grüsser and 
Hagner, 1990, p. 58). 
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 CHAPTER 1 
 
AN INTRODUCTION TO POLYMODAL SENSATION IN  
THE RETINA AND ITS RELATION TO GLAUCOMA  
 
This chapter discusses the nature of polymodal sensation in the visual system and its 
implications for retinal function and disease. Concepts regarding mechanosensation in the 
eye, retinal Transient Receptor Potential (TRP) channel physiology and the pathogenesis 
of glaucoma will be discussed. This chapter also introduces the rationale for this research 
and the primary hypothesis that glaucomatous forces perturb retinal ganglion cell and 
glial calcium signaling by overactivation of the mechanosensitive TRP Vanilloid 4 
(TRPV4) cation channel, resulting in glial reactivity and retinal ganglion cell (RGC) 
excitotoxicity.  
   
2 
1.1 Polymodal Sensation in the Visual System 
Sensory systems (e.g., vision, hearing, touch, taste, smell) encode more than the 
external world, they monitor and adapt to the physical and chemical environment in 
which they exist. For example, in addition to transducing and processing light 
information, cells in the retina respond to physical forces. However, very little is known 
about the physiological mechanisms that mediate mechanosensation in retinal cells. This 
section provides a brief overview of the visual system, a historical perspective on theories 
of vision and how mechanically induced percepts of light might be generated by the same 
molecular mechanisms that affect RGC vulnerability to intraocular pressure (IOP) in 
glaucoma.  
 
1.1.1 Overview of the Visual System 
Visual perception allows sighted animals to rapidly gather information from their 
surroundings, enabling them to efficiently navigate through and interact with their 
external environment. Visible light (electromagnetic radiation of wavelengths between 
~400 and 800 nm), when reflected or emitted by objects in space to the eye, is focused by 
the cornea, pupil and lens onto the retina, creating an image that is transduced by 
photoreceptors in the outer retina into chemical and electric signals that are ultimately 
processed by the retina and brain for visual perception to occur.  
In mammals, phototransduction occurs in photoreceptor outer segments when an 
absorbed photon converts the chromophore 11-cis retinal to all-trans retinal within a 
rhodopsin (in dim-light sensitive rod photoreceptors) or a cone opsin (in bright-light and 
color sensitive cone photoreceptors) G-protein coupled receptor. This triggers a 
   
3 
biochemical cascade that closes cyclic guanosine monophosphate (GMP)-gated cation 
channels, which are active in the absence of light (generating the “dark current”). This 
hyperpolarizes photoreceptors situated in the outer nuclear layer (ONL), reducing 
voltage-gated calcium influx into their synaptic terminals, which decreases vesicular 
release of glutamate within the outer plexiform layer (OPL). Bipolar cells relay this 
information to RGCs as it is processed through parallel horizontal cell pathways within 
the OPL and serial activation of amacrine cell processes in the inner plexiform layer 
(IPL; Livingston, 2002). Although there are several types of bipolar cells, they are 
generally divided into two classes, ON (light responsive) bipolar cells and OFF (light 
responsive) bipolar cells. While OFF bipolar cells are depolarized by glutamatergic input 
from photoreceptors by activation of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) ionotropic receptors, ON 
bipolar cells are hyperpolarized by metabotropic glutamate receptor 6 (mGluR6)-
mediated inhibition of transient receptor potential melastatin 1 (TRPM1) cation channels 
(Shen et al., 2009; Morgan et al., 2009). Release of glutamate from bipolar cell terminals 
in the IPL drives depolarization of postsynaptic amacrine cells and RGCs. Amacrine 
cells, which are located in both the inner nuclear layer (INL) and the ganglion cell layer 
(GCL) shape the receptive field and response properties of RGCs. These features are also 
shaped by the morphology and connectivity of RGC dendritic arbors as well as the 
convergence/divergence of information flow through the retina. RGCs are the only cell 
type that conveys visual information from the retina to the brain. Although there are 
several types of RGCs, they are generally classified as ON, OFF, or mixed ON-OFF 
RGCs (responsive to light turning on or off). They are further functionally characterized 
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as transient or sustained depending on the duration of their response to changes in light 
levels and by their response selectively (e.g., stimulus direction selectivity). While these 
types of RGCs provide image-forming vision to the brain through axonal projections to 
the lateral geniculate nucleus (LGN) of the thalamus, intrinsically photosensitive RGCs 
enervate brain regions that entrain the circadian rhythm such as the suprachiasmatic 
nucleus (Hattar et al., 2002).  
Each LGN receives input from both eyes and is organized into three different types of 
neuronal layers: magnocellular, parvocellular and koniocellular layers. The neurons of 
each layer convey different types of information to the primary visual cortex (V1). 
Neurons in the magnocellular layers transmit low-acuity, colorless motion and depth 
information. They respond to slight changes in luminance with fast and transient signals. 
Parvocellular pathway neurons convey information about color and fine details. The 
koniocellular layers pass on low-acuity information from photoreceptors that respond to 
short wavelengths of light (Carlson, 2007).  
The primary visual cortex is also organized into layers similar to those found in the 
LGN and maintains a retinotopic organization. As visual information is integrated during 
transit through the visual pathways, neurons in the visual cortex become progressively 
specialized and can respond to more complex visual features than retinal cells (e.g., 
orientation or retinal disparity). V1 is an organized mosaic of modules with each module 
representing a small region of the visual field that is proportional to its receptive field 
dimensions. Although these modules, when taken together, comprise the entire visual 
field, they cannot individually represent objects or the totality of a scene. Such 
information requires further integration and is represented more holistically in the visual 
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association cortex (Carlson, 2007; Livingston, 2002).  
Broad anatomical and functional divisions of visual association cortex were first 
noted by Ungerleider and Mishkin (1982) based on their electrophysiological, 
anatomical, and behavioral studies. They identified two main visual pathways by 
studying behavioral changes in monkeys with lesions to specific cortical areas. Monkeys 
with damage to the ventral visual pathway, which includes the infero-temporal cortex, 
exhibited impairments in pattern and object recognition tasks, and were only mildly 
impaired in “landmark” tasks. By contrast, the performance of monkeys with damage to 
the dorsal stream, which includes the posterior parietal cortex, was the opposite on the 
same tasks (Goodale & Milner, 1992). As the ventral stream contributes to conscious 
perception and recognition of objects, faces and color, damage to its specialized 
subregions can specifically impair these types of perceptions (Sacks, 1996). For example, 
damage to the fusiform region of the inferior temporal cortex causes prosopagnosia, the 
inability to recognize faces, a deficit ironically afflicting the portrait artist Chuck Close 
(Farley, 2011). The dorsal stream provides visuomotor guidance and contributes to 
perception of motion, depth, spatial organization and figure/ground segregation. Because 
the dorsal stream is used to recognize spatial relationships, it is also commonly referred 
to as the “where” system. Damage to its specialized subregions also cause peculiar visual 
deficits. For example, bilateral damage to visual area middle temporal (MT) in the 
parietal lobe causes akinetopsia (i.e., motion blindness; Zeki, 1991). Following the 
formation of external representations within discrete brain regions, “binding” of visual 
features through visual system-wide integration as well as the incorporation of 
information from other senses and top-down cognitive processes ultimately brings reality 
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together into a coherent construct. This feat would not be possible without the senses. As 
their lifelong reliability depends on the preservation of sensory cell/neuronal 
homeostasis, it is important to understand not only how the senses function normally, but 
also how cells within sensory systems detect and respond to internal stressors such as 
biomechanical strain. 
 
1.1.2 Force-Light Synesthesia 
In cognitive neuroscience the topic of polymodal sensation is strongly associated with 
synesthesia, a neurological condition in which the perception of a stimulus attribute in 
one modality causes the perception of an additional stimulus attribute in another modality 
(Ward, 2013). As an example, in grapheme-color synesthetes, the sight of a letter also 
produces the perception of color (Fig. 1.1). 
Although synesthesia is considered a rare neurological condition at the systems level, 
we all have synesthesia, at least at the cellular level. In physiological conditions, 
polymodal sensation in sensory tissues is adaptive (Taylor et al., 2013), preserving 
homeostasis at molecular, cellular, and systems levels. By contrast, excessive polymodal 
sensation can be excitotoxic for neurons, causing neurodegeneration and, in the case of 
the visual system, blindness. The polymodal behavior of the retina was first noted more 
than two millennia ago and inspired early theories of vision.  
 
1.1.3 Ancient Theories of Vision 
In the fifth century B.C., Alcmaeon of Croton, a founder of Greek medicine and 
member of the Pythagorean sect, was the first to report that when he applied pressure to 
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his eye, he perceived light (Grüsser & Hagner, 1990). He concluded, “the eye obviously 
has a fire within, for when the eye is struck fire flashes out” (Theophrast, 1994). This 
observation, combined with the fact that the eyes of many vertebrates reflect light 
(iridescent eyeshine from the tapetum lucidum; Ollivier et al., 2004), led another Greek 
physician, Empedocles (419-430 B.C.), to hypothesize that light from the “fire” in the 
eye illuminates the external world, reflecting back from objects to the eye for visual 
perception to occur (Grüsser & Hagner, 1990). Plato (427-347 B.C.) and other 
philosophers refined this theory, including a role for external light in the formation of 
vision through the interaction of external and projected light (Grüsser & Hagner, 1990). 
An elegant experiment by Giovanni Battista Morgagni (1682-1771) disproved the idea 
that physical light is generated in the eye (Grüsser & Hagner, 1990). In a dark room, 
Morgagni indented his eye to generate perceptions of light and an assistant looked for 
evidence of physical light. No light was perceptible by the assistant even though pressure 
phosphenes were readily apparent to Morgagni. Morgagni concluded that the deformed 
eye does not generate light, vision is dependent on external light, and the retina is 
responsive to mechanical strain (Grüsser & Hagner, 1990). Although we now realize that 
pressure phosphenes result from the physiological responses of retinal cells to 
mechanical strain, very little is known about mechanosensation in retinal cells.  
 
1.1.4 Retinal Mechanosensitivity 
All cells and organisms live within mechanically active environments in which they 
must sense and adapt to physical changes. Cells in the retina are no exception. As a 
neural tissue within the eye, they are constantly exposed to shifting osmotic gradients 
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(Fields & Ni, 2010), IOP fluctuations/elevations (Downs et al., 2011), torsional forces of 
vitreal humor during saccades (Hilding, 1954), blood vessel contraction/dilation (Metea 
& Newman, 2006), changes in the structure and compliance of tissues surrounding the 
retina/optic nerve (Zatulina et al., 1989; Quigley et al., 1991; Burgoyne et al., 2005) and 
forces associated with tissue patterning during development (Taylor et al., 2013). In 
excess, biomechanical stress contributes to pathology in many retinal diseases, including 
ischemia, diabetic retinopathy (Suzuma et al., 2001; Pannicke et al., 2006; Wurm et al., 
2008), cytotoxic retinal edema (Bringmann et al., 2004) and glaucoma (Grüsser et al., 
1989; Anderson et al., 2006; Burgoyne, 2011). For example, the optic nerve head (ONH) 
is an important injury site during ocular hypertension. High IOP stretches laminar beams 
and remodels cribriform plates of the lamina cribrosa. This, combined with the outward 
force from IOP, causes the ONH to “cup,” damaging RGC axons (Burgoyne, 2011). In 
addition, IOP elevations force the eye to expand/stretch and thin the sclera (Zatulina et 
al., 1989) and consequent physiological changes in the retina can generate osmotic 
gradients that cause cells to swell or shrink (Weber et al., 1998; Bringmann et al., 2004; 
Wurm et al., 2008; Pinar-Sueiro et al., 2011). Although the mechanisms through which 
excessive cell swelling and IOP compromise the viability of retinal cells are not well 
understood, it is clear that biomechanical strain alters retinal cell physiology through 
mechanosensation. For example, Grüsser et al. (1989) recorded action potentials from the 
optic nerve of a cat and found that when IOP is sufficiently elevated, many RGCs 
increase their firing rate. Because RGCs relay visual information from the retina to the 
brain, the increased firing rate is perceived as light, even though RGC excitation resulted 
from mechanosensory responses rather than light responses. Although this experiment 
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demonstrated that the retina responds to IOP elevations, it was not clear whether RGCs 
directly transduce mechanical stimuli or whether they are excited by synaptic input from 
other, more mechanosensitive cells. Given that an excessive responsiveness to force can 
cause cellular damage (Jaalouk & Lammerding, 2009), if RGCs are directly sensitive to 




Glaucoma is a complex disease with a diverse set of etiologies and a common 
phenotype, the progressive degeneration of RGCs. These projection neurons tend to die 
in the peripheral retina first, causing peripheral vision loss (Kwon et al., 2009). Once 
dead, RCGs cannot be replaced (Crish & Calkins, 2011); consequently, glaucomatous 
vision loss is permanent. Glaucoma is the leading cause of irreversible blindness in the 
world (Giangiacomo & Coleman, 2009) and with an aging population, the global 
prevalence of glaucoma will rise to 80 million affected individuals by 2020 (Quigley & 
Broman, 2006). Eleven million of these patients will suffer from bilateral blindness 
(Quigley & Broman, 2006). The most common type of glaucoma is primary open-angle 
glaucoma (POAG), which will afflict approximately 3.4 million in the United States by 
2020 (Friedman et al., 2004). Glaucoma is most frequent in Africa and Asia (Quigley & 
Broman, 2006). The high rates of glaucoma in these regions may reflect genetic 
predispositions and environmental factors such as socioeconomic status and cultural 
differences (e.g., access to care and treatment compliance; Takusagawa & Mansberger, 
2012).  
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1.1.6 The Standard of Glaucoma Care 
Current glaucoma treatments are limited to attempts to minimize mechanical impact 
by lowering IOP (Bonomi et al., 2001; Sena et al., 2010). IOP elevates when there is too 
much fluid production by the ciliary body (a muscle posterior to the iris that contracts the 
lens during accommodation) and/or too little fluid drainage, which primarily occurs by 
fluid outflow through the trabecular meshwork (TM) and then Schlemm’s canal. IOP can 
be lowered by pharmacological or surgical procedures.  
Pharmacological approaches commonly use eye drops to topically deliver active 
ingredients to targets in ciliary body and/or the TM. The typical first approach is to 
prescribe a once-daily treatment of prostaglandin analogues (e.g., Latanoprost or 
Travoprost), which promote aqueous humor drainage by reducing the outflow resistance 
of the uveoscleral pathway (Gaton et al., 2001). Although this approach lacks systemic 
side effects (other than potential headaches), it can cause conjunctival hyperemia, loss of 
orbital fat, eyelash elongation and darkening of eyelashes, irises and nearby skin 
(Weinreb et al., 2014). β-adrenergic blockers (e.g., Timolol) and α-adrenergic agonists 
(e.g., Brimonidine) reduce aqueous production, but cause ocular irritation and dry eyes in 
addition to allergic reactions and severe systemic effects (e.g., respiratory arrest in young 
children, kidney failure or liver failure; Weinreb et al., 2014). Carbonic anhydrase 
inhibitors (e.g., Dorzolamide) likewise reduce inflow and can cause ocular 
irritation/burning, but systemic side effects of topical treatment are minimal (Weinreb et 
al., 2014). Cholinergic agonists increase fluid outflow, but cause ocular irritation, myopia 
and ciliary muscle spasms, which can decrease vision and cause headaches (Weinreb et 
al., 2014). The efficacy of pharmacological treatments wanes in many patients (Shaarawy 
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et al., 2004). If other active ingredients do not work well or are not tolerated, sometimes 
combination eye drops work (Higginbotham et al., 2002). Otherwise, surgical approaches 
are needed to lower IOP.  
Trabeculectomy is the most commonly used surgical procedure to treat glaucoma. It 
involves removing or lasing part of the TM and/or placing a shunt within the TM to 
facilitate aqueous drainage. This procedure puts patients at 43-104% risk for developing 
cataracts depending on surgery difficulty (Patel & Danesh-Meyer, 2013). Other potential 
complications include: vision loss (18%), wound leaking (14%) shallow/flat anterior 
chamber (13%), eyelid drooping (12%), choroidal detachment (11-14%), 
hyphema/bleeding in the anterior chamber (10-24%), encapsulated bleb (3-12%) and 
suprachoroidal hemorrhaging (0.7%; Moster & Azuara-Blanco, 2014). Given the 
potential lack of efficacy and/or dire complications associated with glaucoma treatment 
(Lichter et al., 2001), it is important to identify new therapeutic strategies. Furthermore, 
IOP reducing therapies cannot reverse retinal damage (Bosco et al., 2008), creating an 
urgent need for new approaches that prevent disease progression at an early stage.  
One blatantly lacking therapeutic approach is to protect the retina directly from the 
effects of IOP.  Unfortunately, no neuroprotective treatments are available for glaucoma 
(Sena et al., 2010); chiefly because the IOP transduction mechanism within RGCs 
remains unknown. Although some people who develop glaucoma have normal IOP 
(Shields, 2008), even such “normal tension” glaucoma patients benefit from IOP 
reduction (Heijl et al., 2002), suggesting that their RGCs might be sensitive to normal 
levels of pressure (Libby et al., 2005; Anderson et al., 2006; Sappington et al., 2009). 
What then determines retinal vulnerability to mechanical strain? The purpose of this 
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research project was to address this question through the identification of 
mechanosensitive molecules within the retina that respond to glaucomatous forces and 
thereby initiate biochemical cascades known to underlie the progressive degeneration of 
RGCs in glaucoma.   
 
1.1.7 Genetic Contributions to Glaucoma  
Risk and RGC Susceptibility 
Glaucoma susceptibility is primarily genetic, but its molecular basis is largely 
enigmatic. Several risk factors contribute to glaucoma susceptibility and they differ for 
distinct types of glaucoma. In primary open-angle glaucoma (POAG), the site of ocular 
fluid drainage (in the angle between the iris and the cornea called the iridocorneal angle, 
or “the angle” for short) remains open at a macroscopic level (Kwon et al., 2009). Risk 
factors for this type of glaucoma include elevated IOP, advanced age, African ethnicity, 
family history, near-sightedness, and decreased corneal thickness (Bonomi et al., 2001; 
Klein et al., 2004; Kwon et al., 2009). Primary acute angle closure glaucoma involves a 
physical blockade of fluid drainage caused by contact between either lens and iris or iris 
and cornea (Berkoff & Sanchez, 2005). This can happen suddenly; for example, when a 
patient’s iris dilates in the dark (Berkoff & Sanchez, 2005). Given a liable anatomy, the 
structural change associated with dilation can greatly elevate IOP, making acute angle 
closure a medical emergency (Berkoff & Sanchez, 2005). Risk factors include Inuit and 
Asian ethnicity, far-sightedness, female gender, thick lenses, and certain corneal 
dimensions (e.g., a small corneal diameter; Giangiacomo & Coleman, 2009). In normal 
tension glaucoma, IOP is below 21 mmHg (Kwon et al., 2009); however, reducing 
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intraocular pressure can still slow disease progression (Drance et al., 2001). This suggests 
that the retinas and optic nerves of these patients are susceptible to normal levels of 
pressure (Crish & Calkins, 2011). Normal tension risk factors include IOP, advanced age, 
race, near-sightedness, family history, migraine, optic disk hemorrhage, and female 
gender (Drance et al., 2001). Pigmentary glaucoma can result from pseudoexfoliation 
syndrome/pigment dispersion syndrome in which the iris breaks apart, disperses, and 
clogs fluid drainage ducts (Takusagawa & Mansberger, 2012). Risk factors for 
pseudoexfoliation syndrome include lower ambient temperatures, sunlight exposure, and 
Caucasian ethnicity (Takusagawa & Mansberger, 2012). Trauma to the eye can cause a 
glaucomatous phenotype by either disrupting normal intraocular fluid dynamics or 
directly damaging the retina/optic nerve (Leon-Ortega & Girkin, 2002). Rare, childhood 
glaucomas (a.k.a. congenital glaucomas or juvenile-onset glaucomas) occur before 35 
years of age, usually involve very high IOP and feature heritable risk (Kwon et al., 2009; 
Rao et al., 2011).  
Glaucoma is a moderately to highly heritable disease, segregating in progeny as either 
a Mendelian trait or a complex multifactorial trait (Wiggs, 2007). There is a family 
history of POAG in 60% of patients and a 10 fold higher risk for first-degree relatives 
(Burdon, 2012). POAG heritability is around 0.81 and endophenotypes (quantitative traits 
contributing to disease) are also passed on at high rates (Burdon, 2012). For example, 
IOP and optic cup diameter (the central cup-like portion of the optic disc where the optic 
nerve exits the eye) have heritability estimates of 0.36 and 0.55, respectively (Klein et al., 
2004). The acute angle glaucoma endophenotype of having narrow angles is 58.8% 
heritable in Asians (Amerasinghe et al., 2010). Because of the heritable nature of 
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glaucomas, linkage studies have associated several loci with POAG, acute angle closure 
glaucoma, normal tension glaucoma, pigmentary glaucoma, and childhood glaucoma 
(Weisschuh et al., 2005). 
Linkage studies and genome wide association studies (GWASs) have uncovered 
several risk alleles and loci for glaucoma. At least 25 gene/locus variants that increase 
risk for POAG have been identified by linkage analysis in large affected families (Rao et 
al., 2011). Most notably, variations in the myocilin gene MYOC (a.k.a. GLC1A) account 
for 3-4% of POAG cases (Burdon, 2011). Several studies suggest that mutations in 
MYOC cause trabecular meshwork (TM) dysfunction, remodeling and/or death, limiting 
ocular fluid outflow (Rao et al., 2011). The first GWAS involving POAG patients found 
two variants at the lysyl oxidase-like 1 (LOXL1) locus. However, the patients with these 
variants had pseudoexfoliation syndrome (Burdon, 2011), highlighting the importance of 
accurate phenotypic distinctions. Additional studies confirmed the occurrence of LOXL1 
polymorphisms in pigmentary glaucoma patients; however, many controls (74%) also 
have the risk allele (compared with 92% in pseudoexfoliation patients; Takusagawa & 
Mansberger, 2012), indicating that additional factors determine whether LOXL1 
polymorphisms contribute to pseudoexfoliation. Possible genetic-disease associations 
with POAG/normal tension glaucoma include loci in or near: optineurin (OPTN/GLC1E), 
WD repeat domain 36 (WD36, GLC1G), neurotrophin-4 (NTF4, GLC1O), TMCO1, ZP4, 
PLXDC2, DKFZp762A217 and SRBD1 (Burdon, 2011; Rao et al., 2011). Another 
disease-related SNP was identified in CDKN2B-AS1 (odds ratio of 1.5). This long, 
noncoding RNA regulates the expression of four genes (TMCO1, CDKN2B-AS1, 
CDKN2A, and CDKN2B), all of which are upregulated in RGCs by high IOP and 
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potentially involved in the stress response leading to apoptosis (Burdon, 2011). These and 
other findings emphasize the importance of relating IOP-dependent transcriptional (e.g., 
Miyahara et al., 2003) and posttranslational (e.g., Huang et al., 2005) alterations to 
pathogenic mechanisms and disease outcome. Although linkage studies and GWASs 
have identified many genes in the major forms of glaucoma (see also Awadalla et al., 
2011 a/b; Kwon et al., 2009), less than 10% of the heritable risk for POAG can be 
accounted for by known genetic associations (Burdon, 2011). Although future exome and 
genome sequencing studies will help to identify rare alleles with large risk that can be 
missed by GWASs, the diversity of risk mechanisms makes it difficult to pinpoint key 
genes in the development of glaucoma. Thus, to understand the bulk of heritable risk and 
the primary pathogenic mechanisms in this complex group of polygenic diseases, there is 
a need for more than associative genomic studies. Further, progress in glaucoma 
treatment requires experimental research to elucidate how risk alleles and their 
interactions with other genetic, physiological and environmental factors contribute to 
forces that drive glaucoma and/or RGC vulnerability. Because many risk alleles remain 
elusive, experimental research is also needed to envision and test possible disease 
mechanisms that could underlie the pathogenesis or progression of neurodegeneration 
and visual dysfunction in glaucoma.  
 
1.1.8 Calcium Dysregulation in Glaucoma 
Calcium dysregulation in RGCs has been implicated in the pathogenesis of glaucoma, 
leading to calcium-mediated biochemical cascades, axonal transport deficiencies, and 
apoptosis (Crish & Calkins, 2011). We (Ryskamp et al., 2011) and others (Tan et al., 
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2006; Crish & Calkins, 2011; Xia et al., 2012) suspect that the impinging forces of IOP 
open mechanosensitive ion channels, excessively elevating the concentration of cytosolic 
calcium ([Ca2+]i) in RGCs and causing apoptosis. For example, high IOP (as seen in 
glaucoma) triggers calcineurin activation, a calcium-dependent phosphatase that, once 
activated in the soma, triggers RGC apoptosis (Huang et al., 2005). Calpain activation 
also occurs in experimental glaucoma models and is thought to contribute to axonal 
transport deficiencies (Huang et al., 2008), depriving RGC cell bodies of retrograde 
trophic support (Quigely et al., 2000). Axonal calcium influx can also accelerate axonal 
degeneration (Knöferle et al., 2010). Moreover, glaucoma risk is increased by taking high 
doses of daily calcium supplements (Wang et al., 2012), or by not taking calcium channel 
blockers (Tomita, 2000). What then transduces glaucomatous forces into RGC Ca2+ 
dysregulation?  
 
1.1.9 Retinal Mechanosensation  
Cells in the eye sense impinging biomechanical strain and become stressed as they 
shift from their homeostatic state. This involves mechanosensation, the biological process 
by which mechanical forces are transduced into physiological signals such as calcium 
influx into brain cells (Xiong et al., 1997; Weber et al., 1999; Goforth et al., 1999; 
Geddes-Klein et al., 2006), driving secondary injury mechanisms (discussed below). 
Mechanosensitive ion channels are among the most sensitive and prevalent types of 
biological force sensors (Martinac, 2004; Kung, 2005). As the cell deforms, 
mechanosensitive ion channels open and allow ions to flow into and/or out of the cell 
depending on channel properties (Vogel & Sheetz, 2006; Christensen & Corey, 2007). 
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Among them, TRPV4 is one of the best-characterized Ca2+-permeable channels (O’Neil 
& Heller, 2005; Suzuki & Mizuno, 2012). TRPV4 senses both physiologically relevant 
forces such as cell stretch and swelling (Liedtke et al., 2000; Alessandri-Haber et al., 
2003; Liedtke & Friedman, 2003; Suzuki et al., 2003; Alessandri-Haber et al., 2004; 
Becker et al., 2005; Chen et al., 2007; Gevaert et al., 2007; Wang et al., 2007; Loukin et 
al., 2010; Sonkusare et al., 2012; Zaika et al., 2013) and traumatic forces (Hamanaka et 
al., 2007; Jian et al., 2008; Hamanaka et al., 2010). Moreover, its activation sensitizes 
neurons to subsequent mechanical stress, with debilitating consequences such as 
neuropathic pain (Alessandri-Haber et al., 2004).  
Equally serious to the damage inflicted during primary mechanical strain is secondary 
activation of gliosis and associated inflammation, swelling/edema, oxidative stress, 
vascular changes, blood-brain/retina barrier breakdown, axonal atrophy, synaptic loss and 
cell death (Dietrich et al., 1994; Cernak et al., 2000; Okie, 2005; Büki & Povlishock, 
2006; Mac Donald et al., 2011; Kamnaksh et al., 2011; Kwon et al., 2011; Cernak et al., 
2011; Xiong et al., 2013). For example, traumatic brain injury (TBI) causes diffuse 
reactive gliosis of astrocytes and microglia, contributing to cerebral edema, inflammation 
and neuronal damage (Kaur et al., 1995; Pifarré et al., 2010; Readnower et al., 2010; 
Risling et al., 2011). Edema and glial swelling from TBI is associated with a 
mechanically induced influx of osmolytes, followed by water (Bourke et al., 1979; 
Unterberg et al., 2004; Kimbler et al., 2012). Gliosis increases almost immediately after 
traumatic ocular injury (TOI) and the extent of astroglial reactivity is used to assess the 
breadth of TBI (Agoston et al., 2009). Inhibiting gliosis (Baptiste et al., 2005; Bosco et 
al., 2008; Voloboueva et al., 2007) and inflammation (Arvin et al., 1996; Tezel et al., 
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2001; Chen et al., 2007) is neuroprotective. Likewise, the effects of TBI-induced edema 
may be reversible if treatment is provided sufficiently early (Zweckberger et al., 2006). 
The pathological events driven by traumatic injury in many ways mimic those observed 
in glaucoma (Crish & Calkins, 2011; Yu-Wai-Man & Griffiths, 2013). As these 
secondary injury mechanisms occur on a slower time scale than the mechanosensory 
response to a transient insult, glaucoma and traumatic ocular injury (TOI) may be 
asymptomatic and unsuspected by the patient until the eye is irreversibly damaged 
(Cockerham et al., 2009). Current clinical interventions rely solely on limiting the 
mechanical impact (reducing IOP or providing physical protection from trauma), but they 
are unable to protect the retina directly from damage because of a largely deficient 
understanding of the basic biological mechanisms that transduce the traumatic impact 
into cellular injury and the mechanisms that mediate the subsequent injury associated 
with calcium dysregulation, cell swelling and glial/immune responses. Thus, there is an 
urgent need to elucidate the molecular mechanisms that determine retinal 
vulnerability to biomechanical strain. Such information will guide the development 
of neuroprotective therapies that promote retinal resilience.  
 
1.2 Overview of Chapters 
Chapters 2-4 provide additional background information to further contextualize my 
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1.2.1 Chapter 2: TRPV1 and Endocannabinoids: Emerging  
Molecular Signals that Modulate Mammalian Vision 
Although this chapter focuses on transient receptor potential vanilloid 1 (TRPV1), 
rather than TRPV4 (the primary molecular subject of this dissertation research), it details 
many important concepts regarding the study of TRP channels in the nervous system, in 
addition to serving as a general primer on TRP channel biology and their potential 
functions within the retina. It is important to keep in mind, however, that TRPV1 and 
TRPV4 are distinct proteins with different stimulus sensitivities, modulators, 
downstream calcium effectors and functions within the visual system.  
 
1.2.2 Chapter 3: From Mechanosensitivity to Inflammatory Responses:  
New Players in the Pathology of Glaucoma 
RGC distress and damage results from mechanical strain and a secondary 
inflammatory response, but the diverse molecular mechanisms involved in the initiation 
and propagation of RGC degeneration are poorly understood. This review provides a 
theoretical overview of glaucoma and emerging pathogenic mechanisms that cause 
degeneration of RGCs and relates intrinsic mechanosensation by RGCs via TRPV4 and 
other force-sensitive pathways to calcium dysregulation and activation of downstream 
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1.2.3 Chapter 4: Localization and Phenotype-Specific Expression of  
Ryanodine Calcium Release Channels in C57BL6 and DBA/2J  
Mouse Strains 
DBA/2J (D2) and C57BL6 (B6) mice are widely used in glaucoma research. D2, but 
not B6, mice develop chronically elevated IOP that causes progressive degeneration of 
RGC axons and somata. B6 acutely develop glaucoma if their IOP is raised by 
obstructing fluid outflow from the eye. This chapter describes an IOP-dependent shift in 
the distribution and expression of an intracellular calcium release channel, ryanodine 
receptor 1 (RyR1), from neurons to Müller glia. Müller glial reactivity precedes RGC 
degeneration and may be initiated early by intrinsic mechanosensitivity to IOP or by 
responsiveness to RGC distress. The discovery that Müller glia respond rapidly to IOP 
elevations, coupled with the observation of early changes in calcium regulation 
mechanisms, indicated a need to study mechanosensation in Müller glia in addition to 
RGCs. As human Müller glia are known to express stretch-activated ion channels (Puro, 
1991), both glial and neuronal mechanosensation are likely involved in the development 
of glaucoma.  
 
1.2.4 Chapter 5: The Polymodal Ion Channel Transient Receptor  
Potential Vanilloid 4 Modulates Calcium Flux, Spiking Rate,  
and Apoptosis of Mouse Retinal Ganglion Cells 
Elevated IOP is a primary risk factor for glaucoma, yet the mechanisms of pressure 
transduction in the retina are essentially unknown. In this chapter we demonstrate that the 
mouse retina expresses mRNA and protein for the polymodal TRPV4 channel, which is 
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known to mediate osmotransduction and mechanotransduction. Antibody labeling of 
TRPV4 revealed neuronal expression that was primarily restricted to perikarya, axons, 
and dendrites of RGCs. Functional TRPV4 expression in RGCs was confirmed by 
calcium imaging combined with pharmacological experiments. RGC responses to 
osmotic pressure occluded their responses to a selective TRPV4 agonist, suggesting 
TRPV4 as a common transduction mechanism. TRPV4-selective agonists increased the 
spiking frequency of RGCs within intact retinas recorded with a multielectrode array. 
Sustained exposure to TRPV4 agonists evoked dose-dependent apoptosis of RGCs. These 
results thus provided the seminal framework for considering TRPV4 as an RGC 
mechanosensor capable of driving a glaucomatous phenotype, in addition to suggesting 
its physiological role in tuning the excitability of RGCs.  
 
1.2.5 Chapter 6: Swelling and Eicosanoid Metabolites Differentially  
Gate TRPV4 Channels in Retinal Neurons and Glia 
This chapter discusses molecular mechanisms by which TRPV4 and glial aquaporin 
water channels transduce cellular volume into a calcium elevation. In it, the stretch-
activated ion channel of Müller glia discovered by Puro (1991) is revealed as TRPV4. 
We also describe the unique discovery that the physiological properties of TRPV4 and its 
force-transduction mechanisms drastically differ in RGCs and Müller glia. Despite this 
difference, we found that calcium influx via TRPV4 exacerbated both neuronal and glial 
swelling in a hypoosmotic solution. For Müller glia, we further identify TRPV4 as the 
missing link in swelling promoted by phospholipase A2 (PLA2) and arachidonic acid 
(AA) signaling. We also demonstrate that aquaporin-4 (AQP4) primarily augments 
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TRPV4 activation by increasing the rate of hypoosmotic swelling, rather than by a direct 
molecular interaction as previously suggested. Our results support a model whereby 
swelling and proinflammatory signals differentially gate TRPV4 in retinal neurons and 
glia with potentially significant consequences for normal and pathological function. 
 
1.2.6 Chapter 7: TRPV4 Signals Generate and Transduce  
Intraocular Pressure in Glaucoma 
IOP reducing therapies are limited by side-effects, complications and efficacy that is 
variable across patients and time. New targets are needed for more effective and better 
tolerated IOP lowering. Additionally, no treatments exist that protect the retina from the 
mechanical effects of IOP. This is unfortunate because such treatments could 
complement IOP-lowering strategies to more effectively stop disease progression. This 
chapter describes our discovery that both of these needs are met by TRPV4 inhibition. 
The requirement of TRPV4 in high IOP maintenance appears to relate to its functionality 
in the TM, because TRPV4 inhibition reduces the extent of TM cell swelling, a 
morphological feature that would otherwise obstruct aqueous humor outflow. Moreover, 
we describe data supporting the sufficiency and necessity of TRPV4 activity in the 
induction of excitotoxicity by glaucomatous forces as well as its ability to potentiate 
NMDA receptor activity, which also contributes to RGC apoptosis in glaucoma models. 
The discovery of TRPV4’s dual role in key pathogenic steps in glaucoma, suggest it as a 
lead target for future therapeutic strategies designed to prevent IOP-related 
neurodegeneration.  
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1.2.7 Chapter 8: Conclusion 
Although glaucoma lacks neuroprotective treatments, we have identified TRPV4 as a 
promising therapeutic target to reduce the mechanosensitivity of retinal neurons and glia 
and to maintain IOP within a safe range. Future research directions are presented to 
outline potential approaches that would further advance our understanding of pathogenic 
roles for TRPV4 in glaucoma/TBI and of how the polymodal nature of TRPV4 might be 
harnessed to create a new generation of visual prostheses. 
Collectively, the findings of this dissertation research provide important insights into 
the pathogenesis of glaucoma and explain a potential mechanism for the generation of 
pressure phosphenes, a polymodal sensory phenomenon that may serve as a warning of 
impending retinal damage and blindness.  
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Figure 1.1 Examples of how neurotypical persons and grapheme-color synesthetes 
might perceive text. 
 
 





TRPV1 AND ENDOCANNABINOIDS: EMERGING MOLECULAR 































Ryskamp DA, Redmon S, Jo AO, Križaj D (2014) TRPV1 and endocannabinoids: 
emerging molecular signals that modulate mammalian vision. Cells 3(3):914-38. 
Reprinted with permission from Cells and MDPI.






















































TRPV1 and Endocannabinoids: Emerging Molecular Signals 
that Modulate Mammalian Vision  
Daniel A. Ryskamp 1,2,†,*, Sarah Redmon1,2,†, Andrew O. Jo 1,† and David Križaj 1,2,3,4,* 
1 Department of Ophthalmology & Visual Sciences, Moran Eye Institute, University of Utah School 
of Medicine, Salt Lake City, UT 84132, USA; E-Mails: sarah.redmon@utah.edu (S.R.); 
u0751604@utah.edu (A.O.J.) 
2 Interdepartmental Program in Neuroscience, University of Utah School of Medicine, Salt Lake City, 
UT 84132, USA 
3 Department of Neurobiology & Anatomy, University of Utah School of Medicine, Salt Lake City, 
UT 84132, USA 
4 Center for Translational Medicine, University of Utah School of Medicine, Salt Lake City,  
UT 84132, USA 
† Those authors contributed equally to this work.  
* Authors to whom correspondence should be addressed; E-Mails: daniel.ryskamp@gmail.com (D.A.R.); 
david.krizaj@hsc.utah.edu (D.K.); Tel.: +1-801-213-2777 (D.K.); Fax: +1-801-587-8314 (D.K.).  
Received: 1 July 2014; in revised form: 27 August 2014 / Accepted: 5 September 2014 /  
Published: 12 September 2014 
 
Abstract: Transient Receptor Potential Vanilloid 1 (TRPV1) subunits form a polymodal 
cation channel responsive to capsaicin, heat, acidity and endogenous metabolites of 
polyunsaturated fatty acids. While originally reported to serve as a pain and heat detector 
in the peripheral nervous system, TRPV1 has been implicated in the modulation of blood 
flow and osmoregulation but also neurotransmission, postsynaptic neuronal excitability 
and synaptic plasticity within the central nervous system. In addition to its central role in 
nociception, evidence is accumulating that TRPV1 contributes to stimulus transduction 
and/or processing in other sensory modalities, including thermosensation, 
mechanotransduction and vision. For example, TRPV1, in conjunction with intrinsic 
cannabinoid signaling, might contribute to retinal ganglion cell (RGC) axonal transport and 
excitability, cytokine release from microglial cells and regulation of retinal vasculature. 
While excessive TRPV1 activity was proposed to induce RGC excitotoxicity, 
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physiological TRPV1 activity might serve a neuroprotective function within the complex 
context of retinal endocannabinoid signaling. In this review we evaluate the current 
evidence for localization and function of TRPV1 channels within the mammalian retina 
and explore the potential interaction of this intriguing nociceptor with endogenous agonists 
and modulators. 
Keywords: retinal ganglion cells; TRPV1 channels; endocannabinoids; CB1 receptors 
 
1. Introduction 
Transient Receptor Potential (TRP) channels form a superfamily of non-selective cation channels 
that provide cells and organs within the vertebrate body with information about the external and 
internal environment. The channels participate in the sensory transduction of light, pain, touch, 
temperature, osmolarity, taste, pheromones, acidity, inflammation, oxidation, metabolic energy and 
polyunsaturated fatty acids [1–7], whereas loss- and gain-of-function TRP channel mutations cause 
diseases that range from visceral organ failure (TRPP2/polycystic kidney disease; TRPC6/focal and 
segmental glomerulosclerosis) to skeletomuscular dysplasias (TRPV4/Charcot-Marie-Tooth disease 
type 2C), locomotor dysfunction (TRPC3; cerebellar ataxia) and blindness (TRPM1; congenital 
stationary night blindness) [8]. Within the brain, TRP channels have increasingly been shown to play 
essential and supportive roles in neuronal and glial signaling [9,10] through monitoring of systemic 
osmo- and thermoregulation [11,12], neuro-glial-vascular coupling [13,14], initiation of neural stress 
responses [15], neuroprotection [16] and neurodegeneration [17]. Despite the accumulated knowledge, 
the primary functions for most TRP isoforms expressed in a cell type-specific manner across the 
vertebrate central nervous system (CNS) remain poorly understood. Functional information on TRP 
signaling is particularly scarce for the retina, which, however, expresses the transcripts of most, if not 
all, known TRP channel isoforms [18]. Localization of TRPs in the retina has been difficult given the 
non-specificity of most available antibodies [18–20]; however, evidence suggests that expression of 
some channels (e.g., TRPM1 & 3, TRPC6, TRPC7 and TRPV4) may be confined to specific subsets of 
retinal cells [10,17,21–23], whereas others (e.g., TRPC1, TRPC3, TRPML1, TRPM7 and TRPP2) 
appear to be expressed across multiple retinal layers [18,19]. The absence of functional information on 
TRP signaling in vertebrate retinas appears ironic given that the original dTRP channel was discovered 
as a light-activated photochannel in Drosophila photoreceptors [1,24]. Nonetheless, amongst the 
important discoveries from recent years is the identification of TRPM1 as the mGluR6-gated cation 
channel that is required for transmission of the light signal in ON bipolar cells [10,25], discovery that 
the Trpm3 gene and its intronically hosted micro-RNA gene (miR-204) are localized to cells residing 
within the inner nuclear layer [18,26] and the demonstration of the central role of TRPC6/7 heteromers 
in phototransduction by melanopsin-expressing RGCs [22]. These studies showed that TRP isoforms 
play fundamental and irreplaceable functions in vertebrate vision. Here, we review potential roles for 
the vanilloid isoform 1 (TRPV1), which while arguably one of the most thoroughly studied TRP 
channels within the PNS and CNS, has remained understudied within the context of retinal physiology 
and visual signaling.  
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TRPV1 was first identified by Julius and coworkers when a single clone of cDNA conferred 
responsiveness to the spicy ingredient from hot chili peppers, capsaicin [2]. With six transmembrane 
domains, a pore between segments 5 and 6 and large intracellular N- and C-termini, this tetrameric 
ligand-gated channel shares a common structure with the other 27 mammalian TRPs as well as with 
the voltage-activated potassium (Kv) channel family [27]. The 6 ankyrin repeats within the N-terminus 
are likely to mediate protein-protein, protein-cytoskeleton and heteromeric interactions as well as 
trafficking, ligand binding and modulation by ATP and calmodulin [7,28–30]. The channel, at  
í60 mV, conducts a slowly developing nonselective cation current with a PCa/PNa of 9.6 and a single 
channel conductance of ~í80 pS at positive and í40 pS at negative membrane potentials. TRPV1 
desensitizes in response to calmodulin binding to N- and C-termini but may change its cation 
permeability during prolonged agonist stimulation, following exposure to protons and/or 
phosphorylation [2,31,32]. Indeed, Ca2+ entry through TRPV1 can be large enough to cause a  
self-impacting negative feedback on channel permeability and downregulation of voltage-operated 
Ca2+ channels [33]. The responses of the channel are additionally determined by splice variations [12], 
heteromultimerization with other TRP channel subunits including TRPV2-4 [34], phosphatidylinositol 4,5-
biphosphate (PIP2) and other membrane-delimited lipids [35–37] and insertion/internalization [38,39].  
A pivotal role for TRPV1, validated by genetic ablation, small interfering RNA knockdown and 
pharmacological experiments [15,40] is dynamic modulation of the neuronal response to injury that 
leads to nociception and hyperalgesia. The channel also contributes to pain transduction through 
polymodal integration of stimuli such as chemicals (capsaicin, resiniferatoxin or gingerol), pain, 
temperature (>42 °C), acidity, shrinking, endocannabinoids (eCBs) and eicosanoids [2,36,41,42].  
TRPV1 permeability and gating are fine-tuned by a multitude of direct and indirect mechanisms. 
The channel is indirectly sensitized by inflammatory mediators such as bradykinin, leukotriene B4, 
histamines and prostaglandins that impact it in part through heteromeric G proteins and tyrosine 
kinase pathways, whereas certain stimuli (heat, protons, voltage) sensitize the channel to the other 
agonists [43,44]. TRPV1 also contains consensus sites for protein kinases A and C and src tyrosine 
kinases that regulate its inactivation properties through phosphorylation [45–48] and should therefore 
be viewed as a complex, highly modulatable sensory switch which can be flipped on or off by 
combinatorial action of modulators, agonists and the intra-/extracellular context [42,43,49]. Although 
functional data on TRPV1 obtained for any particular tissue, cell type, or condition are not 
automatically generalizable, it may be helpful to consider studies of TRPV1 in the brain to appreciate 
the state of our understanding of TRPV1 in its visual extension, the retina.  
2. TRPV1 in the Brain  
2.1. TRPV1 Expression in the Brain 
Although TRPV1 expression is ~20-30-fold lower in the CNS compared to the dorsal root  
ganglion [50–52], a combination of pharmacological, genetic and biochemical data suggest widespread 
distribution across the neural axis from the spinal cord to brain areas that may include the 
hippocampus, hypothalamus, thalamus, cerebellum, cortex and limbic system [53–55]. Accordingly, 
functional studies have implicated the channel in drug addiction, anxiety/fear behavior and long-term 
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memory formation [56–58]. Injection of capsaicin induced changes in thermogenic behavior [59] and 
locomotion [60], presumably by acting on hypothalamic and striatal circuits. Because antibodies, 
radioligand binding and reverse transcription (RT)-PCR assays have provided highly variable 
localization evidence for TRPV1 expression across the brain, and because studies that used similar 
assays often reached different conclusions regarding the contribution of the channel to neuronal 
function [20,30,61–63], there seems to be no uniform consensus on the distribution of TRPV1 
channels in the CNS. Analysis of TRPV1 distribution is further complicated by the heterogeneous 
expression of TRPV1 splice variants, compensatory effects in KO mice, differences in age-dependent 
phenotypes/expression and differential expression across mouse strains/backgrounds [12,50]. Functional 
studies have led to variable conclusions regarding the role of the channel in synaptic  
plasticity [56,57,64]. A paradigmatic example that challenges much of the previous work is the recent 
analysis of Trpv1PLAP–nlacZ reporter mice which suggests that TRPV1 expression within the brain is 
highly restricted, with the most pronounced reporter signals observed within the caudal 
hypothalamus [51], which shares with the retina the susceptibility to high doses of systemic 
capsaicin [65,66]. It is possible, however, that use of reporter mice might have missed alternate 
TRPV1 isoforms and/or resulted in an artificial decrease in endogenous TRPV1 levels [55]. Thus, 
although many details with respect to the cellular/regional distribution of TRPV1 remain to be 
resolved, it is likely that the channel has a broader distribution and range of functions within the CNS 
than generally thought.  
3. TRPV1 in the Retina  
3.1. Overview of Retinal Anatomy and Early Visual Information Processing 
When light enters the eye, it is focused onto the retina by the lens and transduced by photoreceptors 
into electrical and chemical signals that are processed as they are passed through retinal circuits 
towards the brain. In a nutshell, the flow of visual signal consists of a vertical glutamatergic signals 
mediated by excitatory photoreceptor, bipolar and ganglion cell synapses and inhibitory/modulatory 
contributions from horizontal networks mediated by horizontal and amacrine cells, respectively 
(Figure 1).  
Absorption of photons results in the reduction of tonic release of glutamate to postsynaptic 
horizontal cells and bipolar cells, respectively. Bipolar cells transmit this information to RGCs through 
two opposing yet complementary pathways. A non-inverting synapse to OFF bipolar cells mediates the 
excitatory response to decrements of light through ionotropic AMPA/KA receptors. Conversely, the 
ON pathway is based on a metabotropic mGluR6- TRPM1 mechanism whereby glutamate tonically 
suppresses bipolar cells and thus cells become disinhibited by light-induced suppression of glutamate 
release from rods and cones. As bipolar cells forward feed visual information, it is processed through 
parallel and serial pathways that involve feedback interactions with amacrine cells that contribute to 
lateral inhibition that sculpts the spatiotemporal organization of RGC receptive fields. As shown in 
Figure 1, RGCs represent the final output pathway that conveys the visual signal to the midbrain [67]. 
RGC function and output can be influenced by retinal glia that include Müller cells that span the tissue 
(and provide critical ionic, metabolic and modulatory of support for neurons, [68]),  
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protoplasmic astrocytes that line the inner limiting membrane (ILM) and (in vascularized retinas) 
control the permeability of the blood-retina barrier, and microglia, which represent the resident 
immune cells [69]. Whilst organization of retinal circuits represents a key determinant of visual 
information processing, the physiological state of every cell type is dynamically altered through 
activity-dependent and neurodegeneration-driven changes in calcium homeostasis, functional and 
structural connectivity across and between retinal laminae [67,69,70]. TRP channels represent new 
players that play increasingly visible roles in retinal neuronal and glial Ca homeostasis by transducing 
the RGC response to light and driving plasma membrane Ca influx as well as through interactions with 
intracellular Ca stores, heteromerization and activation of purinergic receptors and pannexin 
hemichannels [17–19,21,22,25,71–75].  
Figure 1. A schematic of the retina showing overall arrangement of retinal layers and 
relationship to the critical vascular and pigment layers. An excitatory vertical chain 
(photoreceptors, bipolar cells, ganglion cells) provides a direct route for transmitting visual 
information to the midbrain. Lateral inputs from horizontal cells and amacrine cells 
provide luminance gain control and organization spatiotemporal receptive fields of retinal 
neurons. Müller glia provide most of the functions performed by astrocytes in the brain. 
Astrocytes form the blood-retina barrier together with pericytes and vascular endothelial 
cells. Microglia play a role in developmental pruning and the retinal immune response 
whereas the choroid and posterior ciliary artery feed outer and inner retinal neurons, 
respectively. Adapted from [70].  
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3.2. TRPV1 Channel Distribution in the Retina 
The first evidence suggestive of TRPV1 expression in the retina was obtained by Ritter and  
Dinh [66,76], years before the seminal cloning of TRPV1 in dorsal root ganglia (DRG) [2]. The 
investigators used cupric silver staining to reveal capsaicin-induced neurodegeneration in the rat retina. 
This effect was observed in the IPL and RGCL and was also associated with impaired anterograde 
axonal transport [77]. Interestingly, unilateral transection of the optic nerve prior to capsaicin 
administration prevented contralateral spread of neurodegeneration to RGC projection sites within the 
midbrain [66]. In some cases, capsaicin treatment appeared to damage RGC projections without 
destroying the soma [76], consistent with the documented ability of capsaicin to act on axons in 
peripheral nerves [78]. Subsequently, Szallasi et al. [61], used autoradiography of whole-head 
cryosections to confirm the retina as a binding site for the TRPV1 agonists capsaicin and its ultrapotent 
analog, the Euphorbia resinifera-derived resiniferatoxin.  
Some of these early studies may need to be re-evaluated. Similar to the limitations of approaches 
that exclusively rely on antibody staining, results from studies confined to the use of pharmacological 
agents such as capsaicin (agonist) and capsazepine (antagonist) should take into account non-specific 
and/or mis-targeting effects. TRPV1 was originally called the ‘capsaicin receptor’ based on the active 
ingredient in Capsaicum chili peppers; however, capsaicin has been subsequently shown to also affect 
a range of TRPV1-independent mechanisms that include activation of voltage-gated inward and 
outward currents, impairment of mitochondrial function, inhibition of prostaglandin E2 production and 
importantly, binding to the cannabinoid CB1 receptor [79–82]. The use of the agonist is particularly 
complex within the retinal context, as capsaicin induces large inward currents in ON-bipolar cells that 
mediate an excitatory, inverted, photoreceptor response towards the inner retina. Capsaicin-evoked 
responses within rod and cone ON bipolar cells at first appeared to be indistinguishable from the 
effects mediated by light and mGluR6 antagonists and therefore pointed at a “TRPV1-like” identity of 
the long-sought transduction channel. However, it was soon discovered that ON bipolar light responses 
are unaffected in Trpv1í/í mice, whereas they are eliminated by deletion of another TRP channel, the 
melastatin receptor TRPM1 [10].  While this suggested that capsaicin sensitivity is mediated through 
TRPM1, only partial reduction in the amplitude of capsaicin responses was observed in Trpm1í/í  
mice [25], indicating that TRPM1 might not represent the exclusive capsaicin sensor in ON bipolars. 
Consistent with this, Xu et al. [83] recently reported that the capsaicin response is eliminated in mice 
lacking the mGluR6 receptor, suggesting that the compound also acts on the metabotropic glutamate 
receptor or its downstream Go protein heteromers. Irrespective of the precise mechanism, it is 
especially important to consider potential non-TRPV1-mediated effects when capsaicin is used to 
analyze retinal function or pathology. The results obtained by using the popular competitive antagonist 
capsazepine should likewise be interpreted with caution, as the drug can produce effects in Trpv1í/í 
mice. These include antagonism of voltage-activated Ca2+ channels [84], acetylcholine receptors [85], 
hyperpolarization-activated cation channels (Ih) [86] and stimulation of amiloride-sensitive ENaC 
channels [87].  
Nonetheless, numerous studies demonstrated the presence of TRPV1 mRNA and protein in the 
mammalian retina as well as in teleosts, amphibians and avians [10,18,71,72,88,89], leading Zimov and 
Yazulla to suggest that the role of the channel in visual signaling might be conserved across 
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vertebrates [90,91]. A recent study, using probes and antibodies that detected TRPV1 signals in DRG, 
suggested that TRPV1 mRNA and protein levels in the mouse retina are unusually low [18]. The 
differences between studies are likely to reflect use of different antibodies and staining protocols, but 
also underscore the need for using Trpv1í/í mice as controls for semi-quantitative expression studies.  
A potential role for TRPV1 in ontogeny was suggested by Leonelli et al. [92], who detected stable 
TRPV1 protein expression in embryonic and early postnatal (E19 through P14) rat retinas, followed by 
a marked increase in expression during the transition from eye opening to adulthood (at ~P60). 
Exposure of neonatal rats to capsazepine increased the prevalence of subsets of parvalbumin+ 
amacrine-like cells and increased immunoreactivity (ir) for the presynaptic amacrine marker synapsin 
1b. Capsazepine also reduced the normal, developmentally driven, apoptosis in the isolated neonatal 
rat retina but did not affect retinal layering in the adults; thus, it was proposed that TRPV1 plays a role 
in the wiring of retinal circuits [93].  
Similar to studies in the brain and non-excitable tissues [51,63], immunohistochemical (IHC) 
staining of mammalian retinas has yielded variable, antibody-specific patterns. The most commonly 
reported observation from studies that rely mainly on IHC is prominent TRPV1-ir in RGCs and 
astrocytes. In rat, TRPV1 labeling was confined to a subset of cells in the GCL and within the optic 
nerve head, but was weak within the optic nerve itself [92]. Further consistent with RGC localization, 
axotomy of the optic nerve resulted in decreased TRPV1 expression that was mirrored by an  
injury-induced decline in the population of TRPV1-expressing cells [88,94] and TRPV1-r was also 
detected within retinocollicular projections within the superior colliculus [95]. Suggestive of potential 
presynaptic function, TRPV1-ir puncta in the inner plexiform layer (IPL) colocalized with the synaptic 
vesicle marker synaptophysin. Increased density of labeled axon bundles near the optic nerve head was 
also observed together with the labeling of distinct cell types in the GCL that included large SMI32+ 
cell bodies, axons and dendrites and smaller Thy-1.1+ cells. Consistent with the labeling in retinal 
sections, TRPV1-ir was also observed in somata/dendrites/neurites of immunopanned and cultured 
RGCs [72]. Sappington et al. [72] reported that retinal TRPV1 expression increases with intraocular 
pressure (IOP) and suggested that mechanical activation of the channel induced by chronic increases in 
IOP may drive progressive degeneration of RGCs.  
Trpv1 mRNA signals in immunomagnetically separated postnatal and adult rat RGCs are weaker 
compared to the whole retina [72], indicating the transcripts are likely to be generated in other cell 
types in addition to RGCs. Accordingly, immunolocalization and pharmacological assays implicated 
photoreceptors, bipolar cells, amacrine cells and glia as potential TRPV1 expressors in rodents, 
teleosts and primates [92,96–98]. TRPV1-ir was observed in synaptic terminals of salamander and rat 
photoreceptors [92,98,99], suggesting that the channel could modulate the transmission of the response 
to postsynaptic bipolar and horizontal cells. However, arguing against a major role in 
phototransduction and neurotransmission in the outer retina, photopic and scotopic ERG a- and b- 
waves in Trpv1í/í mice are indistinguishable from field potentials in wild type animals [10]. It is 
possible, however, that the diffuse TRPV1-ir observed in the OPL [72,100] corresponds to Müller glial 
processes and/or resident microglia. Consistent with the microglial locus, TRPV1-ir is present in Iba1+ 
and OX-42+ cells whereas cultured retinal microglia respond to capsaicin [71,92]. TRPV1 expression 
in Müller cells is less clear. Leonelli et al. [92] did not detect TRPV1-ir in rat Müller glia whereas 
Martinez-Garcia et al. [89] reported TRPV1-ir in rabbit Müller cells. Thus, localization to 
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photoreceptors, Müller glia, bipolar cells and/or amacrine cells may be species-specific and the 
identity of TRPV1 signals in the mammalian retina remains a subject for further studies.  
Leonelli et al. [92] detected weak TRPV1-ir puncta in astrocytes that line the vasculature at the inner 
limiting membrane (Figure 1). This was recently confirmed in the functional study by Ho et al. [101] 
who provided evidence that the channel plays a role in guiding astrocyte migration following wound 
injury. Finally, TRPV1-ir was also reported in the retinal pigment epithelium in rabbits and  
humans [89], indicating a yet-to-be-defined role in the ion transport function of these cells that are 
critically important for photoreceptor function and survival. 
The variable results obtained with TRPV1 antibodies and pharmacological agents suggest the need 
for additional functional assays as well as control experiments based on the widely available mice with 
the genetically ablated channel. One example of such an auxiliary method is optical imaging, which 
indeed shows robust, desensitizing, capsaicin-induced [Ca2+]i elevations in mouse RGC somata and 
microglial cells, but not in Müller astroglia or photoreceptors (Figure 2). The identity of the channel 
was additionally confirmed by blocking capsaicin-evoked [Ca2+]i elevations with capsazepine and by 
showing their absence in Trpv1í/í cells [102]. Functional expression of TRPV1 in RGCs and 
microglial cells, together with their absence from photoreceptors and bipolar cells suggests that the 
channel may play a more significant function within the inner retina. 
Figure 2. An acutely isolated and dissociated mouse RGC (blue) and microglial cell (µG; 
green) loaded with fura-2 respond to capsaicin (40 µM) with transient [Ca2+]i elevations 
that inactivate during stimulus application, whereas a representative photoreceptor  
(PR; purple) and Müller cell (MC; red) do not respond to the TRPV1 agonist (see [19,103] 
for methods). 
 
3.3. Endogenous and Synthetic TRPV1 Agonists and Retinal Signaling 
Because TRPV1 receptors are unlikely to experience conspicuous nociceptive, mechanical and 
noxious thermal stimuli in the healthy retina, their primary activators of are likely to be endogenous 
polyunsaturated fatty acids. TRPV1 is gated by precursors and derivatives of arachidonic acid 
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commonly lumped together into the “endovanilloid/endocannabinoid” (eCB) category of signaling 
metabolites that are ubiquitous across all retinal layers [98]. These may include anandamide 
(Arachidonoyl ethanolamide; AEA), unsaturated N-acyl-dopamines (e.g., N-Arachidonoyl dopamine; 
NADA), 2-arachidonoglycerol (2-AG, an ester formed from arachidonic acid and glycerol) and 
lipoxygenase metabolites of arachidonic acid (hydroperoxyeicosatetraenoic acids; HpETEs) [36] 
(Figure 2).  
eCBs affect TRPV1 activity directly and indirectly via activation of cannabinoid receptors (CBRs), 
a 2-isoform family of G protein-coupled receptors with ~44% amino acid similarity that are associated 
with intracellular cAMP metabolism and downstream activation of the MAPK-ERK pathway. Type I 
CB receptors (CB1Rs) are most abundant GPCR within the CNS and all TRPV1-expressing primary 
sensory neurons express CB1R in vitro [104]. The complexity of eCB composition translates to their 
biological effects. Thus, AEA activates TRPV1 and CB1Rs, whereas 2-AG is a full agonist of CB1Rs 
and CB2Rs but does not affect TRPV1 [105]. eCB biosynthesis from phospholipid precursors is 
primarily activity-dependent and follows activation of Ca2+-dependent phospholipases (including 
phospholipases A2 and C). For example, 2-AG (which, unlike anandamide is expressed at high levels 
in the CNS) is primarily synthesized by phospholipase C and by diacylglycerol lipase (DAGL) acting 
on the second messenger diacylglycerol (DAG) [106] (Figure 3). Both AEA and 2-AG freely diffuse 
across the membrane but can be released into extracellular space to affect neural activity via 
presynaptic and/or postsynaptic binding sites. eCBs target pre- and/or postsynaptic TRPV1 channels 
and were reported to bind the cognate TRPV2-4 isoforms with moderate-to-high efficacy and potency 
(EC50 ~3.7 µM) [107]. The EC50 values for binding of cannabinoid compounds to CBs and TRPV1 are 
typically in the micromolar range, although some (such as NADA) can bind TRPV1 in the nanomolar 
range [82]. Thus, eCB release will exert a multimodal effect through separate CBR and vanilloid 
receptor mechanisms, but may also trigger reciprocal interactions between the two. Interestingly, 
coactivation of excitatory (TRPV1) and inhibitory (CB1R) eCB-dependent mechanisms can be 
concentration-dependent whereby CB1R-mediated effects predominate at low (nM) levels of AEA and 
TRPV1-mediated effects are more pronounced at higher (~µM) concentrations [104]. Alternatively, 
the two effectors of AEA might be activated sequentially, with stimulation of high-affinity CB1Rs 
preceding subsequent activation of TRPV1 [108]. Moreover, reciprocal interaction between the GPCR 
and the ion channel may involve CB1R-mediated sensitization or desensitization of TRPV1 through 
PKA/PKC-dependent regulation of its phosphorylation state [109]. With respect to the retina, CB1R 
transcripts were found in both plexiform layers [99,110,111], whereas DAG lipases were localized to 
OFF bipolar cells [112]. Given the prominent localization of TRPV1 in the inner retina, it is plausible 
that Ca2+-dependent eCB release, associated with periods of intense ON- and OFF RGC activation 
results in indirect (CBR-mediated) and direct TRPV1 modulation. As if this is not complicated 
enough, arachidonic acid and its downstream eicosanoid metabolites also activate TRPV4, a 
polymodal vanilloid receptor homolog that acts as a RGC osmosensor [17]. The properties of natural 
stimuli (light) that lead to endocannabinoid concentrations high enough for retinal TRPV1 and/or 
CB1R activation remain to be identified.  
Enzymatic synthesis and degradation of endovanilloid/eCBs is a likely rate-limiting step in TRPV1 
activation and inhibition. AEA is degraded by the fatty acid amide hydrolase (FAAH), resulting in the 
production of ethanolamine and arachidonic acid (AA), whereas 2-AG can be hydrolyzed by 
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monoacylglycerol lipase (MAGL), Į/ȕ-hydrolase domain 6, 12 (ABHD6/ABHD12), and/or 
cyclooxygenase-2 (COX-2) [for retinal distributions see [112,113]. FAAH is ubiquitously expressed 
across the brain and the retina, with expression reported in subsets of photoreceptors, RGCs, 
dopaminergic and cholinergic amacrine cells and horizontal cells [98,112,114]. IHC studies in fish 
colocalized FAAH with CB1Rs and TRPV1 within presynaptic terminals of the IPL and OPL [90,91]. 
FAAH expression in photoreceptors is consistent with the observed AEA uptake [100] and localization 
of CB1 receptors [99]. The NMDA inhibitor MK801 reduced retinal FAAH activity [88], possibly by 
downregulating the Ca2+-dependent modulation of the enzyme. FAAH-mediated catabolism of 
anandamide may be suppressed by PEA, which is present rat, cat and monkey retinas, potentiating 
eCB signaling in vivo [115]. The augmentation of eCB signaling by inhibition of FAAH can produce 
effects that markedly differ from those elicited by CB1 agonists [116], consistent with synergistic 
action on TRP channels. Likewise, the breakdown of the FAAH metabolite arachidonic acid by  
12-lipoxygenase (12-LO) and 15-lipoxygenase (15-LO) generates 12(S)-HpETE and 15(S)-HpETE, 
which also bind and activate TRPV1 [117,118]. It would be interesting to see whether the retinas of 
FAAHí/í mice favor eCB signaling over that of endovanilloids and how this affects the responses of 
retinas to light/darkness. 
Figure 3. Cellular activity initiates synthesis of endocannabinoids/endovanilloids, which 
activate (arrows) or modulate (closed circles) TRPV1 and TRPV4 activity and thereby 
regulate physiological responses. 2-AG (2-arachidonoylglycerol), AA (arachidonic acid), 
AEA (anandamide), CB1 (cannabinoid receptor type I), CB2 (cannabinoid receptor type I), 
DAG (diacylglycerol), FAAH (fatty acid amide hydrolase), GPCR (G protein-coupled 
receptor), HpETEs (hydroperoxyeicosatetraenoic acids), LO (lipoxygenase), NADA  
(N-arachidonoyl dopamine), NAPE (N-acylphosphatidylethanolamine), NAPE-PLD 
(NAPE-specific phospholipase D), PIP2 (phosphatidylinositol 4,5-bisphosphate), PKC 
(protein kinase C), PLA2 (phospholipase A2), PLC (phospholipase C).  
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To understand TRPV1 function in the retina one must differentiate the stimulatory effects of 
endogenous and synthetic cannabinoids on visual signaling and their protective effects in pathological 
paradigms. Systemic exposure to marijuana produces a dazzling variety of visual experiences that 
include increased photosensitivity [119], changes in color discrimination [120] and double/blurred 
vision [96,121], with a mechanism of action that is likely to involve both retinal and cerebral targets. 
The psychoactive ingredient in marijuana, ǻ9-tetrahydrocannibinol (THC), mimics eCBs through its 
stimulation of CB1 receptors but does not activate TRPV1. Cannabinoid effects within the retina were 
also shown to be complex under experimentally tractable conditions. Amongst the observed effects are 
modulation of intracellular signaling in most retinal cell types including potassium and calcium 
currents in amphibian and fish photoreceptors [96,122], voltage-operated currents in rodent  
RGCs [123] and transmitter release from amacrine and bipolar processes in teleosts and mice [97,124].  
Data from exogenous CB1 agonists, eCB measurements, and FAAH inhibition has suggested an 
important role for eCB signaling in neuroprotection. THC lowers IOP and protects the retina from 
excitotoxic damage [96,125,126]. Analogously, synthetic cannabinoids evinced remarkable protection 
for photoreceptors and bipolar cells in a rat model of retinitis pigmentosa [127] and were suggested to 
reduce retinal pigment epithelium (RPE) and RGC damage in models of ischemia, glaucoma, diabetic 
retinopathy, oxidative damage and/or traumatic ocular injury. Suggestive of lost protection, decreased 
levels of 2-AG have been reported in ocular tissues from glaucoma patients [128]. FAAH inhibition 
elevates AEA in young, but not old, rat retinas, an effect that was associated with CB1-dependent 
RGC neuroprotection following axotomy [129]. In a study of ischemic-reperfusion (I-R),  
Nucci et al. [88] used high IOP (~120 mmHg) to block blood flow within and induce RGC loss in the 
rat retina. The cytotoxic effect of I-R was antagonized by systemic FAAH inhibition or intravitreal 
injection of MetAEA, a stable analogue of anandamide. MetAEA-mediated neuroprotection was 
blocked by inhibition of either CB1 or TRPV1, indicating that both receptors might be involved in 
neuroprotective effects of anandamide. Other studies showed that cells exposed to excitotoxic 
conditions can be rescued with eCBs, possibly by suppressing excessive release of glutamate, 
depolarization-mediated Ca2+ overloads and/or excessive firing within the retina [123,124,130]. It is 
unclear if TRPV1 and CB1Rs regulate the same neuroprotective pathway [but see 102]. Moreover, it 
remains to be seen whether CB1 and/or TRPV1 inhibition or genetic deletion exacerbate RGC loss in 
I-R. While eCBs act via CB1Rs [98], the consequences of parallel activation of TRPV1 were not 
assessed. Thus, it is not known whether CB1R activation protects retinal neurons synergistically with 
TRPV1 and/or CB1Rs provide protection by antagonizing Ca2+ overloads mediated by TPRV1. In 
either case, CB1Rs and TRPV1 represent novel potential targets that might confer neuroprotection 
within the retina without causing excitotoxicity. A bottleneck in investigating these potentially 
ubiquitous signaling pathways in the retina has been that, in contrast to the effects of synthetic 
cannabinoids applied to (isolated, cultured) retinal cells, the biological functions of eCBs, TRPV1 and 
their interactions across retinal circuits remain almost entirely unknown.  
3.4. Is TRPV1 Neurodegenerative or Neuroprotective? 
The expression of TRPV1 in the IPL and GCL [66,72,92] implies a potential role for pathological 
enhancement of RGC excitability, post-synaptic voltage-operated Ca2+ influx and glutamate  
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receptor-mediated currents that lead to cell injury via Ca2+ overload. Consistent with this, maximal 
TRPV1 activation has been shown to cause neuronal and glial excitotoxicity in other areas of the 
brain [131–134]. Expanding the results from early studies in the retina [66,77], a recent study reported 
that capsaicin exposure is sufficient to induce apoptosis in cultured RGCs [72]. Intravitreal injection of 
capsaicin likewise caused retinal thinning and increased the number of Fluoro-Jade B positive cells in 
the GCL and INL, particularly in axotomized retinas, an effect that was blocked by capsazepine [94]. 
Because TRPV1 channels contribute to mechanosensation in some cell types [42,135], but see [136], 
exposure to hydrostatic pressure was employed to test whether TRPV1 might represent the intrinsic 
pressure-sensitive pathway through which RGCs respond to elevated IOP. Cultured RGCs and 
microglia were placed into a pressure chamber and the authors reported increased [Ca2+]i when the 
pressure was raised by 70 mm Hg [71,72]. The observation that excessive TRPV1 activity is 
excitotoxic for RGCs, potentially due to Ca2+ overload [72,137], is a valuable step forward in our 
understanding of TRPV1 pathophysiology within the retina. By providing evidence that the channel 
might be intrinsically sensitive to pressure, these data provide an attractive model for  
mechanically-induced Ca2+ dysregulation and RGC remodeling/apoptosis in IOP-induced retinal 
disease. However, the experimental paradigm has recently been questioned within the context of 
glaucoma [138], as intended pressure application within the standard laboratory incubator may not 
have reached the intended pressure differential across the plasma membrane due to  
non-compressibility of water. Moreover, loss of TRPV1 channels is not protective in mouse glaucoma 
models [17]. Nonetheless, the mechanobiology of IOP and distribution of mechanical forces across 
retinal tissue under pathological conditions remains a key challenge in retinal research. This includes 
characterization of the pressure gradient between the inner and outer eye, which might result in the 
expansion of the orbit [73] and the optic nerve head [139]. TRPV1, which may sense mechanical 
stress under certain conditions (such as mechanical hyperalgesia or cell shrinking) [42] might 
therefore play an accentuated role in retinal pathology. 
While TRPV1 activation might be deleterious under some conditions, it has been associated with 
neuroprotection in other contexts [140]. Recent findings [16], which show that IOP-induced damage to 
RGCs is augmented in Trpv1í/í animals, suggest that a novel neuroprotective function for TRPV1 
channels. RGC injury in Trpv1í/í mice and capsazepine-treated rats was associated with inhibited 
anterograde axonal transport of a fluorescently tagged marker, axonal loss and astrogliosis in the 
microbead occlusion glaucoma model. TRPV1 ablation also suppressed a post-IOP  
exposure-dependent increase in RGC firing and increased the amount of depolarizing current needed 
to reach the RGC firing threshold. The authors suggest that TRPV1 activity rescues RGCs by 
promoting their excitability during retinal stress. Another protective mechanism might involve 
TRPV1-dependent release of the protective interleukin 6 (IL-6) from activated microglia [141],  
as TRPV1 inhibition by iodo-resiniferatoxin (specific) and Ruthenium Red (non-specific) 
prevented hydrostatic pressure-induced release of IL-6 and NFțB translocation into the nucleus of 
microglia [71]. A recent in vivo study by Sakamoto et al. [142] showed that TRPV1 agonists 
(capsaicin or SA13353) might evince a paradoxical suppression of NMDA-mediated excitotoxicity of 
rat RGCs. This effect was prevented by capsazepine, CGRP (8–37) (calcitonin gene-related peptide 
receptor antagonist) or RP67580 (tachykinin NK1 receptor antagonist). CGRP and substance P, which 
are increased by electrical stimulation of the retina [143] and metabolic stress [144],  
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were protective [142]. Low levels of systemic capsaicin were reported to elevate the CGRP 
concentration and reduce apoptosis in the GCL of rats with STZ-induced diabetic retinopathy [144]. 
Taken together, the results from capsaicin exposure studies appear contradictory and unresolved. It 
appears that TRPV1 activity can be beneficial or detrimental to RGCs depending on the disease model, 
the extent of TRPV1 activation and activation of auxiliary calcium effectors, however, there is also the 
serious concern of concomitant overstimulation of capsaicin-sensitive mechanisms such as TRPM1 
that needs to be addressed in future work.  
3.5. TRPV1 and Retinal Vasoregulation 
TRPV1 is expressed in vascular endothelial cells and arteriolar smooth muscle cells [20,51,145,146] 
and may modulate vascular tone and permeability by serving as a source of Ca2+ for NO synthesis. 
Donnerer and Lembeck [147] first showed that capsaicin evokes vascular responses that are 
independent of sensory innervation. TRPV1’s contribution to the regulation of blood distribution 
appears to be tissue-specific, as TRPV1 agonists can cause neurogenic vasodilation (in the skin) and 
vasoconstriction (in skeletal muscle) [148–150]. In the retina, TRPV1-ir colocalized with vascular 
endothelial cells at the inner limiting membrane [92], suggesting that the channel might also modulate 
vascular flow and/or permeability in this tissue, possibly via Ca2+-dependent upregulation of inducible 
and endothelial NO synthase isoforms [151] and/or production of CGRP [145,152]. eCB analogs 
reduced proliferation of human retinal vascular endothelial cells [153], suggesting additional roles in 
the regulation of vascular leakage and integrity of the blood-retina-barrier.  
TRPV1 expression in astrocytes lining blood vessels within the inner retina is also likely to 
modulate glial control of vascular tone and/or Ca2+-dependent astrogliosis [101]. Inflammation that 
accompanies reactive gliosis of protoplasmic astrocytes and Müller glia can itself affect  
blood-retina-barrier permeability, vascular leakage and oxidative damage [73]. As these events are 
particularly hazardous to RGCs, both pathological and neuroprotective aspects of TRPV1 and eCB 
activity may offer potential benefits for treating traumatic, inflammatory and ischemic optic 
neuropathies in diabetic retinopathy, ischemia, optic neuritis and glaucoma.  
4. Conclusions 
Although TRPV1 expression has been documented across many cell types and in species across 
phyla ranging from fish to nonhuman primates, at present remarkably little definitive information is 
available about what the channel is doing in visual processing, retinal development and homeostatic 
functions of retinal neurons, glia and vasculature. At the very least, it seems that the network 
comprised of TRPV1 channels, CB1 receptors, eCBs /eicosanoids, kinases and phosphatases  
(Figure 3) represents a novel neuromodulatory system that could tune the excitability of retinal 
neurons through amplification or dampening of retinal output and/or contribute to activity-dependent 
refinement and retinal patterning of visual circuits. The polymodal properties of the TRPV1 channel 
suggest that, similar to its sibling TRPV4 [17,73], eCB-dependent modulation of Ca2+ entry could 
drive numerous Ca2+-dependent processes associated with normal and pathological retinal physiology. 
The prominent functional expression of TRPV1 channels in RGCs and microglia (Figure 2) and the 
stupendous complexity of endovanilloid/endocannabinoid signaling (Figure 3) suggest that the 
















































Cells 2014, 3 927 
 
channels could modulate the diverse presynaptic inputs to RGCs as well as participate in nonretrograde, 
light-dependent, modulation of retinal output. It will be important to determine how TRPV1 activators 
and modulators orchestrate channel properties and its interactions with voltage and calcium effectors 
such as voltage-operated Ca2+ channels, NMDA receptors and Ca2+-dependent transcription factors 
(e.g., NFAT, NFkB, c-fos and DREAM). A particularly interesting area of research will be to evaluate 
the role of CB1R–TRPV1 interactions, especially under pathological conditions where cannabinoids 
can provide significant neuroprotection [98]. Given that TRPV1 was identified as a potential 
intracellular Ca2+ release channel [154] studies are also needed to evaluate its relationship to Ca2+ 
release from intracellular stores and activation of store-operated currents, which have been shown to 
play an increasingly prominent function in retinal Ca2+ homeostasis [74,103,155,156]. Because light-
dependent changes in [Ca2+]i levels are the main driver of tonic neurotransmission that characterizes 
retinal signaling in light and darkness [157], Ca2+ influx and clearance in retinal neurons are under 
tight control. A clear example of such exquisite control are photoreceptors where µV changes in 
presynaptic membrane potential translate into discernable differences in [Ca2+]i within photoreceptor 
terminals and visual perception [158,159]. Thus, even modest [Ca2+]i elevations mediated by 
physiological TRPV1 activation could have significant repercussion for downstream visual signaling. 
Finally, taking into account the reported roles for TRPV1 in hypertonic transduction and 
mechanosensation [160], it will be of interest whether the channel also contributes to retinal 
osmoregulation and intrinsic responsiveness to IOP and/or mechanical trauma. This would implicate 
this polymodal channel in key aspects of retinal homeostasis and response to stress. In summary, the 
determination of the role that TRP channels play in invertebrate vision together with the elucidation of 
TRPV1 function in acute and chronic pain represent two of the pinnacles of modern neuroscience. In 
comparison, TRPV1 research in the mammalian visual system is in its infancy and more studies are 
needed to better define the involvement of this channel in sensory transduction at the single cell level 
within the retina, function of visual circuits and the pathogenesis/etiology of blinding diseases. 
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FROM MECHANOSENSITIVITY TO INFLAMMATORY 
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draft of the background and sections pertaining to research in David’s lab. I also helped 






















Krizaj D, Ryskamp DA, Tian N, Tezel G, Mitchell CH, Slepak VZ, Shestopalov VI 
(2013) From mechanosensitivity to inflammatory responses: new players in the pathology 
of glaucoma. Current Eye Research 39(2):105-119. Reprinted with permission from 
Current Eye Research and Informa Healthcare. 

























Current Eye Research, Early Online, 1–15, 2013
! Informa Healthcare USA, Inc.
ISSN: 0271-3683 print / 1460-2202 online
DOI: 10.3109/02713683.2013.836541
REVIEW ARTICLE
From Mechanosensitivity to Inflammatory Responses:
New Players in the Pathology of Glaucoma
David Krizˇaj1,2,3, Daniel A. Ryskamp1,3, Ning Tian1,3, Gu¨lgu¨n Tezel4,
Claire H. Mitchell5,6, Vladlen Z. Slepak7 and Valery I. Shestopalov8,9,10
1Department of Ophthalmology and Visual Sciences, 2Department of Physiology, 3Program in Neuroscience,
University of Utah School of Medicine, Salt Lake City, UT, USA, 4Department of Ophthalmology & Visual
Sciences, University of Louisville, Louisville, KY, USA, 5Department of Anatomy and Cell Biology, 6Department
of Physiology, University of Pennsylvania, Philadelphia, PA, USA, 7Department of Molecular Pharmacology,
8Department of Ophthalmology, Bascom Palmer Eye Institute, 9Department of Ophthalmology, Cell Biology and
Anatomy, University of Miami Miller School of Medicine, Miami, FL, USA, and 10Vavilov Institute for General
Genetics, Moscow, Russia
ABSTRACT
Purpose of the study: Many blinding diseases of the inner retina are associated with degeneration and loss of
retinal ganglion cells (RGCs). Recent evidence implicates several new signaling mechanisms as causal agents
associated with RGC injury and remodeling of the optic nerve head. Ion channels such as Transient receptor
potential vanilloid isoform 4 (TRPV4), pannexin-1 (Panx1) and P2X7 receptor are localized to RGCs and act as
potential sensors and effectors of mechanical strain, ischemia and inflammatory responses. Under normal
conditions, TRPV4 may function as an osmosensor and a polymodal molecular integrator of diverse mechanical
and chemical stimuli, whereas P2X7R and Panx1 respond to stretch- and/or swelling-induced adenosine
triphosphate release from neurons and glia. Ca2þ influx, induced by stimulation of mechanosensitive ion
channels in glaucoma, is proposed to influence dendritic and axonal remodeling that may lead to RGC death
while (at least initially) sparing other classes of retinal neuron. The secondary phase of the retinal glaucoma
response is associated with microglial activation and an inflammatory response involving Toll-like receptors
(TLRs), cluster of differentiation 3 (CD3) immune recognition molecules associated with the T-cell antigen
receptor, complement molecules and cell type-specific release of neuroactive cytokines such as tumor necrosis
factor-a (TNF-a) and interleukin-1b (IL-1b). The retinal response to mechanical stress thus involves a diversity
of signaling pathways that sense and transduce mechanical strain and orchestrate both protective and
destructive secondary responses.
Conclusions: Mechanistic understanding of the interaction between pressure-dependent and independent
pathways is only beginning to emerge. This review focuses on the molecular basis of mechanical strain
transduction as a primary mechanism that can damage RGCs. The damage occurs through Ca2þ-dependent
cellular remodeling and is associated with parallel activation of secondary ischemic and inflammatory signaling
pathways. Molecules that mediate these mechanosensory and immune responses represent plausible targets for
protecting ganglion cells in glaucoma, optic neuritis and retinal ischemia.
Keywords: ATP, calcium, cytokines, glaucoma, glia, inflammation, mechanosensation, retinal ganglion cells
INTRODUCTION
The spatiotemporal properties of retinal ganglion cell
(RGC) action potentials within the axons of the optic
nerve represent the entire visual output projected
from the eye to the brain. Loss of RGCs therefore
culminates in vision loss in debilitating blinding
diseases such as ischemia, diabetic retinopathy
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and glaucoma.1 While the biological mechanisms that
compromise RGC viability in retinal disease are
currently under intense experimental scrutiny, poten-
tially useful insights into the disease etiology might be
obtained from the observation that RGC degeneration
may, at least initially, occur without injury to other
classes of retinal neurons.1,2 Many studies have
investigated the anatomical and molecular mechan-
isms that could account for the selective vulnerability
of RGCs in glaucoma and diabetes. It has been
suggested that RGCs are uniquely vulnerable to
disruptions in energy supply3 mitochondrial func-
tion4 and axonal transport5 due to the need to support
metabolically expensive long-distance axons. This
need is tended through continuous supply of glucose,
oxygen and signaling molecules across the blood–
retina barrier (BRB), which in turn requires intact
function of pericytes, astroglia, microglia and Mu¨ller
cell endfeet that interface between the vascular endo-
thelium and RGC somata/axons. Astroglia contribute
to the metabolic homeostasis of RGCs through glu-
cose/lactate transport mediated by monocarboxylate
transporters (MCTs), glucose transporters (SLC2A),
glutamate transporters, Gamma-aminobutyric acid
(GABA) transporters and the proposed glutamate-
glutamine shuttle driven by the bidirectional System
N (SN1) transporter.6–8 While blood vessels and glia
maintain the ocular immune privilege by shielding
the retina from systemic inflammation, glaucomatous
RGC dysfunction might also involve the breakdown
of the glial-vascular-immune interface, resulting in
increased vascular permeability, hypoxia/ischemia,
release of free radicals, cytokines, eicosanoids and
growth factors and access of auto-immune mol-
ecules.5,9 Importantly, RGCs are uniquely susceptible
to trauma and biomechanical strain, leading to their
selective loss in several debilitating blinding
diseases.9,10
Excessive mechanical stress compromises the via-
bility of many sensory systems, including hearing,
somatosensation and vision.11,12 Glaucoma, the blind-
ing disease most commonly associated with patho-
logical mechanical stress in the eye, is a designation
that covers many distinct eye diseases unified by
anterior chamber dysfunction, optic neuropathy and
glial activation. Its etiology is linked to many known
risk factors that include mechanical, genetic (mono-
genic or polygenic), epigenetic and environmental
factors, and possibly combinations thereof.13 A major
risk factor for developing primary open angle glau-
coma (which accounts for the majority of glaucoma
patients) is ocular hypertension9,14 caused by
increased production or decreased outflow of aqueous
humor within the anterior chamber.15 Positive correl-
ations between intraocular pressure (IOP) levels and
RGC loss, and between duration of elevated IOP and
RGC axon loss, have been reported for glaucomatous
mice, rats, primates and humans.9,14,16,17 Currently,
pharmacological targeting of increased IOP represents
by far the most common clinical treatment of glau-
coma. Because the disease is too often identified by
the time when axonal atrophy and somatic degener-
ation reach the irreversible terminal stage, there is an
increasing interest in early diagnosis and neuropro-
tective strategies that will complement IOP reduction
within the anterior eye.18 Both require us to under-
stand the mechanotransduction mechanism at the
target (RGCs). As discussed below, application of
pressure/stretch triggers influx of calcium ions into
RGCs through several classes of putative mechan-
osensitive ion channels. Given that excessive calcium
entry overloads cells with calcium and drives neur-
onal death in many neurodegenerative diseases in the
retina and the brain,19–21 mechanosensitive channels
represent obvious neuroprotection targets in
glaucoma.
Although pharmacological targeting of IOP-
elevations represents by far the most common clinical
treatment of glaucoma, recent studies suggest that the
disease also involves pressure-independent mechan-
isms mediated by vascular, glial and immune cells.
Reactive astroglia and microglia appear to regulate
RGC survival through parallel and intersecting path-
ways that encompass elevated levels of the vasocon-
strictor endothelin-1, inflammatory chemokines and
cytokines (e.g. TNF-a, IL-1b and IL-18), ATP, eicosa-
noids and/or damage-associated molecular patterns
(DAMPs) released by injured and dying RGCs, which
in turn activate multiple RGC targets, including TNF-
a, TGF-b, IL receptors, the inflammasome and T-cell
antigen receptor (TCR)/major histocompatibility com-
plex (MHC) immune complexes.22–27 Secondary
insults, triggered by molecules released from injured
RGCs, together with cytokines released from reactive
glia and immune molecules arriving from leaky blood
vessels may further disrupt the blood retina barrier
and facilitate additional infiltration of circulating
immune cells,28,29 thereby fueling RGC damage
inflicted by the primary mechanical stress.22,30,31
Obviously, diagnosis and treatment of glaucoma will
need to simultaneously address the primary (pres-
sure-related) and secondary (inflammatory and ische-
mic) symptoms as well as consider the possibility that
glaucomatous injury is exacerbated through feedback
interactions between primary and secondary
pathways.
The aim of this mini-review is to describe recent
developments in glaucoma research, focusing on
genetic, physiological and pharmacological studies,
many from the authors’ laboratories. We introduce
molecular mechanisms that underlie intrinsic RGC
mechanosensation, showcase the intimate relationship
between immune and inflammatory pathways in
glaucoma and conclude by identifying a novel retinal
immune recognition mechanism that might contribute
to glaucomatous remodeling in the inner retina.






































































All cells and organisms live within mechanically
active environments in which they must sense and
adapt to physical forces such as hydrostatic pressure,
osmotic swelling/shrinkage, shear flow and develop-
mentally driven tissue stretch.32,33 Cells in the eye
are additionally exposed to intraocular pressure, the
magnitude of which reflects the elasticity of ocular
tissues and the balance between production and
drainage of aqueous humor within the anterior
chamber. Biomechanical strain, exerted by the IOP,
was suggested to play a central role in the normal
development of the vertebrate retina through scleral
expansion and continuous stretching of the eye.
Consistent with this view, IOP dissipation blocked
ocular expansion even as the neural retina continued
to grow.34,35 Furthermore, Coulombre showed that
IOP-deprived chick retinas are forced to increase
their thickness, suggesting that mechanical stress is
required for proper establishment of retinal circuits.
Thus, as observed in other tissues,33,36 morphogen-
esis, migration, adhesion, osmoregulation and con-
tractility of developing ocular cells are likely to be
influenced by mechanical forces that include IOP.
Given that vision loss in animal glaucoma models
and humans reflects the magnitude and time course of
IOP elevations,9,14,16,17,37 it would appear that the
identification of mechanosensitive mechanisms
within RGCs, retinal vasculature and glia should
represent a priority target in glaucoma research.
Potential candidate mechanisms might include pres-
sure- and/or stretch-sensitive ion channels, enzymes,
cytoskeletal proteins, extracellular matrix proteins
or combinations thereof. Force-induced stretching of
focal adhesion junctions could, for example, reveal
intracellular binding sites for cytoskeletal proteins
and influence activation of mechanosensitive ion
channels.38,39 Another possibility is that the pressure
gradient across axons within the optic nerve mechan-
ically and/or biochemically impairs axonal transport
between the cell body and midbrain synapses, depriv-
ing RGCs of critical ‘‘neurotrophic factors’’.40–44 The
perfusion pressure difference between arm-measured
blood pressure and IOP is a strong risk factor for
incidence and progression of open angle glaucoma.18
Variants of the ‘‘vascular hypothesis’’45,46 suggest that
the primary defect in glaucoma is due to vasoconstric-
tion and insufficient blood supply, caused by compro-
mised arterial flow through the capillaries connected to
the peripapillary choroid and the circle of Zinn–Haller.
There is, however, little clear evidence that chronic IOP
increases observed in most ocular hypertensive
patients directly affect ocular blood flow. The bio-
mechanics of this process, especially with respect to the
late remodeling of the optic nerve head, has been
reviewed elsewhere.24,47
The observations that some of the earliest actions
of increased IOP target the dendritic field size, the
number of synapses as well as light-evoked responses
of RGCs48–53 suggested that the primary retinal
pressure sensors may be RGCs themselves.
Consistent with this view, pressure-induced reduc-
tions in axon thickness and deformation of the optic
nerve head in primate glaucoma models appear later
than abnormalities in the dendritic arbors.54 How do
RGCs sense mechanical stress? Ocular hypertension
could affect the cells through compressive forces
(force/cross sectional area) and/or tensile strain
(local stretch of the tissue). A major role for compres-
sion is doubtful given that the neural retina is entirely
enclosed within the eye. However, even in healthy
eyes IOP-driven increases in ocular volume could
exacerbate tensile forces that impinge on pre-stressed
extracellular matrix, cytoskeleton and plasma mem-
brane structures. The pressure–volume relationship
described by Friedenwald’s ocular rigidity coefficient
(‘‘resistance exerted against distending forces’’) is
between 0.0126mm Hg/mL and 0.0224mm Hg/
mL.55,56 According to Pallikaris et al.,57, 20mm Hg
increase in IOP ought to increase the volume of the
human eye by !30 microliters whereas tonometric
measurements from living eyes give a larger volume
increment of !45 microliters,58 which leads to the
prediction that a 20mm Hg increase in IOP would
expand the ocular volume by !1%. Showing that
retinal cells respond to 1% stretch would confirm that
they are directly sensitive to the tensile forces driven
by IOP changes that are commonly observed in
glaucoma. Ocular rigidity is lower in glaucoma
compared to healthy subjects.59 Thus, an increase in
IOP will provoke larger tensile stretch forces across
membrane/matrix proteins in glaucomatous RGCs
compared to healthy cells and should be more
efficacious in crossing the thresholds of intrinsic
mechanosensitive mechanisms. Mechanical forces
and submicrometer displacements generated by IOP
elevations are comparable to the measured free




The long-standing question in glaucoma research has
been whether RGCs are themselves capable of
transducing mechanical stimuli generated by physio-
logical changes in IOP amplitude. In vitro, in vivo and
preclinical evidence published in recent years shows
that RGCs are themselves highly sensitive to mech-
anical forces.9,62–67 RGC viability has been shown to
be affected by physical compression, tensile stretch,
prolonged swelling and IOP elevations, which, in
intact preparations, were able to induce changes in the
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molecular composition and synaptic organization
within hours to weeks.63,68–70
The recently identified Transient Receptor Potential
(TRP) and Piezo channels represent obvious candi-
dates for retinal IOP transducers. While little is known
about the Piezo family, the seven subfamilies of the
TRP superfamily – so named after their Drosophila
homolog, which plays a key role in phototransduction
– are crucial for the perception of sensory information
in vertebrates and invertebrates.11 Most TRP isoforms
are nonselective cation channels that are permeable to
Ca2þ, therefore their activation serves as suitable
trigger for many different types of intracellular
signaling events. Members of four TRP subfamilies,
specifically of the vanilloid (TRPV), ankyrin (TRPA),
polycystin (TRPP), and canonical (TRPC) families are
relevant to mechanosensation. These channels are
only weakly sensitive to depolarization but open in
response to a wide variety of mechanical, osmotic,
chemical and thermal stimuli.22 RGCs express
mechanosensitive TRPC1, 3-, 6-, 7- and TRPV1- and
4-channel isoforms.66,71–73 TRPV4 is a particularly
attractive candidate as a glaucoma mechanosensor
because, while strongly expressed in RGCs, it is
excluded from other types of retinal neuron.66
Selective TRPV4 agonists, such as 4a-PDD and
GSK1016790A, induce calcium influx into RGCs and
increase the rate of spontaneous RGC firing, whereas
excessive TRPV4 stimulation induces RGC apoptosis
but spares other retinal neurons.66,74
Mechanosensitive TRPV4-mediated responses could
account for the increased excitability and reduced
RGC survival induced by experimental elevation of
IOP or membrane stretch.66 The precise mechanism
through which membrane tension activates RGC
TRPV4 channels is unclear. The mutually not incom-
patible mechanisms include direct activation by lipid
stretch,75 phospholipase A2 or through mechano-
chemical feedback involving b1 integrins and/or
focal adhesion kinases.76,77
It remains to be determined whether excessive
calcium influx through TRPV4 channels contributes to
calcium dysregulation that has been linked to the
pathogenesis of glaucoma in animal studies and
clinical trials.23,78,79 Interestingly, the risk for develop-
ing the disease in humans is increased by taking high
daily doses of calcium supplements80 or by not taking
calcium channel blockers.78 At the very least, calcium
ions are going to play a central role in cytoskeletal
reorganization that underpins dendritic/axonal
remodeling in glaucoma. According to the model
shown in Figure 1, local Ca2þ influx driven by
excessive TRPV4 activation contributes to increased
baseline [Ca2þ]i levels and RGC hyperexcitability. This
leads to activation of Ca2þ-dependent genes belong-
ing to NFAT (nuclear factor of activated T-cells), c-fos,
DREAM (DRE antagonistic modulator protein) and/or
CREB (cAMP response element-binding protein)
families and triggers Ca2þ-dependent catabolic
enzymes such as calcineurin and calpains, as well as
the cytoskeletal remodeling pathways involving actin
and/or microtubular assemblies.8,23,81–86 Calcium
levels also modulate the opening probability of
purinergic channels and pannexin hemichannels and
could affect their responsiveness to mechanical
stimuli. Consistent with this, TRPV4-mediated Ca2þ
entry was shown to regulate ATP release, which, via
P2X7 receptors, could exacerbate mechanically-
induced cell injury and facilitate release cytoactive
molecules such as endothelin and/or TNF-a.87,88
FIGURE 1. Proposed model for RGC mechanotransduction. Pressure-induced membrane stretch activates plasma membrane TRPV4
channels leading to calcium entry, activation of Panx1 and ATP release. This leads to secondary activation of P2X channels and P2Y
receptors on neurons and glial cells. Calcium dysregulation may then trigger dendritic and axonal remodeling, inflammation, glial
reactivity, RGC hyperexcitability, and eventually, apoptosis.




































































The emergence of new models of mechanical
gating33,89 suggests that force transduction cannot be
disentangled from intracellular biochemistry. Hence,
while the direct mechanosensory function of TRPV4
figures most prominently, the polymodal features of
TRPV4 activation, such as sensitivity to swelling and
inflammatory agents75,76 place the channel squarely
within the crossroads of mechanosensing, inflamma-
tory signaling and anatomical remodeling.
Inflammatory mediators would exacerbate RGC
injury, induced by mechanically generated TRP-
mediated Ca2þ overload (Figures 1 and 2).
According to this view, TRPV4 signaling represents
an epicenter that links primary, pressure-induced
RGC damage to secondary pathophysiological mech-
anisms mediated by glial-vascular inputs (delineated
below). Pannexin channels link the mechanosensitive
release of ATP to P2X7 receptor-mediated death of
RGCs.
MECHANOSENSITIVE RELEASE OF
ATP VIA PANNEXINS AND
AUTOSTIMULATION OF P2X7R
RECEPTORS ON RGCS
In the eye, the mechanical strains resulting from
increased IOP are also associated with ATP release.
This ATP can mediate physiological and pathological
responses through binding to purinergic P2 receptors,
the ligand-gated ion channels activated by ATP.90–92
Several isoforms of ionotropic P2X receptors, includ-
ing P2X3-5 and P2X7 were reported to be expressed in
RGCs.93 Increased concentrations of extracellular ATP
are present in the aqueous humor of human patients
with acute94 or chronic95 glaucoma. Extracellular ATP
is also elevated in the retina following acute eleva-
tions in IOP from rat and bovine retina,68,96 and
preliminary data suggest a prolonged increase in
retinal ATP occurs in primate and rat models of
chronic glaucoma.97,98 Because extracellular ATP is
rapidly degraded in the central nervous system (CNS)
by ecto-ATPases, such sustained increase is the
evidence of a prolonged release from stressed neural
cells. While the ATP released in response to mechan-
ical strain can act at multiple receptors, the P2X7
receptor is of particular interest given its ability to
initiate both inflammatory responses and neuronal
death.99,100 Since RGCs express P2X7Rs, stimula-
tion with its agonist, 20(30)-O-(4-Benzoylbenzoyl)
adenosine-50-triphosphate (BzATP), elevates intracel-
lular Ca2þ and kills RGCS in vitro.101 BzATP also kills
RGCs in vivo; this death is inhibited by P2X7R
blockers MRS 2540 and Brilliant blue G.102
This suggests that the mechanosensitive release of
ATP accompanying elevation of IOP may influence
ganglion cell health in acute and chronic
glaucoma.103,104
FIGURE 2. Schematic diagram of signaling mediated by surface receptors and Panx1 in the injured retina. Although signaling by
TNFRs, TLR4 (signals through MyD88 and/or TRIF) and Ca2þ can feed directly into NF-kB activation, TLR3 signaling via TRIF first
results in the transcription of type 1 interferon genes. These can also promote NF-kB-regulated transcription (dashed arrow).
Ultimately, the maturation of pro-IL-1b into IL-1b via inflammasome pathways perpeturates inflammation and worsens the
glaucomatous damage.
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Given the pathological effects of excess extracellu-
lar ATP on ganglion cells, the cellular source of this
released ATP and the signaling pathways leading to
this release are of interest. Although Mu¨ller cells
release ATP into the region surrounding RGCs upon
mechanical stimulation, its rapid dephosphorylation
into adenosine may limit the concentrations reaching
RGC membranes.105,106 In a healthy retina with little
mechanically-evoked ATP release, ATP dephosphor-
ylation regulates P2X7 receptor activity, because
P2X7R requires relatively high concentrations of
ATP for activation.107 In disease, sufficient ATP to
activate the P2X7 receptors may come from the efflux
of ATP through channels in close proximity to the
P2X7 receptor on the membrane, with local concen-
trations high enough to autostimulate the receptors.
The pannexin-1 (Panx1) channel, which can be
recruited and directly activated by P2X7R, has been
recently implicated in this role.67,108–110
Pannexins are membrane channels with a high
single channel conductance of 500 pS that are perme-
able to molecules over 1 kDa.111 Unlike connexin gap
junction proteins, pannexin channels are not coupled
to partners in adjacent cells but instead act as pores
connecting the cell interior to extracellular space;
opening of the pore is tightly regulated to maintain
cellular integrity.109 Pannexins are widely distributed
and have important implications for inflammation, as
discussed below. However, pannexins have two char-
acteristics essential to the current context; they are
highly permeable to ATP and open upon application
of mechanical strain to the membrane.67 Whether
pannexins are themselves the primary mechanosensor
or activated by other upstream mechanosensitive
sensors through Rho kinase,112 their ability to release
ATP in proximity to P2X7 receptors upon stretch of
the membrane implicates them in connecting elevated
IOP with activation of the p2X7 receptors.
This pannexin/P2X7R system was recently found
to translate mechanical strain into receptor activation
in ganglion cells.113 RGCs strained by stretching on a
silicone substrate, or swollen with hypotonic solution,
released ATP. This release was inhibited by pannexin
blockers carbenoxolone, probenecid and inhibitory
peptide, 10Panx, implicating the pannexin channel in
the efflux. Importantly, this mechanosensitive release
came from isolated immunopanned cells, identifying
RGCs themselves as a cellular source of releasable
ATP. Whole cell ion currents activated by swelling
were reduced by pannexin channel blockers by
removal of extracellular ATP with apyrase or by
P2X7R blockers A438079, AZ10606120 and zinc.
Together, these observations strongly support a
model whereby the mechanosensitive release of ATP
through pannexin channels on RGCs autostimulates
P2X7 receptors on the cells.
The consequences of this mechanosensitive auto-
stimulation are likely to be more complex than
originally thought. Although stimulation of the
P2X7R is widely associated with cell death, the
expression of pannexins114 and P2X7 receptors115,116
in healthy adult RGCs suggests that death is not a
necessarily consequence of receptor stimulation.
However, the massive ATP release that accompanies
excessive mechanical strain may push the system into
a pathological state. The location of the pannexin/
P2X7 receptors may also influence the function of this
mechanosensitive ATP release and autostimulation.
According to immunohistochemical analysis, Panx1
and P2X7 proteins are expressed on both the soma
and neurites of isolated ganglion cells.113 As much of
the mechanical strain in glaucoma occurs at or near
the optic nerve head,117 expression of this mechan-
osensitive signaling pair along neurites suggests the
system may translate strain in the optic nerve head to
local damage in ganglion cell axons.
THE ROLE OF PANNEXIN1-
ACTIVATED PATHWAYS IN RGC
INJURY
The Panx1 protein forms large non-selective mem-
brane channels and is implicated in paracrine signal-
ing and regulation of the inflammasome. Compared
to connexin hemichannels, Panx1 channels are less
sensitive to extracellular Ca2þ, and open when intra-
cellular Ca2þ increases, suggesting them to serve as an
additional pathway for Ca2þ influx across membrane
in pathological conditions.118–120 Importantly, Panx1
membrane channels have superior permeability to
ATP, which prompted referring to them as ‘‘the ATP
channels’’ suitable for paracrine signaling in astro-
cytes, neurons and other cell types.88 As described
above, pannexins are implicated in massive ATP
release by glial and blood endothelial cells is typically
observed in various pathologies.89–92 Moreover, Panx1
channels were shown to regulate the inflamma-
some.121,122 The Panx1-mediated pathway activates
faster in pathogenic conditions, i.e. after stress, injury
and cytokine exposure, when cells were shown to
decrease the number of gap junctions in the plasma
membrane in favor of hemichannels made of either
connexins or pannexins.123–125 Mechanistically, the
abnormal opening of Panx1 channels is facilitated by a
combination of pathogenic stimuli typically released
after stress or injuries, including mechanical stress,
extracellular Kþ, ATP, glutamate, cytokines and Zn2þ
and proteolysis by active caspase-3.109,126–129
Recent studies utilizing gene knockdown and
knockout mouse models suggested that Panx1 plays
a key role in ischemic death of multiple types of
neurons.130,131 Several reports showed that over-
stimulation of the Panx1 channels facilitate neuronal
loss in models of stroke, glaucoma, retinal ischemia,
spreading depression and enteric colitis.99,130–135




































































Because RGCs express high levels of Panx1 and are
extremely susceptible to ischemic injury, we tested the
hypothesis that activation of Panx1 directly facilitates
rapid and selective loss of RGC neurons in ischemia.
Our data generated using the Panx1 knockout mice,
which are significantly protected from ischemic injury,
showed that two distinct neurotoxic processes are
mediated by these channels in ischemic conditions.130
As revealed by dye transfer and calcium imaging
assays, one mechanism involves permeation of RGC
plasma membranes. This causes an imbalance of small
molecules, and, in particular, an influx of Ca2þ and the
efflux of ATP.130,132,136 Ca2þ overload, which activates
Ca2þ-dependent proteases and facilitates apoptosis,
can occur directly via Ca2þ-insensitive Panx1 channels
(Figures 1 and 2). In addition, an opening of Panx1
channels can occur via the P2X7R-dependent mech-
anism in response to several external and internal
stimuli of physiological or pathological nature, which
prompted researchers to name P2X7R-Panx1 a ‘‘death
complex’’.99,120,137–139 It is plausible that prolonged
opening of Panx1 can be triggered by a combination of
pathological factors such as increases in extracellular
concentration of known agonists including ATP, Kþ,
Zn2þ, glutamate and pro-inflammatory cytokines.
67,109,124,128,140 Such a combination is common in
retinal or brain ischemia (stroke) and other CNS
injuries.99,130,131
The second process that is interrupted in the Panx1
knockout is the activation of caspase-1 and inflamma-
some-mediated production of IL-1b and IL-18.84–86
The inflammasome is a macromolecular complex, first
characterized in macrophages108,141 and, more
recently, in glia and neurons.122 The well-known
pathway for transcriptional activation of IL-1b and
IL-18 genes involves stimulation of TNF and Toll-like
receptors (TLRs),28,142–146 which causes the activation
of NF-kB (nuclear factor kappa-light-chain-enhancer
of activated B cells)-dependent gene transcription
(Figures 2 and 3). Thus, production of these ILs
depends on two independent pathways: (1) transcrip-
tional activation via the NF-kB pathway and (2)
proteolytic processing of IL precursors by the
inflammasome.
How does Panx1 contribute to inflammasome acti-
vation? One feasible mechanism is a direct interaction
with the inflammasome complex that facilitates pro-
teolytic processing of caspase-1 and results in Il-1b
release, as reported by Pelegrin and Surprenant.141 The
second mechanism of Panx1-mediated inflammasome
activation involves transcriptional activation of IL-1b,
since the large pore of the Panx1 channel can provide a
gateway for the entry of pro-inflammatory molecules
into the cell, leading to stimulation of intracellular
membrane receptors such as TLR3.86,108,141 TLR3, as
well as surface receptors TLR4 and TNFR, cause
transcriptional activation of NF-kB (Figure 2) and
have been recently implicated in several
neurodegenerations, including glaucoma.147–149 In
a similar fashion, the activation Panx1 and,
subsequently, the inflammasome can be triggered via
stimulation of P2X7 receptors by extracellular
ATP.150,151 It was demonstrated that Panx1 is essential
for P2X7R-induced proteolytic cleavage of caspase-1
and subsequent IL-1b maturation/release, which can
be blocked by pharmacological blockade of the Panx1
channels with small interfering RNA, mimetic peptide
or carbenoxolone.108,121,151,152 Likewise, genetic abla-
tion of Panx1 resulted in a robust neuroprotection in
mouse models of enteric colitis and traumatic brain
injury.39,43 Importantly, a study of neuron-specific
Panx1 knockout mice demonstrated that Panx1-
mediated neurotoxicity is facilitated by the endogen-
ous, neuronal inflammasome.84,122 Neuronal types
expressing high levels of Panx1, such as RGCs, are
vulnerable to Panx1-mediated death in response to
certain pathological and pro-inflammatory stimuli.
Opening of Panx1 channels was shown to be inde-
pendent of TLR activation.86 Combined with our own
results,130 this finding allowed us to propose a model
where Panx1 acts in parallel, not downstream of
TLRs. This model implies synergy between the
MyD88-NF-kB pathway and Panx1-mediated pro-
cesses for IL-1b processing and secretion. Indeed,
cytokine maturation appears to be a crucial step in
the neurotoxic pro-inflammatory program that is
activated in injured CNS via the MyD88-NF-kB path-
way.122,130,153 Consistent with our hypothesis, the
extent of neuroprotection in Panx1 knockout mice is
similar to that observed in the knockouts of caspase-1,
P2X7 receptor, TNF receptors 1/2, TLR3/4 and condi-
tional knockouts of NF-kB.130,142,154–158 In a similar
fashion, pharmacological blockade of P2X7R, NALP1/
3 or ASC subunits of inflammasome showed robust
neuroprotection in various CNS injuries,84,85,151,159 a
strong evidence for neurotoxic effects of inflamma-
some activation.
TNFR and TLR Signaling Promote
Inflammation through NF-iB, Driving RGC
Degeneration
Increased glial production of TNF-a in the glaucomat-
ous human retina and optic nerve has been implicated
in RGC death and inflammatory processes through
the TNFR signaling.28,160–162 High-throughput charac-
terization of the retinal proteome has recently indi-
cated a prominent up-regulation of TNFR-mediated
apoptosis pathway and inflammation signaling in
human glaucoma.161 Retinal proteins exhibiting
increased expression in glaucoma have included
TNF-a, TNFR1 and various downstream adaptor/
interacting proteins, such as TNFR1-associated death
domain protein (TRADD) and the members of the
TNFR-associated factor (TRAF) family, and protein
Membrane Receptors and Channels in RGC Pathologies 7



































































kinases involved in TNF-a/TNFR1 signaling.
Proteomics data support that a complex crosstalk
relationship between multiple signaling pathways
determines diverse bioactivities of TNF-a.28 Besides
the proteolytic caspase cascade, co-activation of
calpain-mediated pathways, mitochondrial dysfunc-
tion and endoplasmic reticulum stress may reinforce
each other during RGC apoptosis in glaucoma.
Regarding TNFR-mediated inflammation signaling,
proteomics analysis of the glaucomatous human
retina has produced data supporting NF-kB activa-
tion, JAK/STAT signaling and inflammasome assem-
bly.161 Proteomics analysis of RGC and astrocyte
samples has also showed cell-specific regulation of
TNF-a signaling in experimental glaucoma, such as
caspase activation leading to apoptosis in RGCs, but
NF-kB activation promoting cell survival and inflam-
mation in astrocytes.162 In addition, the type of
receptor preferentially used is important in determin-
ing the outcomes of TNF-a signaling. This multifunc-
tional cytokine can bind two different receptors of the
TNFR superfamily, TNFR1 (p55) and TNFR2 (p75).
TNFR1 appears to be the primary receptor for both
neurodegenerative and inflammatory consequences of
TNF-a signaling in glaucoma.161 This is because a
death domain present on the intracellular region of
TNFR1, but not present in TNFR2, leads to apoptotic
cell death, while signaling through TNFR2 leads
primarily to cell proliferation. TNFR1 is also the
primary signaling receptor responsible for the major-
ity of TNF-a-mediated inflammatory responses, par-
ticularly those mediated by the soluble TNF-a
required for inflammation.28,163
The glaucomatous human retina also exhibits up-
regulation of TLR signaling149 (Figures 2 and 3).
Innate immune activity in the CNS can be triggered by
numerous pathways after recognition of invading
pathogens or tissue stress/injury by pattern recogni-
tion receptors,164 which include TLRs and nucleotide-
binding oligomerization domain-like receptors
(NLRs). Although TLRs are membrane-spanning
receptors, NLRs are cytoplasmic sensors that form a
platform for the assembly of the inflammasome, a
multiprotein complex that processes pro-ILs into their
mature forms via proteolytic cleavage by caspase-1,165
as is evident in glaucoma.161,162 TLRs recognize a
wide variety of pathogen-associated molecular pat-
terns and also the DAMPs expressed during tissue
stress or injury.166 Recent proteomics studies of
human glaucoma and animal models have revealed
that glial cells, including both microglia and astroglia,
are the main cell types that express a repertoire of
TLRs, as well as several inflammasome-related mol-
ecules.149,162 In addition, there is in vitro evidence
FIGURE 3 Retinal signaling and cellular remodeling mediated by TLR, TNF and immune molecules involves neuronal-glial circuits.
The activation of TLR4, TNFRs and TCRs can promote NF-kB-regulated transcription, generating pro-IL-1b, which is then processed
into IL-1b and secreted. This drives glial reactivity and furthers inflammation (e.g. the release of more TNF-a), thus perpetuating the
inflammatory cycle. As RGCs are damaged and killed, they may release DAMPS (e.g. certain HSPs) that activate innate immune
receptors such as TLR4 and thereby worsen glaucoma. The activation of TCR/CD3 may be involved in glaucomatous dendritic
remodeling, which may disturb normal circuit functions and degrade the fidelity of visual processing.




































































indicating that glaucomatous stress-related intrinsic
ligands, such as heat shock proteins (HSPs) and
oxidation products, can activate glial TLRs and
stimulate T cells.149 After recognizing specific molecu-
lar patterns, TLRs recruit adaptor proteins, such as
MyD88, and activate NF-kB (Figure 2), a major
transcription factor for the expression of pro-inflam-
matory cytokines.167 Proteomic data from human
glaucoma and animal models, along with the findings
of in vitro treatment experiments, support the notion
that the glial TLR signaling initiated by glaucomatous
stress-related ligands includes MyD88-dependent
pathways.149
NF-kB activation after binding TNFRs and TLRs
triggers the transcriptional activation of pro-ILs that
are processed into their active forms by the inflam-
masome.165 Glaucomatous retinal proteome exhibits
increased glial expression of specific kinases
involved in the NF-kB activation pathway, such as
receptor-interacting serine-threonine kinase (RIPK),
NF-kB-inducing kinase (NIK), and inhibitory kappa
B (IkB) kinases (IkKs), including a master regulator,
IkKgamma (NF-kB essential modulator), and phos-
phorylation of NF-kB subunits, NF-kB1-p105/p50
and p65.161,162 Although NF-kB regulates neuronal
survival programs, including in the retina and optic
nerve,168 this transcription factor is a master regula-
tor of the inflammatory responses leading to sec-
ondary neurodegenerative processes.167,169 The NF-
kB pathway may similarly play a major role in
regulation of glia-driven pro-inflammatory processes
during glaucomatous neurodegeneration.162 As
implicated in other neurodegenerative diseases,170
TNF-a/TNFR signaling, TLR signaling and the
inflammasome together exhibit the potent inflamma-
tory capacity with beneficial and detrimental out-
comes in glaucoma. NF-kB, as being a common
player of inflammation through TNFR or TLR
signaling, appears to be a promising treatment
target to provide immunomodulation in glaucoma171
and deserves further studies.
Function and Possible Mechanisms of
Activation of Immune Molecules in the
Retina
Recent studies demonstrated that genes typically
associated with the immune system, such as those in
the MHC and complements, are expressed by neurons
in various regions of the CNS, including retina, and
may play important roles in synapse formation during
normal development and pathogenesis in CNS dis-
eases.25,172–177 Consistent with this notion, genetic
deletion or mutation of a number of MHC class I
genes (such as a MHCI co-subunit b2-microglobulin
or a key component of MHCI receptor complex
CD3z), complements or complement receptors result
in the failure of development of the eye-specific
segregation of RGC axonal projections to the
dLGN.25,174,178,179 On the other hand, over-expression
of MHCI molecules caused effects on the retinogen-
iculate projections opposite to that of MHCI or
complement mutations.180 Furthermore, the expres-
sion of complements is up-regulated in glaucomatous
retinas,181 and over-expression of MHCI molecules
significantly enhanced the recovery of locomotor
abilities after spinal cord injury.181
The precise molecular mechanisms of how MHCI
molecules and complement cascade expressed by
CNS neurons are activated, and how they regulate
the normal development and pathogenesis of CNS
diseases are unclear. It was suggested that the
expression and activity of MHCI molecules and
complement cascade are regulated by neuronal
activity. Consistently, retinal activity was found to
regulate the level of mRNA of MHCI molecules in
the dorsal lateral geniculate nucleus (dLGN).173 In
retina, the effects of CD3z seem to be cell-type and
neurotransmitter-specific. Xu et al.,25 reported that
CD3z is specifically expressed by RGCs and mice
with genetic mutation of CD3z exhibited a selective
reduction of glutamate receptor-mediated synaptic
transmission of RGCs. It was also postulated that
activation of immune molecules in neurons could
produce similar intracellular signals as those gener-
ated in immune cells but with different ultimate
effects, such as altering synaptic development,
strength, neuronal morphology or circuit properties
downstream of synaptic activity25,182,183 (Figure 3). In
the immune system, activation of CD3z triggers
several downstream cascades, including a Ras-
MAPK pathway and actin-based cytoskeleton
reorganization, which regulates immune cell polar-
ization, migration and dendritic growth.184–186 It has
been shown that most components of these cascades
are expressed in the CNS and implicated in activity-
dependent synaptic plasticity.182,187 In addition,
direct activation of CD3z on hippocampal neurons
affects cell morphology by promoting dendritic
pruning through a tyrosine-based phosphorylation
signaling motif common to the immune system.172
Furthermore, neuronal activity in the retina is also
suggested to regulate the complement-dependent
activation of the resident immune cells in retina,
microglia, which in turn regulates the developmen-
tal remodeling of RGC axonal projection during
normal development through a process similar to
‘‘phagocytosis’’.178 Recent studies also implied that
retinal microglia might play an important role in
RGC death in glaucomatous retinal degener-
ation.188–190 These observations strongly support
the possibility that the immune molecules and
cells could regulate the neuronal structure and
function through mechanisms similar to those in
the immune system.
Membrane Receptors and Channels in RGC Pathologies 9




































































Analysis of signaling pathways associated with RGC
injury points at intracellular involvement of ubiqui-
tous messenger molecules such as Ca2þ and ATP,
which could participate in intrinsic mechanosensa-
tion and drive feedback pathways associated with
secondary glial and vascular mechanisms. Because
[Ca2þ]i maintenance is critically important for the
regulation of excitability, cytoskeletal integrity,
metabolism and synaptic function, disruption of
Ca2þ homeostasis would ultimately lead to anatom-
ical and physiological remodeling observed in glau-
coma. Recent evidence suggests that such Ca2þ
overloads in RGCs could be mediated by TRPV4,
P2X7R and/or pannexin channels. The effect of
mechanical stress on resident mechanosensitive
channels has to be placed within the larger context
encompassing secondary inflammatory and immune
responses driven by feedback loops between injured
RGCs, astrocytes, microglia and the vascular endo-
thelium. Inflammatory cytokines and complement
molecules released from glial and endothelial cells
could drive the plasma membrane P2X7R-Panx1
complex as well as complex arrays of immune/
inflammatory signaling molecules that might include
TNF-a, IL-1b, Toll-like and T-cell receptors. The
ensuing reconfiguration of intracellular signals is
proposed to involve the NF-kB pathway and activa-
tion of the inflammasome complex.
Current glaucoma treatments are limited to mini-
mization of mechanical impact mediated by elevated
IOP and lack tools that would protect RGCs by
targeting the mechanosensing mechanisms and/or
secondary inflammatory/immune pathways within
the retina. Thus, development of novel neuroprotec-
tive treatments depends on our ability to characterize
the force transduction mechanisms that mediate
retinal IOP sensing (TRPV4, Panx1 and P2X7R dis-
cussed here) together with the role of secondary
interactions between RGCs and the surrounding
vascular endothelial cells, pericytes, astrocytes,
Mu¨ller cells and microglia.
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a b s t r a c t
The DBA/2J (D2) and C57BL6 (B6) mouse strains are widely used in research as models for anxiety,
addiction and chronic glaucoma. D2, but not B6, animals develop elevated intraocular pressure (IOP) that
leads to progressive degeneration of retinal ganglion cell (RGC) axons and perikarya. Here we compare
the expression and localization of intracellular ryanodine receptor (RyR) Ca2þ store mechanisms in
retinas from D2 and B6 animals. A subset of experiments included retinas from D2-Gpnmbþ mice as
strain-speciﬁc controls for D2s. RT-PCR analysis showed 6e8 -fold upregulation RyR1, but not RyR2 or
RyR3 transcripts, in D2 retinas. The upregulation was more pronounced in D2 retinas categorized as
exhibiting moderate or severe glaucoma eyes compared to eyes with no/little glaucoma. In B6 retinas,
RyR1 was expressed in neuronal perikarya/processes across all three retinal layers whereas little labeling
was observed in astrocyte, microglial or Müller cell processes. In contrast, RyR1 antibodies strongly
labeled radial processes of in D2 Müller glia, in which the staining colocalized with the activated glial
stress marker GFAP. RyR1 staining in 1 month-old D2-Gpnmbþ strain resembled expression in B6 retinas
whereas moderate RyR1, but not GFAP, localization to Müller glia was observed in 10e12 months e old
D2-Gpnmbþ eyes. Both RyR1-ir and GFAP-ir were augmented in the microbead injection model of acute
experimental glaucoma. We conclude that RyR1 exhibits differential expression and localization in two
ubiquitously used mouse lines. While RyR1 signals can be regulated in a strain-speciﬁc manner, our data
also suggest that RyR1 transcription is induced by early glial activation and/or elevation in intraocular
pressure.
! 2011 Elsevier Ltd. All rights reserved.
1. Introduction
It is increasingly evident that glaucoma is a multifactorial
disease involving complex interactions between multiple genes,
vascular factors, innate and adaptive immune system and envi-
ronmental factors (Gordon et al., 2002). Many features of the
human disease have been replicated in mouse models of chronic
glaucoma. Themost widely used DBA/2J (D2) strain is characterized
by recessive mutations in Gpnmb (GpnmbR150X) and Tyrp1
(Tyrp1b) genes which cause an increase in IOP at >6 months (John
et al., 1998; Libby et al., 2005). D2 animals consequently express
a phenotype that is similar to the chronic age-related glaucoma in
humans with increased intraocular pressure (IOP), progressive
degeneration of retinal axons, loss of RGC perikarya, glial activation,
retinal remodeling and excavation of the optic nerve head
(Anderson et al., 2002; Danias et al., 2003; Libby et al., 2005; Soto
et al., 2008).
The D2 phenotype includes multiple contributions from genes
that are distinct from the two mutations that regulate aqueous
outﬂow in the anterior chamber. For example, the D2 strain varies
from the B6 strain that is commonly used as a “wild-type” strain in
terms of anxiety, locomotor behavior, visual behavior,
hippocampus-dependent learning performance, addiction, water
consumption, life span and susceptibilities to a wide variety of
stresses (Belzung and Griebel, 2001; Lucki et al., 2001; Puk et al.,
2008; Barabas et al., 2011). At least 77 genes and ESTs show >1.5-
fold mean increase in brains of adult B6 compared to D2 mice,
with particular changes in genes that regulate signaling pathways,
gene regulation and metabolism (Misra et al., 2007; Singh et al.,
2007). With respect to calcium regulation, B6 and D2 tissues
differ in expression of several Ca2þ-associated proteins that include
ionotropic glutamate receptors (NMDA2B), voltage-operated Ca2þ
* Corresponding author. Tel.: þ1 801 213 2777; fax: þ1 801 587 8314.
E-mail address: david.krizaj@hsc.utah.edu (D. Kri!zaj).
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channels, calcium/calmodulin-dependent protein kinase II (Cam-
KII), calcineurin phosphatases, inositol triphosphate receptors and
a MAP kinase (Esplin et al., 1994; Grice et al., 2007). We focused on
ryanodine receptors (RyRs) which play a crucial role in neuronal
function as well as in the etiology of neurodegenerative diseases
such as Alzheimer, Parkinson’s, Huntingdon’s diseases and spino-
cerebellar ataxia (Guo et al., 2011; Kasumu and Bezprozvanny, in
press). Ca2þ release from ryanodine stores ampliﬁes Ca2þ-depen-
dent signals induced by voltage-operated, glutamatergic and
purinergic signals resulting in increased excitability of neuronal/
glial cells (Nedergaard et al., 2010). Given that ryanodine signaling
in optic astrocytes is directly activated by hydrostatic pressure
(Mandal et al., 2010) and that D2 animals develop glaucoma
following persistent elevation in IOP (John et al., 1998; Libby et al.,
2005; Soto et al., 2008), it would seem important to determine
whether RyR expression and cellular localization are affected in D2
mice. Because the expression and localization of ryanodine receptor
isoforms in the mouse retina are not known, we ﬁrst compared the
abundance of RyR transcripts in B6 and D2 retinas and determined
the localization of the two main retinal RyR isoforms in the mouse
retina. We also tested the hypothesis that the dramatic phenotype
observed in D2 animals derives, in part, from elevation in IOP.
Our data show that the two strains exhibit marked differences in
the expression of genes coding for RyR1, but not RyR2 or RyR3,
isoforms. The D2 phenotype was associated with a shift in RyR1
expression to activated Müller astroglia. Similar shifts were
observed following experimental elevation of IOP, suggesting that




Animals were maintained in a pathogen-free facility under a 12-
hour lightedark cycle (Utah) and 14 h light/10 h dark cycle (Jack-
son) with standard rodent chow available ad libitum. D2 and D2-
Gpnmbþ mice were obtained from The Jackson Laboratory and/or
from Dr. Simon John’s (JAX) colony. The D2-Gpnmbþ mice are
homozygous for a wild-type allele of Gpnmb on a D2 genetic
background. The strain develops iris disease similar to that in D2s
but does not develop increased IOP or axonal degeneration (Howell
et al., 2007). In contrast, aging D2 animals show progressive loss of
RGCmarkers and loss of RGCs (John et al., 1998; Howell et al., 2007;
Barabas et al., 2011). All experiments adhered to the NIH Guide for
the Care and Use of Laboratory Animals and the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research and were
approved by the Institutional Animal Care and Use Committee at
the University of Utah.
2.2. Semiquantitative RT-PCR
Total RNA from retina was extracted with Trizol and total RNA
was converted to cDNA using the SuperScript III First-Strand
Synthesis kit from Invitrogen. Real-time PCR was performed on
a thermocycler (GeneAmp 5700; ABI, Foster City, CA) using Power
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA)
reagents according to the manufacturer’s instructions. Table 1 lists
the primers used. Two sets of primers were used for identiﬁcation
of the RyR1 isoform. After ampliﬁcation, the ratio of gene-of-
interest mRNA to glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) reference gene was calculated for each sample. A random
sample at in the 1-month cohort was assigned a value of 1 and
other values calculated relative to the sample. Every experiment
consisted of samples from at least 5 animals, each gene was studied
in 3e5 separate experiments.
2.3. In situ hybridization
In situ hybridization and probe synthesis were performed as
described previously (Punzo and Cepko, 2007). Sp6 RNA poly-
merase was used to generate the probes by sub-cloning part of the
coding sequence into pGEMT-Easy (Promega). The forward primer
for RyR1 was: AGAGGGCGATGAAGATGAGAA; reverse primer:
AAGATGTCCCCGTGTTTGTC. The forward primer for RyR2 was
AAACACCAGCCTTCGGAGTA; the reverse primer was TAGCCAAA
GATGGGAAGGTG (Table 1). For cryosections, the eyes were
dissected in PBS (0.1 M Phosphate Buffer solution), ﬁxed in 4% PFA
(Paraformaldehyde)/PBS at RT, washedwith PBS and equilibrated in
10 min steps of increasing concentrations of sucrose (5e30%). The
tissue was embedded in 1:1 mixture of OCT and 30% sucrose in PBS
for 15min and freeze dryed in dry ice/ethanol. For parafﬁn sections,
retinas were ﬁxed for 30 min in 4% PF/PBS at RT, washed with PBS
and dehydrated to 100% ethanol using a ladder of increased EtOH
concentrations before embedding in 50/50 xylene/parafﬁn (60 "C;
15 min) and 100% parafﬁn (4 # 30 min at 60 "C).
2.4. Tonometer measurements
IOP was measured inmice between 10:00 AM and 1:00 PMwith
the TonoLab rebound tonometer (Colonial Medical Supply, Fran-
conia, NH/Tyolat, Helsinki, Finland). Mice were sedated with
intraperitoneal injection of Avertin with ﬁnal amount calculated by
weight (e.g., 0.5 ml for 21e24 g animals). Animals were placed on
a jack stand platform and the tonolab was clamped on a ring stand
and centered onto the mid-cornea. During measurements animals
were neither restrained nor touched. Each eye was measured
twenty consecutive times, the highest and lowest values were
discarded and the values were averaged. At 1 month, the pooled
mean IOP for D2 eyes was not signiﬁcantly different from B6 eyes
(12.80$ 0.55 vs.12.08$ 0.64mmHg). At 9months, IOP levels in D2
eyes were signiﬁcantly increased with respect to B6 eyes
(21.50 $ 1.58 vs. 11.0 $ 0.66 mm Hg, N ¼ 15; P < 0.001; Manne
Whitney unpaired test).
2.5. Immunohistochemistry
Immunostaining followed previously described protocols
(Rentería et al., 2005; Ryskamp et al., 2011). Fixed transverse
sections of the retina were washed in PBS for 15 min before per-
meabilization and blocking with 0.5% Triton X-100 and 10% goat
Table 1
List of forward and reverse primers used for RT-PCR analysis. The RyR1 gene was
tested with two separate sets of primers.
Gene Forward Reverse
Gapdh ACT TCA ACA GCA ACT
CCC ACT CTT C
GGG TGG TCC AGG GTT TCT TAC TC
RyR1-A AGT CAA GAC GCT CCG
CAC CAT C
GGC TCG TCC TCA TCT TCG CTC TT
RyR1-B TAC TTC GAC ACA ACC
CCA CA
ACA GTC TCC AGC AGG GAA GA
RyR2 CTA CCC GAA CCT CCA
GCG ATA CT
GCA AAA GAA GGA GAT GAT GGT GTG
RyR3 ATG AGC CGG ATA TGA
AGT GTG ACG A
TGA ATG ATG GCC AGC AAG ATG AC
Brn3a AGA GAC AGA AGC AGA
AGC GGA TGA
GCC CCC AAA TGA GAG CAG AAA CTT
Gfap GGA CAT CGA GAT CGC
CAC CTA CAG
TGA CCT CAC CAT CCCGCA TCT C
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serum. The slides were incubated with primary antibodies in the
blocking solution for 4 h at RT, washed twice in PBS and subse-
quently incubated for 4 h with secondary antibodies. The primary
antibodies utilized in the study were anti-RyR1 (rabbit polyclonal;
1:100, Millipore/Chemicon AB9078, Temecula, CA) raised against
a peptide from human RyR1; as per manufacturers datasheet, in
Western blots the antibody produces a band at the appropriate
M.W. (also, see Medina-Ortiz et al., 2007). The anti-RyR2 (rabbit
polyclonal; Millipore/Chemicon AB9080) antibody was derived
from a synthetic peptide based on human protein and has been
characterized previously (García-Pérez et al., 2008). The anti-GFAP
(mouse monoclonal; 1:500; Sigma); anti-glutamine synthetase
(mouse monoclonal; 1:1000; BD Biosciences) and anti-Brn3a
(mouse monoclonal; 1:100; Santa Cruz Biotechnology) have been
well characterized. The secondary antibodies were goat anti-mouse
or goat anti-rabbit IgG (H þ L) conjugated to ﬂuorophores (Alexa
488 and Alexa 594; Invitrogen), diluted 1:500 or 1:1000, goat anti-
mouse Cy3 from Jackson ImmunoResearch at 1:1000 or Mac1-
CD11b-AlexaFluor 488 from BD Pharmingen at 1:200. After incu-
bation, sections on slides were washed in PBS and mounted using
Vectashield (Vector, Burlingame, CA). Negative controls without
a primary antibody showed no staining. Immunoﬂuorescent and
differential interference contrast (DIC) images were acquired at
depths of 12 bits on a confocal microscope (Zeiss LSM 510) using
488 nm Ar (10%) and 594 nm He/Ne (100%) lines for ﬂuorophore
excitation, suitable band-pass or long-pass ﬁlters for emission
detection and 40"/1.2 NA oil objectives. The analysis was per-
formed in sections obtained from at least 3 animals at each age
examined.
2.6. Microbead injection
The injection protocol roughly followed the procedure
described in Chen et al. (2011). During the week prior to microbead
injection, IOP was measured two or three times to establish
a baseline. In preparation for the microbead injection procedure,
pupils were dilated with 1% tropicamide (Bausch & Lomb,
Rochester, NY) and mice were deeply sedated with an intraperi-
toneal injection of Ketamine/Xylazine (90 mg/10 mg per kg body
weight). Heat pads were used to maintain body temperature. 0.5%
proparacaine (Bausch & Lomb) was applied to the eyes for topical
analgesia. The cornea was punctured with a sharp needle and some
of the aqueous humor was gently drained. Using a 5.0 ml syringe
(Hamilton; Reno, NV), 2 ml of a microbead solution (polystyrene
FluoSpheres with diameter of 15 mm at a concentration of
1 " 107 beads/ml in PBS; Invitrogen) was slowly injected into the
anterior chamber of a randomly selected eye. 2 ml of PBS was
injected into the other eye of each mouse as an internal control.
Injected eyes were treated with 0.5% erythromycin (Bausch &
Lomb) and mice were closely monitored until consciousness was
regained. Mice were allowed to recover for 72 h before biweekly
IOPmeasurements resumed. Of 10 eyes injectedwithmicrobeads, 3
showed a persistent elevation in IOP compared to PBS-injected
contralateral controls. These three were used for data shown in
Fig. 7.
2.7. Axon damage assessment
The severity of glaucoma was assessed in PPD-labeled nerves
using an established grading scheme (Howell et al., 2007). Eyes
were classiﬁed with no or early (no detectable axon damage/loss
compared to B6), moderate (10e50% damage) or severe (>50%
damage) glaucoma. The total number of examined retinas was
No/Early glaucoma (9 months, N ¼ 8; 12e15 months, N ¼ 3);
Moderate (9 months, N ¼ 3; 12e15 months, N ¼ 3), Severe glau-
coma (9 months, N ¼ 2; 12 months, N ¼ 4; 15 months, N ¼ 4).
3. Results
In this study, we employed two strategies to gain deeper insight
into the expression and distribution of intracellular transport
mechanisms in the D2 retina. Semi-quantitative reverse tran-
scription (RT)-PCR was used to compare total retinal mRNA content
of transcripts coding for ryanodine receptor Ca2þ release channels
in B6 and D2mice. In the second approach, in situ hybridization and
immunohistochemistry were used to identify the retinal localiza-
tion of RyR1, the intracellular Ca2þ release channel that exhibited
the most prominent upregulation of transcription in D2 retinas.
3.1. RyR1 signals in the B6 retina
Real-time PCR on cDNAs isolated from intact tissue showed that
mRNA for RyR isoform 1 is transcribed in the B6 strain (Fig. 1A). The
RyR1 antisense probe showed prominent signals within the inner
nuclear (INL) and ganglion cell layers (RGCL) (Fig. 1B).
Broadly consistent with in situ hybridization results, RyR1
protein was localized across all retinal strata, along neuronal cell
bodies in INL and RGCL and in dendrites and axons within the IPL
and NFL (Fig. 1C). While RyR1 signals were never observed in outer
segments (OSs) of rods or cones, RyR1 immunoreactivity (ir) was
more pronounced in the ellipsoid/inner segment region (Fig. 1C,
arrowheads) and was also observed in the ONL. RyR1-ir was
stronger in the IPL sublamina a compared to sublamina b, sug-
gesting that RyR1-mediated Ca2þ release could be disproportion-
ately associated with OFF retinal signaling. RyR1 staining
colocalized with the RGC marker Brn3a (Fig. 1D). Consistent with
previous observations in spinal motoneurons (Ouardouz et al.,
2003), RyR1 signals were observed in the nerve ﬁber layer prox-
imal to RGC somata and in unmyelinated axonal projections
entering the ONH (Fig. 1C and D). Staining of the astrocyte-rich
lamina that represents the transition zone from the ONH to the
optic nerve was lower compared to the NFL, the proximal ONH and
themyelinated portion of the nerve vitread from the retina (Figs. 1C
and 2A). Axonal staining in B6 retinas was distinct from glutamine
synthetase (GS)- and Glial Fibrillary Acidic Protein (GFAP) signals
localized to Müller cell and astrocyte processes at the ILM
(Fig. 1EeG). Given the recent demonstration of the protective role
of complement inhibition in glaucomatous degeneration (Howell
et al., 2011) we also tested whether RyR1s are localized to retinal
microglial cells. However, no colocalization was observed between
RyR1 and Mac-1:AlexaFluor-488 immunolabeled cells residing in
the IPL (Fig. 1H).
B6 sections almost never evinced GFAP-ir in the IPL/INL or the
ONH whereas the RyR1 antibody strongly labeled the NFL entering
the optic cup (arrowheads in 2A) and ﬁbers within the optic nerve.
Accordingly, little colocalization with glutamine synthetase or
GFAP was observed in the ONH (Fig. 2B). RyR1 labeling of the
astrocyte-rich prelaminar region was always weak.
3.2. RyR1 signals in D2 and D2-Gpnmbþ retinas
D2 retinas expressed RyR1 mRNA (Fig. 3A) which was localized
mainly to the INL (Fig. 3B). Retinas with severe glaucoma exhibited
a trend towards higher RyR1 mRNA content compared to retinas
with no or early glaucoma, almost reaching signiﬁcance with
respect to Severe vs. No/Early glaucoma (Fig. 3C).
In contrast to the highly uniform and reproducible immuno-
staining pattern in B6 retinas, RyR1 signals in D2 retinas were
variable in terms of neuronal vs. glial expression. The anti-RyR1
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antibody labeled thin radial processes in the inner retina of 9
month-old D2 animals with no detectable axonal loss (“no or early
glaucoma”) (arrowheads; Fig. 3Di). Such RyR1-ir processes, which
were rarely labeled in B6 retinas, extended from the ILM towards
the OPL. These signals colocalized with glutamine synthetase
(Fig. 3H) and GFAP (Fig. 3D and F), an intermediate ﬁlament which
represents an early glial marker for retinal stress and is upregulated
in Müller cells following acute or chronic elevation in IOP
(Lam et al., 2003; Xue et al., 2006). The intensity of RyR1-ir and
GFAP-ir in radial processes appeared to be accentuated in retinas
Fig. 2. B6 retinas, RyR1 expression in the optic nerve head. (A) The RyR1 antibody labels the retinal nerve ﬁber layer (NFL; arrowheads), the ONH (arrow) and the myelinated
portion of the optic nerve whereas RyR1 expression in the astrocyte lamina is modest. Scale bar ¼ 100 mm. (B) Double labeling for RyR1 and GS shows little GS signal within the ONH
of the B6 retina. Scale bar ¼ 10 mm.
Fig. 1. RyR1 gene expression, mRNA and protein distribution in the B6 retina. (A) Amplicons for RyR1 and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) isolated from the
total retinal pool and separated on a 20% agarose gel. (B) In situ hybridization analysis of 12 month-old B6 retinas exposed to RyR1 antisense probes. The reaction product is localized
to perikarya in INL and RGC layers. Weak labeling is seen in the ONL, with the labeling of rod inner segments by the antisense probe. Radial processes spanning the retina are weakly
labeled. Scale bar ¼ 50 mm (C) RyR1 localization in an adult (9 month-old) B6 retina. The RyR1 antibody labels rod ellipsoids and inner segments (arrowheads), perikarya within the
INL, RGCL and the IPL; RyR1-ir in the sublamina a is more pronounced compared to sublamina b. Scale bar ¼ 20 mm (D) 12 months-old retina. RyR1 signal in the RGCL colocalizes
with the RGC marker Brn3a. (EeG) 15 months-old retina. RyR1 signal in the RGCL and ILM shows little colocalization with glutamine synthetase (GS) or GFAP. Scale bar ¼ 10 mm
(H & I) RyR1-ir does not colocalize with the microglial marker Mac-1. Scale bar ¼ 20 mm in H, 10 mm in I.
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classiﬁed into ‘moderate’ (N ¼ 6) and ‘severe’ (N ¼ 12) axonal
degeneration categories (Fig. 3EeI). In extreme cases of severe
glaucoma, retinas exhibited characteristics typical of Phase 3
‘remodeling’ (Marc et al., 2003) with disappearance of RGC/dis-
placed amacrine perikarya, depletion of the INL and hypertrophy of
glial processes which encased the remaining neuronal perikarya
and reinforced both retinal laminas (OLM & ILM; Fig. 3I). In such
remodeled retinas, glial processes appeared to lose the RyR1 signal
(Fig. 3Ii and ii), however, the sample sizewas limited (N¼ 2 animals
at 15 months of age with severe glial hypertrophy). Intensity of
RyR1-ir in radial processes varied between individual retinas
within each category; panels E and F display retinal sections from
two eyes withmoderate glaucoma that exhibited different amounts
of RyR1 signal.
RyR1 staining in D2 eyes was emphasized in the ONH tissue
surrounding the ‘excavated’ area in moderate and severe glau-
comatous eyes (asterisk in Fig. 3K). We also investigated whether
RyR1 signals in glaucomatous eyes are upregulated in astrocytes in
addition to Müller glia. As shown in the inset of Fig. 3K, little
colocalization was observed between the astrocyte marker and
RyR1-immunopositive nerve processes within the optic lamina.
The appropriate control strain for D2 animals are D2-Gpnmbþ
mice which are homozygous for a wild-type allele of Gpnmb on the
D2 genetic background. Similar to D2s, D2-Gpnmbþ mice develop
iris disease but do not exhibit increased IOP or axonal degeneration
(Howell et al., 2007). Localization of RyR1 mRNA in D2-Gpnmbþ
retinaswas similar to signals observed in B6 andD2 retinas (Fig. 4B).
Likewise, the pattern of RyR1-ir and GFAP-ir in 1 month-old (N¼ 3)
and a subset of 10e12 month-old D2 -Gpnmbþ retinas resembled
the staining observed in B6 retinas (N ¼ 4/10) (Fig. 4C and D).
However, the majority of 10e12 month-old D2 -Gpnmbþ retinal
samples (6/10 animals) exhibited RyR1-ir within processes that
traversed the INL. These processes were GFAP-immunonegative
(data not shown) but colocalized with the Müller glial marker
glutamine synthetase (Fig. 4EeF). The intensity of RyR1-ir in such
D2-Gpnmbþ retinaswas similar to signals seen inNo/Earlyglaucoma
D2 retinas (Fig. 3D). In contrast to D2 tissue, however, GFAP
expression mirrored B6 signals in the majority of 10e12 month-old
Fig. 3. RyR1 expression in D2 retina. (A) PCR products for RyR1 and GapdhmRNA from the total retinal pool. (B) D2 retinas labeled by the RyR1 antisense probe. The reaction product
is localized to perikarya in INL and RGC layers. The antisense probe weakly labels the ONL, rod inner segments and radial processes spanning the retina. Scale bar ¼ 50 mm (C) RT-
PCR for RyR1, expressed aswfold change with respect to age-matched B6 retinas. (D) RyR1 and GFAP localization in No/Early glaucoma D2 retina. Some, but not all, radial RyR1-ir
processes expressed GFAP (arrowheads). (E) Moderate glaucoma retina, double labeled for RyR1 and BRN3a, a Z-stack from 12 consecutive sections. Scale bar ¼ 20 mm. (F) Moderate
glaucoma. There is an upregulation and partial colocalization of RyR1- and GFAP-ir processes in the IPL and the ILM/RGCL. Scale bar ¼ 20 mm. (G) Severe glaucoma, double labeled
for RyR1 and Brn3a. Scale bar ¼ 10 mm. (H) Severe glaucoma, retina labeled for RyR1 and glutamine synthetase. Scale bar ¼ 20 mm. (J) Severe glaucoma in a 15 month-old D2 retina
exhibiting glial hypertrophy and retinal remodeling. Scale bar ¼ 10 mm (J & K) ONH regions from two moderate glaucoma eyes. (J) The RyR1 antibody labels the NFL, ONH and the
myelinated region of the optic nerve. Scale bar ¼ 100 mm. (K) Moderate glaucoma. RyR1 signal surrounds the excavated region within the ONH (asterisk). Inset: Severe glaucoma.
Double labeling of the glial laminar region in the optic nerve shows modest colocalization between RyR1 and GFAP signals. Scale bar ¼ 10 mm.
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D2-Gpnmbþ eyes (N ¼ 8/10; Fig. 4D) whereas GFAP-ir processes
extending into the INLwere observedwithin circumscribed patches
of two D2-Gpnmbþ retinas (data not shown). With respect to RyR1
staining, differences between RyR1 staining in 10e12 months-old
D2-Gpnmbþ animals could reﬂect different animal subpopulations
and/or differential responses to the loss of Tyrp1b. Consistent with
the latter hypothesis that suggests aging-dependent stress associ-
ated with iris disease, RyR1-ir was more pronounced in Müller cells
from adult D2-Gpnmbþ samples compared to 1 month-old eyes.
3.3. RyR1 mRNA is upregulated in D2 retinas
The RyR family is comprised of 3 isoforms (RyR1-3) that are
ubiquitously expressed across neurons and glia. Real-time PCR on
cDNAs isolated from intact B6 and D2 tissue showed that mRNAs
for all 3 RyR isoforms are transcribed in both strains. RyR1 mRNA
levels in D2 retinas were consistently higher compared to B6
control retinas (Fig. 1). The upregulation was observed at 1 month
after birth (6.94 # 1.07 efold increase over WT; P < 0.01; Man-
neWhitney unpaired test) and persisted up to 15 months, the most
advanced age studied (5.33 # 1.01-fold increase; P < 0.01, Man-
neWhitney unpaired test) (Fig. 1A). To determine whether RyR1
upregulation was a strain-speciﬁc, was associated with elevated
IOP or loss of the Tyrp1b gene, we analyzed two time points in
retinas from D2-Gpnmbþ mice. RyR1 expression in D2-Gpnmbþ
retinas (N ¼ 4) was not signiﬁcantly different from B6 retinas at 1
month, but showed an increase at 5 months that was signiﬁcant
compared to B6 (N ¼ 8) and D2 (N ¼ 6) eyes (P ¼ 0.0003; one-way
ANOVA). Thus, at least in 1 month-old animals, transcription of
RyR1 is not affected by general strain-speciﬁc features and the
differences must lie downstream of the mutant Gpnmb gene
whereas RyR1 mRNA levels may be elevated in older animals,
possibly reﬂecting a strain-dependent or Tyrp1b-dependent
phenotype.
3.4. RyR1 is localized to glia in an acute glaucoma model
We next tested whether upregulation of RyR1 signals within
glial cells was an IOP-dependent process. IOP in B6 eyes was
elevated by injection of Alexa488 nm-conjugated microbeads
(Chen et al., 2011). Fourteen days following injection, the IOP was
elevated in injected eyes from 3/10 animals. In these eyes, the IOP
was 23.57 # 2.96 mm Hg compared to 12.93 # 1.40 mm Hg in PBS-
injected contralateral eyes (N ¼ 3; P ¼ 0.0047). GFAP immunore-
activity in Müller cells was enhanced in all microbead-injected eyes
that exhibited elevated IOP (Fig. 6B), consistent with increased
resistance tomechanical stress (Bringmann et al., 2009). In contrast
to GFAP signals in D2 retinas which often showed patches of strong
GFAP-ir interspersed with weaker staining, GFAP-ir in eyes exposed
to experimentally-induced IOP elevations appeared to be uniform
across the retina. Colocalization between GFAP and RyR1 signals
was observed in the proximal retina (Fig. 6B), suggesting that glial
activation in this glaucoma model is also associated with increased
expression of RyR1. Taken together, this data shows that develop-
ment of glaucoma is associated with isoform-speciﬁc changes in
expression of intracellular Ca2þ release channels.
Fig. 4. RyR1 expression in D2-Gpnmbþ retinas. (A) PCR products for RyR1 and Gapdh mRNA from the total retinal pool. (B) In situ hybridization signals in D2-Gpnmbþ retinas show
similar localization to B6 and D2 retinas. Scale bar ¼ 50 mm (C & D) 1 month and 12 months-old retinas, double labeled for RyR1 and GFAP show little colocalization. Scale
bars ¼ 20 mm (EeF) A subset of 11e12 months-old D2-Gpnmbþ retinas showed RyR1-ir signals within the ILM and IPL regions. These processes colocalized with glutamine
synthetase. Scale bars ¼ 10 mm.
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3.5. Expression and localization of the RyR2 isoform
is unchanged in the D2 retina
The antisense riboprobe localized RyR2 transcripts to INL, RGCL
and ONL regions (Fig. 7B). Similar to previously reported staining in
the rabbit (Shoshan-Barmatz et al., 2007), RyR2 signals in the
mouse were observed across all retinal layers with a predominant
labeling of Brn3a-immunopositive perikarya in the RGCL and the
nerve ﬁber layer (Fig. 7C and H). Localization of RyR2 in D2 retinas
was similar to the localization observed in B6 eyes (Fig. 7EeI). RyR2
staining in D2 retinas did not overlap with glutamine synthetase-ir
processes in the ONL (Fig. 7F) or GFAP-ir in the IPL (Fig. 7E), indi-
cating low levels of RyR2 expression in activated Müller glia. At
high confocal gains, weakly labeled RyR2-ir signals that were
difﬁcult to distinguish from background labeling were occasionally
observed in the IPL (Fig. 7I). This data suggests that RyR2 in the
mouse retina is a predominantly neuronal isoform.
In contrast to RyR1, expression of the RyR2 and RyR3 genes was
relatively unchanged between 1 month and 15 month-old retinas
of B6 and D2 eyes (Fig. 5B & C) excepting a transient increase that
was measured for RyR2 at 5 months (1.72 ! 0.15 -fold; N ¼ 3;
P < 0.001; KruskaleWallis nonparametric ANOVA). We also
compared expression of RyR2 and RyR2 genes in 5 month-old D2-
Gpnmbþ retinas (N ¼ 4 for each strain) and observed no signiﬁcant
differences in expression for RyR2 (P ¼ 0.3418, one-way ANOVA) or
RyR3 (P ¼ 0.7816; one-way ANOVA).
4. Discussion
In this paper we determined the localization of RyR1 and RyR2
channels in the mouse retina and compared their expression
between widely used “wild-type” B6 and “glaucoma model” D2
mouse strains. We show that expression and localization of RyR1,
but not RyR2, isoforms exhibit both strain-speciﬁc and IOP-
dependent features, suggesting that RyRs contribute to patholog-
ical remodeling of neuronal-glial interfaces in chronic glaucoma.
RyR1 riboprobes and anti-RyR1 antibodies labeled neuronal
perikarya together with cellular processes. This pattern of RyR1
immunoreactivity in the B6 mouse was largely consistent with
previously reported data from the rabbit retina (Shoshan-Barmatz
et al., 2007). In contrast to the rabbit in which the RyR1 antibody
labeled the outer segment, RyR1 and RyR2 signals in mouse
photoreceptors were mainly conﬁned to the ER-rich inner segment
and cell body regions. Thus, these channels are likely to participate
in the well-known feedback between voltage-operated channels,
ER and mitochondria (Kri!zaj et al., 2003). Another interesting
feature of RyR1 immunoreactivity in the B6 mouse retina was the
consistently stronger staining of the IPL sublamina b compared to
the sublamina a, possibly suggesting a more prominent role for
Ca2þ-induced Ca2þ release (CICR) in the retinal OFF pathway.
Retinal RyR1 mRNA content was increased w2.5-fold in 1
month-old D2 compared to B6 retinas, preceding the onset of iri-
docorneal angle closure, IOP elevation and degeneration of RGC
axons (John et al., 1998; Danias et al., 2003; Libby et al., 2005;
Inman and Horner, 2007). This effect was not observed in
previous microarray studies of retinal gene expression, most likely
because RT-PCR is more sensitive for detecting changes in gene
expression (Steele et al., 2006; Guo et al., 1999); however, at least
one study identiﬁed several genes associated with voltage-
operated Ca2þ entry and ER signaling which could participate in
CICR (Panagis et al., 2010). RyR1 upregulation in D2 retinas coin-
cided with increased levels of GFAP and early glial activation, which
precede the onset of increased IOP by several months (Inman and
Horner, 2007; Bosco et al., 2011). Several pieces of evidence
suggest that RyR1 expression could play a role in the pathogenesis
of glaucoma: (1) There was a consistent trend towards higher RyR1
mRNA transcript content in retinas categorized as expressing
moderate/severe glaucoma compared to no/early glaucoma; (2)
The abundance of RyR1 mRNA in D2 retinas was higher than in D2-
Gpnmbþ retinas; (3) The intensity of RyR1 signals in Müller glia
coincided with the severity of glaucoma; and (4) The phenotype of
retinas with experimentally-induced IOP elevations retinas was
similar to the moderate/severe glaucoma phenotype in D2 retinas.
Given that the onset of RyR1 upregulation in D2 eyes coincided
with appearance of GFAP signals inMüller glia, the regulation of the
RyR1 gene is likely to be associated with activation of Muller glia
rather than RGC death. Müller cells are in a good topographic
position to be the ﬁrst retinal cell type to sense and respond to
changes in IOP through ER-rich endfeet which transduce mechan-
ical stimulation through regenerative [Ca2þ] increases (Keirstead
and Miller, 1995; Newman, 2001; Li et al., 2001). It is unclear
whether Müller glial RyR channels are directly activated by
hydrostatic pressure as reported for optic nerve astrocytes (e.g.,
Mandal et al., 2010) or by Ca2þ inﬂux through stretch- and
pressure-sensitive plasma membrane channels (Puro, 1991;
Lindqvist et al., 2010; Ryskamp et al., 2011). In either case, the
astroglial response tomechanical and neurochemical stress is likely
to include augmented CICR. Intracellular Ca2þ release channels
tend to malfunction at early stages of neurodegeneration
(Nedergaard et al., 2010) and it is therefore not inconceivable that
suppression of RyR-mediated ampliﬁcation of intracellular Ca2þ
signals will be protective with respect to glial activation and gliotic
Fig. 5. RyR gene expression in B6 and D2 retinas. (A) RT-PCR. RyR1 transcripts are
strongly upregulated in D2 compared to B6 retinas. Analysis of D2-Gpnmbþ samples
shows no difference from B6 expression at 1 month but a signiﬁcant upregulation at 5
months. (B & C) RyR2 and RyR3 mRNA levels show no consistent differences between
B6 and D2 retinas.
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remodeling observed in retinal ischemia, diabetic retinopathy and/
or glaucoma (Marc et al., 2003; see also Frandsen and Schousboe,
1991; Niebauer and Gruenthal, 1999; Popescu et al., 2002; Stirling
and Stys, 2010; Kasumu and Bezprozvanny, in press).
The increase in the expression of Müller cell RyRs ﬁts the
general context of upregulated Ca2þ-dependent signal transduction
pathways in D2 retinas (reviewed in Whitmore et al., 2005; Crish
and Calkins, 2011), early Müller cell activation in D2 retinas
Fig. 6. Acute glaucoma model. B6 eyes were injected with PBS (A) or microbeads (B) and colabeled with RyR1 and GFAP antibodies. Microbead-injected eyes exhibited prominent
GFAP-ir which showed partial colocalization with RyR1. In contrast, no colocalization was observed in sham controls.
Fig. 7. RyR1 expression and localization in B6m D2 and D2-Gpnmbþ retinas. (A) PCR amplicons for RyR2 and Gapdh. (B) ISH for RyR2. The reaction product is localized to perikarya in
INL, RGCL and distal ONL. Scale bar ¼ 50 mm (C & D) RyR2 immunolocalization in the adult B6 retina. The RyR2 antibody labels all retinal layers, with a prominent signal in the RGCL.
(EeI) D2 retinas. (E) Inner retina. Double labeling for RyR2 and GFAP shows little colocalization. Scale bar ¼ 10 mm. (F) Outer retina. Double labeling for RyR2 and glutamine
synthetase in the ONL. RyR2-ir photoreceptor processes do not colocalize with radial processes of GS-ir Müller cells. Scale bar ¼ 5 mm (Gi & ii) Moderate glaucoma, double labeling
for RyR2 and Brn3a. The RyR2 antibody labels cell bodies of RGCs (arrowheads) and axonal processes in the NFL (arrow). Scale bar ¼ 10 mm. (H) Severe glaucoma. Scale bar ¼ 20 mm
(Ii-iii) Severe glaucoma. Double labeling for RyR2 and GS shows little colocalization in the IPL. Scale bar ¼ 10 mm.
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(Inman and Horner, 2007), augmented neuronal excitability and
susceptibility to stress in D2 animals (Esplin et al., 1994) and the
increasingly recognized role of glial RyRs in axonal injury (Stirling
and Stys, 2010). B6 and D2 mouse strains exhibit numerous
differences in biochemistry, physiology and behavior, including
higher levels of angiotensin AT1 receptors, GABA receptor/chan-
nels, endothelin and complement signaling in D2 animals (DuBois
et al., 2006; Golding et al., 2011; Howell et al., 2011), lower levels
of protein kinase C and COMT (Bowers et al., 1995; Grice et al.,
2007) and differential expression of NMDA receptors, voltage-
operated Ca2þ channels and calcineurin (Esplin et al., 1994; Grice
et al., 2007).
However, our data argue against a simple glaucoma vs. non-
glaucoma dichotomy of retinal RyR1 and GFAP expression. The
early upregulation of RyR1, Gfap and microglial markers in D2
retinas (Inman and Horner, 2007) suggests that at least part of the
RyR1 expression phenotype might be derived from Gpnmb loss of
function rather than glaucoma per se. This conjecture is supported
by the observation that RyR1 mRNA levels were elevated in D2
animals that had not (yet) exhibited glaucomatous RGC degenera-
tion. Furthermore, the expression pattern of RyR1 signals in
a subset of adult D2-Gpnmbþmice suggests that their retinas differ
from both B6 and D2 animals. In particular, RyR1 signals that were
observed in some GFAP-immunonegative D2-Gpnmbþ Müller cells
indicate that the RyR1 genemay be expressed in the absence of glial
activation. Consistent with our observations, Porciatti et al. (2010)
have recently shown that B6 and D2-Gpnmbþ eyes differentially
respond to spatial contrast, manifesting differential strain-speciﬁc
organization of inner retinal circuits. As expected, contrast gain
control mechanisms also differed between B6 vs. D2, and D2 vs. D2-
Gpnmbþ eyes (Porciatti et al., 2010). It remains to be determined
whether moderate RyR1 expression in Müller cells is associated
with the D2 phenotype or whether the RyR1 gene is regulated by
the mild IOP increase and iris disease observed in D2-Gpnmbþ
animals (Howell et al., 2007).
In contrast to consistent upregulation of RyR1, expression or
localization of RyR2, the main neuronal and retinal isoform, did not
change in D2 retinas. Likewise, RyR3, typically considered an
embryonic/neonatal isoform expressed at low levels in non-
neuronal tissues or co-expressed with RyR2 (Bertocchini et al.,
1997), showed no changes in mRNA transcript levels in D2
animals (Fig. 7). We conclude that retinal intracellular Ca2þ release
channels express plasticity in terms of isoform-speciﬁcity, tran-
scription and localization. RyR1 expression and localization is highly
sensitive to genetic and environmental inﬂuences that include the
strain, iris disease, retinal gliosis and acute or chronic changes in IOP.
Acknowledgements
The work was supported by the National Institutes of Health
(RO1EY13870, T32DC008553, P30EY014800), The Foundation
Fighting Blindness, Knights Templar Eye Foundation, Moran TIGER
award and by the unrestricted grant from Research to Prevent
Blindness to the Moran Eye Center at the University of Utah. We
thank Drs. Gareth Howell and Simon John (Jackson Labs and HHMI)
for generously providing D2 and D2-Gpnmbþ founder mice, for help
in classiﬁcation of D2 eyes and for illuminating discussions.We also
thank Dr. Jessica Li (University of Utah) for teaching us to perform
retinal microinjections.
References
Anderson, M.G., Smith, R.S., Hawes, N.L., Zabaleta, A., Chang, B., Wiggs, J.L.,
John, S.W., 2002. Mutations in genes encoding melanosomal proteins cause
pigmentary glaucoma in D2 mice. Nat. Genet. 30 (1), 81e85.
Barabas, P., Huang, W., Chen, H., Koehler, C.L., Howell, G., John, S.W., Tian, N.,
Rentería, R.C., Kri!zaj, D., 2011. Missing optomotor head-turning reﬂex in the
DBA/2J mouse. Invest. Ophthalmol. Vis. Sci. 52, 6766e6773.
Belzung, C., Griebel, G., 2001. Measuring normal and pathological anxiety-like
behaviour in mice: a review. Behav. Brain Res. 125 (1e2), 141e149.
Bertocchini, F., Ovitt, C.E., Conti, A., Barone, V., Schöler, H.R., Bottinelli, R.,
Reggiani, C., Sorrentino, V., 1997. Requirement for the ryanodine receptor
type 3 for efﬁcient contraction in neonatal skeletal muscles. EMBO J. 16,
6956e6963.
Bosco, A., Steele, M.R., Vetter, M.L., 2011. Early microglia activation in a mouse
model of chronic glaucoma. J. Comp. Neurol. 519, 599e620.
Bowers, B.J., Christensen, S.C., Pauley, J.R., Paylor, R., Yuva, L., Dunbar, S.E.,
Wehner, J.M., 1995. Protein and molecular characterization of hippocampal
protein kinase C in C57BL/6 and DBA/2 mice. J. Neurochem. 64, 2737e2746.
Bringmann, A., Iandiev, I., Pannicke, T., Wurm, A., Hollborn, M., Wiedemann, P.,
Osborne, N.N., Reichenbach, A., 2009. Cellular signaling and factors involved in
Müller cell gliosis: neuroprotective and detrimental effects. Prog. Retin Eye Res.
28, 423e451.
Chen, H., Wei, X., Cho, K.S., Chen, G., Sappington, R., Calkins, D.J., Chen, D.F., 2011.
Optic neuropathy due to microbead-induced elevated intraocular pressure in
the mouse. Invest. Ophthalmol. Vis Sci. 52, 36e44.
Crish, S.D., Calkins, D.J., 2011. Neurodegeneration in glaucoma: progression and
calcium-dependent intracellular mechanisms. Neuroscience 176, 1e11.
Danias, J., Lee, K.C., Zamora, M.F., Chen, B., Shen, F., Filippopoulos, T., Su, Y.,
Goldblum, D., Podos, S.M., Mittag, T., 2003. Quantitative analysis of retinal
ganglion cell (RGC) loss in aging DBA/2NNia glaucomatous mice: comparison
with RGC loss in aging C57/BL6mice. Invest. Ophthalmol. Vis. Sci. 44, 5151e5162.
DuBois, D.W., Perlegas, A., Floyd, D.W., Weiner, J.L., McCool, B.A., 2006. Distinct
functional characteristics of the lateral/basolateral amygdala GABAergic system
in C57BL/6J and DBA/2J mice. J. Pharmacol. Exp. Ther. 318, 629e640.
Esplin, M.S., Abbott, J.R., Smart, M.L., Burroughs, A.F., Frandsen, T.C., Litzinger, M.J.,
1994. Voltage-sensitive calcium channel development in epileptic DBA/2J mice
suggests altered presynaptic function. Epilepsia 35, 911e914.
Frandsen, A., Schousboe, A., 1991. Dantrolene prevents glutamate cytotoxicity and
Ca2þ release from intracellular stores in cultured cerebral cortical neurons.
J. Neurochem. 56, 1075e1078.
García-Pérez, C., Hajnóczky, G., Csordás, G., 2008. Physical coupling supports the
local Ca2þ transfer between sarcoplasmic reticulum subdomains and the
mitochondria in heart muscle. J. Biol. Chem. 283, 32771e32780.
Golding, B.J., Overall, A.D., Gard, P.R., 2011. Strain differences and the role of AT(1)
receptor expression in anxiety. Int. J. Mol. Epidemiol. Genet. 2, 51e55.
Gordon, M.O., Beiser, J.A., Brandt, J.D., Heuer, D.K., Higginbotham, E.J., Johnson, C.A.,
Keltner, J.L., Miller, J.P., Parrish, R.K., Wilson, M.R., Kass, M.A., 2002. The ocular
hypertension treatment study: baseline factors that predict the onset of
primary open-angle glaucoma. Arch. Ophthalmol. 20, 714e720.
Grice, D.E., Reenilä, I., Männistö, P.T., Brooks, A.I., Smith, G.G., Golden, G.T.,
Buxbaum, J.D., Berrettini, W.H., 2007. Transcriptional proﬁling of C57 and DBA
strains of mice in the absence and presence of morphine. BMC Genomics 8, 76.
Guo, Q., Fu, W., Sopher, B.L., Miller, M.W., Ware, C.B., Martin, G.M., Mattson, M.P.,
1999. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in
presenilin-1 mutant knock-in mice. Nat. Med. 5, 101e106.
Guo, Y., Johnson, E.C., Cepurna, W.O., Dyck, J.A., Doser, T., Morrison, J.C., 2011. Early
gene expression changes in the retinal ganglion cell layer of a rat glaucoma
model. Invest. Ophthalmol. Vis. Sci. 52, 1460e1473.
Howell, G.R., Libby, R.T., Marchant, J.K., Wilson, L.A., Cosma, I.M., Smith, R.S.,
Anderson, M.G., John, S.W., 2007. Absence of glaucoma in D2 mice homozygous
for wild-type versions of Gpnmb and Tyrp1. BMC Genet. 8, 45.
Howell, G.R., Macalinao, D.G., Sousa, G.L., Walden, M., Soto, I., Kneeland, S.C.,
Barbay, J.M., King, B.L., Marchant, J.K., Hibbs, M., Stevens, B., Barres, B.A.,
Clark, A.F., Libby, R.T., John, S.W., 2011. Molecular clustering identiﬁes comple-
ment and endothelin induction as early events in a mouse model of glaucoma.
J. Clin. Invest. 121, 1429e1444.
Inman, D.M., Horner, P.J., 2007. Reactive nonproliferative gliosis predominates in
a chronic mouse model of glaucoma. Glia 55, 942e953.
John, S.W., Smith, R.S., Savinova, O.V., Hawes, N.L., Chang, B., Turnbull, D., Davisson, M.,
Roderick, T.H., Heckenlively, J.R., 1998. Essential iris atrophy, pigment dispersion,
and glaucoma in D2 mice. Invest. Ophthalmol. Vis Sci. 39, 951e962.
Kasumu, A., Bezprozvanny, I. Deranged calcium signaling in Purkinje cells and
pathogenesis in spinocerebellar ataxia 2 (SCA2) and other Ataxias. Cerebellum,
in press 2010 May 18 [Epub ahead of print].
Keirstead, S.A., Miller, R.F., 1995. Calcium waves in dissociated retinal glial (Müller)
cells are evoked by release of calcium from intracellular stores. Glia 14, 14e22.
Kri!zaj, D., Lai, F.A., Copenhagen, D.R., 2003. Ryanodine stores and calcium regulation
in the inner segments of salamander rods and cones. J. Physiol. 547, 761e774.
Lam, T.T., Kwong, J.M., Tso, M.O., 2003. Early glial responses after acute elevated
intraocular pressure in rats. Invest. Ophthalmol. Vis. Sci. 44, 638e645.
Li, Y., Holtzclaw, L.A., Russell, J.T., 2001. Müller cell Ca2þwaves evoked by purinergic
receptor agonists in slices of rat retina. J. Neurophysiol. 85, 986e994.
Libby, R.T., Anderson, M.G., Pang, I.H., Robinson, Z.H., Savinova, O.V., Cosma, I.M.,
Snow, A., Wilson, L.A., Smith, R.S., Clark, A.F., John, S.W., 2005. Inherited glau-
coma in DBA/2J mice: pertinent disease features for studying the neuro-
degeneration. Vis. Neurosci. 22, 637e648.
Lindqvist, N., Liu, Q., Zajadacz, J., Franze, K., Reichenbach, A., 2010. Retinal glial
(Müller) cells: sensing and responding to tissue stretch. Invest. Ophthalmol. Vis.
Sci. 51, 1683e1690.
W. Huang et al. / Experimental Eye Research 93 (2011) 700e709708
























Lucki, I., Dalvi, A., Mayorga, A.J., 2001. Sensitivity to the effects of pharmacologically
selective antidepressants in different strains of mice. Psychopharmacology
(Berl) 155, 315e322.
Mandal, A., Shahidullah, M., Delamere, N.A., 2010. Hydrostatic pressure-induced
release of stored calcium in cultured rat optic nerve head astrocytes. Invest.
Ophthalmol. Vis. Sci. 51, 3129e3138.
Marc, R.E., Jones, B.W., Watt, C.B., Strettoi, E., 2003. Neural remodeling in retinal
degeneration. Prog. Retin Eye Res. 22, 607e655.
Medina-Ortiz, W.E., Gregg, E.V., Brun-Zinkernagel, A.M., Koulen, P., 2007. Identiﬁ-
cation and functional distribution of intracellular Ca channels in mouse lacrimal
gland acinar cells. Open Ophthalmol. 1, 8e16.
Misra, V., Lee, H., Singh, A., Huang, K., Thimmulappa, R.K., Mitzner, W., Biswal, S.,
Tankersley, C.G., 2007. Global expression proﬁles from C57BL/6J and DBA/2J
mouse lungs to determine aging-related genes. Physiol. Genomics 31,
429e440.
Nedergaard, M., Rodríguez, J.J., Verkhratsky, A., 2010. Glial calcium and diseases of
the nervous system. Cell Calcium 47, 140e149.
Newman, E.A., 2001. Propagation of intercellular calciumwaves in retinal astrocytes
and Müller cells. J. Neurosci. 21, 2215e2223.
Niebauer, M., Gruenthal, M., 1999. Neuroprotective effects of early vs. late admin-
istration of dantrolene in experimental status epilepticus. Neuropharmacology
38, 1343e1348.
Ouardouz, M., Nikolaeva, M.A., Coderre, E., Zamponi, G.W., McRory, J.E., Trapp, B.D.,
Yin, X., Wang, W., Woulfe, J., Stys, P.K., 2003. Depolarization-induced Ca2þ
release in ischemic spinal cord white matter involves L-type Ca2þ channel
activation of ryanodine receptors. Neuron 40, 53e63.
Panagis, L., Zhao, X., Ge, Y., Ren, L., Mittag, T.W., Danias, J., 2010. Gene expression
changes in areas of focal loss of retinal ganglion cells in the retina of DBA/2J
mice. Invest. Ophthalmol. Vis Sci. 51, 2024e2034.
Popescu, B.O., Oprica, M., Sajin, M., Stanciu, C.L., Bajenaru, O., Predescu, A.,
Vidulescu, C., Popescu, L.M., 2002. Dantrolene protects neurons against kainic
acid induced apoptosis in vitro and in vivo. J. Cell. Mol. Med. 6, 555e569.
Porciatti, V., Chou, T.H., Feuer, W.J., 2010. C57BL/6J, DBA/2J, and DBA/2J.Gpnmb mice
have different visual signal processing in the inner retina. Mol. Vis. 16,
2939e2947.
Puk, O., Dalke, C., Hrabé de Angelis, M., Graw, J., 2008. Variation of the response to the
optokinetic drum among various strains of mice. Front Biosci. 13, 6269e6275.
Punzo, C., Cepko, C., 2007. Cellular responses to photoreceptor death in the rd1
mouse model of retinal degeneration. Invest. Ophthalmol. Vis. Sci. 48, 849e857.
Puro, D.G., 1991. Stretch-activated channels in human retinal Muller cells. Glia 4,
456e460.
Rentería, R.C., Strehler, E.E., Copenhagen, D.R., Krizaj, D., 2005. Ontogeny of plasma
membrane Ca2þ ATPase isoforms in the neural retina of the postnatal rat. Vis.
Neurosci. 22, 263e274.
Ryskamp, D.A., Witkovsky, P., Barabas, P., Huang, W., Koehler, C., Akimov, N.P.,
Lee, S.H., Chauhan, S., Xing, W., Rentería, R.C., Liedtke, W., Krizaj, D., 2011. The
polymodal ion channel transient receptor potential vanilloid 4 modulates
calcium ﬂux, spiking rate, and apoptosis of mouse retinal ganglion cells.
J. Neurosci. 31, 7089e7101.
Shoshan-Barmatz, V., Zakar, M., Shmuelivich, F., Nahon, E., Vardi, N., 2007. Retina
expresses a novel variant of the ryanodine receptor. Eur. J. Neurosci. 26,
3113e3125.
Singh, S.M., Treadwell, J., Kleiber, M.L., Harrison, M., Uddin, R.K., 2007. Analysis of
behavior using genetical genomics in mice as a model: from alcohol preferences
to gene expression differences. Genome 50, 877e897.
Soto, I., Oglesby, E., Buckingham, B.P., Son, J.L., Roberson, E.D., Steele, M.R.,
Inman, D.M., Vetter, M.L., Horner, P.J., Marsh-Armstrong, N., 2008. Retinal
ganglion cells downregulate gene expression and lose their axons within the
optic nerve head in a mouse glaucoma model. J. Neurosci. 28, 548e561.
Steele, M.R., Inman, D.M., Calkins, D.J., Horner, P.J., Vetter, M.L., 2006. Microarray
analysis of retinal gene expression in the DBA/2J model of glaucoma. Invest.
Ophthalmol. Vis. Sci. 47, 977e985.
Stirling, D.P., Stys, P.K., 2010. Mechanisms of axonal injury: internodal nano-
complexes and calcium deregulation. Trends. Mol. Med. 16, 160e170.
Whitmore, A.V., Libby, R.T., John, S.W., 2005. Glaucoma: thinking in newways-a rôle
for autonomous axonal self-destruction and other compartmentalised
processes? Prog. Retin Eye Res. 24, 639e662.
Xue, L.P., Lu, J., Cao, Q., Hu, S., Ding, P., Ling, E.A., 2006. Muller glial cells express
nestin coupled with glial ﬁbrillary acidic protein in experimentally induced
glaucoma in the rat retina. Neuroscience 139, 723e732.
W. Huang et al. / Experimental Eye Research 93 (2011) 700e709 709
   
CHAPTER 5 
 
THE POLYMODAL ION CHANNEL TRANSIENT RECEPTOR 
POTENTIAL VANILLOID 4 MODULATES CALCIUM FLUX, 















Ryskamp DA, Witkovsky P, Barabas P, Huang W, Koehler C, Akimov NP, Lee SH, 
Chauhan S, Xing W, Rentería RC, Liedtke W, Križaj D (2011) The polymodal ion 
channel transient receptor potential vanilloid 4 modulates calcium flux, spiking rate, and 
apoptosis of mouse retinal ganglion cells. The Journal of Neuroscience 31(19):7089-
7101. Reprinted with permission from The Journal of Neuroscience. 


























The Polymodal Ion Channel Transient Receptor Potential
Vanilloid 4 Modulates Calcium Flux, Spiking Rate, and
Apoptosis of Mouse Retinal Ganglion Cells
Daniel A. Ryskamp,1,2* Paul Witkovsky,4* Peter Barabas,1*Wei Huang,1 Christopher Koehler,5Nikolay P. Akimov,5
Suk Hee Lee,6 Shiwani Chauhan,1Wei Xing,1 Rene´ C. Rentería,5Wolfgang Liedtke,6 and David Križaj1,2,3
1Department of Ophthalmology & Visual Sciences, John A. Moran Eye Center, 2Interdepartmental Program in Neuroscience, and 3Department of
Physiology, University of Utah School of Medicine, Salt Lake City, Utah 84132, 4Department of Ophthalmology, New York University School of Medicine,
New York, New York 10016, 5Department of Physiology and Center for Biomedical Neuroscience, University of Texas Health Science Center at San Antonio,
San Antonio, Texas, and 6Department of Medicine and Neurobiology, and Center for Translational Neuroscience, Duke University Medical Center, Durham,
North Carolina 27710
Sustained increase in intraocular pressure represents a major risk factor for eye disease, yet the cellular mechanisms of pressure
transduction in the posterior eye are essentially unknown. Here we show that the mouse retina expresses mRNA and protein for the
polymodal transient receptor potential vanilloid 4 (TRPV4) cation channel known tomediate osmotransduction andmechanotransduc-
tion. TRPV4 antibodies labeled perikarya, axons, and dendrites of retinal ganglion cells (RGCs) and intensely immunostained the optic
nerve head. Mu¨ller glial cells, but not retinal astrocytes or microglia, also expressed TRPV4 immunoreactivity. The selective TRPV4
agonists 4!-PDD and GSK1016790A elevated [Ca2!]i in dissociated RGCs in a dose-dependent manner, whereas the TRPV1 agonist
capsaicin had no effect on [Ca2!]RGC. Exposure to hypotonic stimulation evoked robust increases in [Ca
2!]RGC. RGC responses to
TRPV4-selective agonists and hypotonic stimulation were absent in Ca2!-free saline and were antagonized by the nonselective TRP
channel antagonists Ruthenium Red and gadolinium, but were unaffected by the TRPV1 antagonist capsazepine. TRPV4-selective
agonists increased the spiking frequency recorded from intact retinas recordedwithmultielectrode arrays. Sustained exposure toTRPV4
agonists evoked dose-dependent apoptosis of RGCs. Our results demonstrate functional TRPV4 expression in RGCs and suggest that its
activationmediates response tomembrane stretch leading to elevated [Ca2!]i andaugmentedexcitability. ExcessiveCa
2! influx through
TRPV4predisposesRGCs to activationofCa2!-dependentproapoptotic signalingpathways, indicating thatTRPV4 is a component of the
response mechanism to pathological elevations of intraocular pressure.
Introduction
Cells of multicellular organisms experience mechanical stimuli
that range from the direct mechanical impact of pulling and
stretching to changes in osmotic and hydrostatic pressure (Wang
and Thampatty, 2006; Bourque, 2008). Mechanical stretch or
pressure activates ion channels in the plasmamembrane (Loukin
et al., 2010a,b), resulting in depolarization, increased intracellu-
lar Ca2! concentration ([Ca2!]i) (Zabel et al., 1996; Wu and
Davis, 2001), and changes in gene expression, cell shape, and
cytoskeletal organization (Naruse et al., 1998; Thodeti et al.,
2009).
Recent studies have established that members of the transient
receptor potential (TRP) superfamily transduce visual, chemical,
thermal, mechanical, painful, and osmotic stimuli into Ca2!
fluxes (for review, see Liedtke and Kim, 2005; Kung, 2005; Chris-
tensen and Corey, 2007; Sharif-Naeini et al., 2008). We are par-
ticularly interested in the possibility that the vertebrate retina,
which is exposed to systemic blood pressure, hydrostatic pressure
from the CSF, and intrinsic intraocular pressure (IOP), contains
one or more pressure-sensitive TRP channels. Pathological ele-
vations in IOP or systemic pressure represent primary risk factors
for glaucoma, a group of inherited optic neuropathies character-
ized by apoptotic loss of retinal ganglion cells (RGCs), degener-
ation of the optic nerve, and progressive loss of visual fields
(Quigley, 2005; Whitmore et al., 2005). The cellular pathophysi-
ology of glaucoma is not well understood, in part because the
mechanisms that couple the mechanical stimulus ("IOP) to cel-
lular signal transduction remain to be characterized.
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In eukaryotic cells, the TRP vanilloid 4 (TRPV4) channel
(GenBank accession number NM_022017) represents a poly-
modal mechanism that transduces osmotic pressure, shear force
stimuli, mechanical stretch, and moderate warmth (!27–37°C)
into cation influx with a preference for Ca2" (PCa/PNa !6)
(Liedtke et al., 2000; Gu¨ler et al., 2002; O’Neil and Heller, 2005).
The channel may be activated by intracellular mediators such as
arachidonic acid and cytochrome P450-dependent formation of
5,6-epoxyeicosatrienoic acid (Vriens et al., 2004, but see Loukin
et al., 2009). In neural tissues, TRPV4 expression has been local-
ized to sensory neurons in dorsal root and trigeminal ganglia,
inner ear hair cells, Merkel cells, hippocampal and hypothalamic
neurons, and astrocytes (Liedtke et al., 2000; Reiter et al., 2006;
Benfenati et al., 2007; Shibasaki et al., 2007; Alessandri-Haber et
al., 2009). Mice lacking TRPV4 have defects in noxious mecha-
nosensation and pressure sensation (Liedtke and Friedman,
2003; Suzuki et al., 2003), whereas the functional ortholog of
TRPV4 in the worm Caenorhabditis elegans, OSM-9, mediates
osmotic, mechanical, and chemical avoidance (Liedtke et al.,
2003). Together, these findings suggest that TRPV4 represents an
evolutionarily conserved element of the neural response to me-
chanical stimulation.
We report here that TRPV4 is expressed in RGC somata and
optic axon fibers. Transient activation of TRPV4 induced Ca2"
influx and increased the excitability of ganglion cells, whereas
sustained activation resulted in RGC apoptosis. The prominent
expression of TRPV4-immunoreactivity (IR) at the optic nerve
head (ONH), and the role of TRPV4 in gating Ca2" entry and
RGC firing, implicate this channel in the retinal remodeling that
occurs during chronic increases in IOP.
Materials andMethods
Animals
C57BL/6J mice of either sex were obtained from commercial suppliers,
whereas B6.Cg-Tg(Thy1-CFP)23Jrs/J (hereafter, Thy1:CFP) animals or
retinal sections were a kind gift from Dr. Ning Tian (University of Utah,
Salt Lake City, UT). The animals were maintained in the University
animal quarters on a 12 h light/dark cycle. Mice were fed lab chow and
water ad libitum. Mice were killed before isolation and dissociation of
retinas (Duncan et al., 2006). Animal handling and anesthetic procedures
were approved by University Institutional Animal Care committees and
conform to National Institutes of Health guidelines.
Histology
Eyes were enucleated, and their corneas and lenses dissected away. The
remaining posterior pole of the eye was fixed by immersion for 1 h at
room temperature in freshly prepared 4% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.2, then washed 3# 10 min in pH 7.2 PBS. Fixed
eye tissue was then immersed for 12–16 h in 30% sucrose at 4°C, embed-
ded in OCT (Ted Pella), cryostat sectioned at 16 !m, and mounted on
Superfrost slides (Fisher Scientific). After drying for 1 h at 37°C, slides
were stored frozen ($80°C) until used. Dissociated cells were isolated
with papain (7 U/ml; Worthington), plated on concanavalin A-coated
coverslips, fixed in 4% paraformaldehyde in 0.1 M phosphate buffer, pH
7.2, for 30 min, washed 3# 10 min in pH 7.2 PBS, and stored at 4°C.
Immunohistochemistry. For fluorescence immunocytochemistry, cry-
ostat sections were thawed and washed in PBS, then placed for 30 min to
1 h in blocking solution (10 ml of PBS, 30 !l of Triton X-100, 100 mg of
bovine serum albumin, 100 !l of 10% w/v Na azide solution). Primary
and secondary antibodies were diluted in blocking solution and applied
for 2 and 1 h, respectively, at room temperature, with three intervening
washes in PBS. After a final set of washes in PBS, the sections were
covered in VectaShield (Vector Laboratories).
Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end
labeling assay. Retinas were embedded, cryosectioned, and processed for
terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick
end labeling (TUNEL) following the protocol by Gavrieli et al. (1992).
After 30min rehydration in 70% ethanol, 2# 5min rinses in PBS and 1%
Triton-X in 1% citrate buffer, pH 7.3, the slides were subjected to a final
rinse in PBS. Slides were then incubated for 30min in the reaction buffer
(30 mM Trizma-HCl, 140 mM Na" cacodylate, 1.0 mM CaCl2, 0.2% Tri-
ton X-100, pH 7.2). Positive controls were treated with DNase I (Roche
Diagnostics) (10 U/ml) in the reaction buffer. Next, slides were treated
for 1 h with 0.03 U/!l terminal transferase and 4 !M biotin-16-dUTP
(Roche Diagnostics). The reaction was terminated in 30mMNa" citrate,
300 mMNaCl, and 0.2% Triton X-100 in PBS (5 min), and rinsed in PBS
(2#5min), exposed to 1%bovine serum albumin in PBS for 20min, and
rinsed. As a negative control, the retinal sectionswere processed omitting
the incubation step with terminal deoxynucleotidyl transferase during
DNA labeling. Apoptotic cells were visualized with a confocal micro-
scope (LSM510; Zeiss) and categorized by size. We found that our fixa-
tion protocol resulted in!1!m shrinkage in the diameter of dissociated
Brn3a-IR cells in retinal sections. Therefore, the TUNEL analysis com-
pared cells with a diameter of%6 !m (presumed RGCs) to photorecep-
tor cells with diameters of 3–5 !m (the identity of photoreceptors was
confirmed by immunostaining for mouse cone arrestin (a gift from Dr.
Wolfgang Baehr, University of Utah, Salt Lake City, UT) and rhodopsin
(Santa Cruz Biotechnology). A cell was deemed to be TUNEL positive if
the fluorescent signal completely filled the cell body.
Image acquisition and processing
Sections were examined by confocal microscopy (LSM 510, Zeiss; or PM
800, Nikon). Digital images were acquired separately from each laser
channel, then recombined. Files were further processed with deconvolu-
tion software (AutoQuant Imaging). Adjustments of contrast and inten-
sity were made in Photoshop (Adobe); any such adjustments were made
uniformly to the entire image.
Western blot
We essentially followed the procedure outlined in previous publications
(Liedtke and Friedman, 2003; Phan et al., 2009). In brief, homogenized
retinal tissue was subjected to protein preparation and denaturation, and
proteins (10 !g per lane) were separated on an SDS gel, then immuno-
blotted to polyvinylidene difluoride membranes. After blocking with
milk powder, TRPV4 was immunodetected using the above antibody
(Phan et al., 2009) and peroxidase-based chemoluminescence.
Primary and secondary antibodies
Table 1 shows the primary and secondary antibodies used in this study.
Multiple commercially available anti-TRPV4 antibodies (ACC-034, Alo-
mone Labs; LS-A8583, MBL International Corporation; OSR00136W,
Affinity Bioreagents; and ab63003, Abcam)were tested by immunostain-
ing and Western blots in wild-type and TRPV4-null mice. However, the
only antibody that proved completely satisfactory was LS-C94498 (Lifes-
pan Biosciences), based on the following criteria: (1) The antibody
stained Western blot bands of 85 and 106 kDa from retinal tissue har-
Table 1. Primary antibodies and their sources and dilutions
Target Company Catalog number
TRPV4 Alomone Labs ACC-034 rabbit 1:500–1:1000
TRPV4 MBL International Corporation LS-A8583 rabbit 1:200–1:1000
TRPV4 Affinity Bioreagents/Thermo Scientific
Pierce/OSenses
OSR00136W rabbit 1:200–1:1000
TRPV4 Abcam Ab63003 rabbit 1:200–1:1000
TRPV4 Lifespan Biosciences LS-C94498 rabbit 1:200–1:1000
Brn3a Santa Cruz Biotechnology sc-8429 mouse 1:100
Cone arrestin Gift from Dr. Wolfgang Baehr (University
of Utah)
Mouse 1:100–1:500
Rhodopsin Santa Cruz Biotechnology sc-57433 mouse 1:100
ChAT Chemicon AB144-P goat 1:200
GAD-65 Developmental Studies Hybridoma
Bank
GAD-6 mouse 1:1000
GFAP Sigma G3893 mouse 1:500
GFP Santa Cruz Biotechnology sc-9996 mouse 1:100–1:500
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vested from wild-type mice but not from TRPV4-null mice (see Fig. 1);
(2) it colocalized with green fluorescent protein (GFP) in RGCs from
transgenic animals in which GFP was driven by the Trpv4 gene promoter
(see Fig. 2C); and (3) it detected protein bands of appropriate molecular
mass from HEK293 cells transfected with Trpv4 cDNA, whereas the
bands were missing in immunoblots from nonexpressing cells (Fig. 1).
All TRPV4-IR data reported in the present study were obtained with the
anti-TRPV4 antibody LS-C94498. No immunostaining was observed
when the primary antibody was omitted.
Semiquantitative RT-PCR
Total RNA from retina was extracted with Trizol, and total RNA (2!g of
total RNA used for first-strand synthesis with oligo-dT and primers) was
converted to cDNA using the SuperScript III First-Strand Synthesis kit
from Invitrogen. PCR products were amplified in a thermocycler (Veriti,
ABI) with nucleic acid stain (SYBRGreen, ABI) reagents according to the
manufacturer’s instructions. Amplification of PCR products was mea-
sured by fluorescence associated with binding of double-stranded DNA
to SYBRGreen in the reactionmixture. After an initial denaturation step
of 50°C for 2 min and 95°C for 10 min, PCR was repeated for 40 cycles at
95°C for 15 s, 58°C for 30 s, and 72°C for 30 s. After amplification, the
ratio of gene-of-interest mRNA to a housekeeping gene, glyceraldehyde-
3-phosphate dehydrogenase (Gapdh), was calculated for each sample.
Five to 10 independent biological replicates (retinas) were used at each
age.
Generation of a bacterial artificial chromosome transgenic mouse
line with a fluorescent reporter driven by the Trpv4 promoter
A mouse bacterial artificial chromosome (BAC) harboring the Trpv4
gene was modeled by “recombineering” (Copeland et al., 2001), so that
the copepod-GFP coding region was placed directly after the ATG start
codon of mouse Trpv4. In addition, this BAC was engineered to not
harbor exons 10–14, so that a functional ion channel could not arise
from the transgene. Engineered DNA served as a transgenesis template,
which was constructed following standard procedures (Zhao et al.,
2008). Of four resulting transgenic lines, the one used revealed robust
fluorescence in trigeminal ganglion sensory neurons (not illustrated),
both in acute sections and acute dissociations, colocalizing with TRPV4
immunolabeling. This line was outcrossed for five or more generations
before analysis of retinas.
Calcium imaging
Calcium imaging was performed on acutely isolated retinal cells, as de-
scribed previously (Szikra et al., 2009). In brief, dissociated retinal cells
were plated on concanavalin A-coated (0.2 mg/ml; Sigma) coverslips,
loaded with fura-2 AM (1–5 !M; Invitrogen) for 15–30 min and washed
for 10 min in dye-free L-15 medium. Cells were viewed with Nikon Ti
inverted or 600EF upright microscopes using 20! 0.95 numerical aper-
ture (NA), 40! 0.85 NA, or 40! 1.25 NA objective lenses. Excitation for
340 and 380 nm filters (Chroma and Semrock) was provided by a 150W
Xenon arc lamp (DG4, Sutter Instruments). Fluorescence emission was
high-pass filtered at 510 nm and captured with cooled digital CCD cam-
eras (HQ2, Photometrics). Data acquisition and F340/F380 ratio calcula-
tions were performed by NIS Elements software. Fluorescence imaging
was performed on regions of interest (ROIs) encompassing the RGC
perikaryon, typically at 3 ! 3 binning. Background fluorescence was
measured in similarly sized ROIs in neighboring areas devoid of cells.
After sequential image acquisition (0.167–0.5 Hz) of cell fluorescence at
340/380 nm, the background was subtracted. Calibration of free [Ca2"]i
was performed in vivo using 10 !M ionomycin and 10 mM Ca2" or 0
Ca2"/3 mM EGTA. The apparent free [Ca2"]i was determined from the





where R is the ratio of emission intensity at 510 nm evoked by 340 nm
excitation versus emission intensity at 510 nm evoked by 380 nm excita-
tion, Rmin is the ratio at zero free Ca
2", Rmax is the ratio at saturating
Ca2", and the dissociation constantKd for Ca
2"-fura 2 at room temper-
ature was taken to be 224 nM (Neher, 1995). Glutamate (100 !M) was
added at the beginning of each experiment to control for neuronal health,
type, and responsiveness. DMSO, the solvent for the indicator dye, did
not induce any responses in RGCs (data not shown). Previous studies
using Mn2" quenching showed that 95% of the fura-2 fluorescence em-
anates from the cytosol in the cells (Szikra et al., 2009). Experiments were
conducted at room temperature, and encompassed stimulationwith glu-
tamate, TRPV4, and TRPV1 agonists and antagonists.
Cell identification
RGCs in short-term culture were identified initially by morphology and
perikaryal size (7–15 !m). In a subset of experiments, RGCs isolated
fromThy1:CFP retinas were used and identified by intrinsic fluorescence
(Raymond et al., 2009). Alternatively, test neurons isolated from wild-
type retinas were confirmed as RGCs by immunocytochemistry. In each
experiment, a 100 !M glutamate stimulus was used to confirm that the
visually identified putative RGCs expressed ionotropic glutamate recep-
tors. Presumed RGCs responded to 30 mM KCl with rapid high-
amplitude increases in [Ca2"]i, indicating that the cells were healthy and
maintained their excitability. In a subset of experiments, cells recorded
during stimulation with hypotonic saline or TRPV4 agonists were fixed
and immunostained with TRPV4 and Brn3a antibodies.
Solutions and reagents
The isotonic superfusing saline contained the following (in mM): 133
NaCl, 2.5 KCl, 2 CaCl2, 1.5 MgCl2, 1.25 NaH2PO4, 10 HEPES hemiso-
dium salt, 10 glucose, 1 pyruvic acid, 1 lactic acid, and 0.5 glutathione. In
Ca2"-free solutions, no external Ca2" was added, and the saline was
supplemented with 1mM EGTA. The osmolarity and pH of each external
solution was measured before each experiment. pH was adjusted to 7.4
with NaOH. Osmolarity was measured with a vapor-pressure osmome-
ter (VAPRO); for control saline, osmolarity was 280 mOsm. For experi-
ments involving hypotonic stimulation, the isotonic ringer contained
132 mM mannitol and the NaCl concentration was reduced to 57.5 mM.
Hypoosmotic solutions were prepared by reducing the final concentra-
tion of mannitol to 44.5 mM without changing the ionic composition. In
a subset of experiments using hypotonic stimulation, cells were coloaded
with fura-2 AM" calcein AM (1 !M; Invitrogen). Calcein fluorescence
was elicited using 490 nm excitation filters. Because calcein fluorescence
is Ca2" independent and volume dependent, it was used as a measure of
changes in the cell volume.
Unless otherwise indicated, the salts and reagents were purchased
from Sigma. Ruthenium Red and capsaicin were purchased from Ascent
Scientific. Capsaicin and capsazepine were also purchased from Tocris.
4"-PDD was obtained from LC Laboratories.
Multielectrode array recordings and data analysis
Multielectrode array (MEA) recordings were performed usingmultielec-
trode, extracellular recording chambers (MEA1060 system, MultiChan-
nel Systems) consisting of an array of 60 planar electrodes, each 10!m in
diameter, spaced 100 !m apart for a total array size of 700 !m2, as
described previously (Rentería et al., 2006). Briefly, young adult C57BL6J
mice were killed after 1 h of dark adaptation, and an eye was removed
under dim red illumination. The retina was dissected and placedwith the
ganglion cell side against the recording electrodes using a piece of nitro-
cellulose paper as support. The retina was typically placed on the array
within a millimeter of the optic nerve head, and a manipulator (Cell
Micro Controls) was used to hold the tissue down with slight pressure.
Retinas were perfused at room temperature for 30 min and at 30°C for
another 30 min before recordings were started, the temperature was
maintained at 30°C thereafter, and spontaneous spiking in the dark was
recorded. The perfusion saline was either Ames’ medium or Ringer’s
modified solution as follows (in mM): 124 NaCl, 2.5 KCl, 2 CaCl2, 2
MgCl2, 1.25 NaH2PO4, 26 NaHCO3, and 22.2 glucose; the pHwasmain-
tained at 7.3–7.4 by bubbling with 95% O2/5% CO2 mixed gas. Voltage
signals sampled at 50 kHz were bandpass filtered at 100 Hz to 3 kHz, and
waveforms that crossed a negative voltage threshold (set at$5.5 SDs of
the mean noise) were recorded to disk for off-line analysis. Under these
conditions, nearly all recorded cells are likely to be RGCs (Rentería et al.,
2006).
Spike trains for each RGC were determined by spike sorting based on
clustering in principal component space using software (Offline Sorter,
Plexon). Not every detected waveformwas assigned to a unit; obvious auto-
matic sorting errorswere corrected for each clustermanually (Rentería et al.,
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2006). Time stamps of the action potentials of
each sortedunitwere used to generate peristimu-
lus timehistograms (30 s bins). The average spike
rates during the 3 min period before and after
drug application were determined for every re-
corded cell and expressed as the percentage
change in firing in thepresenceof drug.This nor-
malization allowed for comparison of cells with
varied initial spike rates. The very few cells that
had zero rates before application and spiking
during drug application were considered to have
increased by 100%.
Statistical analysis
Data are expressed as the mean ! SEM, with
the number of cells, slides, or animals indicated
by N. Cell diameter data are expressed as the mean ! SD. Statistical
comparisons between two treatments in the same cell were determined
using the t test; unless indicated otherwise, comparisons between differ-
ent groups were evaluated by the Mann–Whitney test or the Wilcoxon
signed rank test. Data obtained in multielectrode array studies were an-
alyzed with the Wilcoxon signed rank test. A value of p " 0.05 was
considered statistically significant.
Results
TRPV4mRNA and protein in the mouse retina
RT-PCR was performed using total RNA extracted from adult
(postnatal day 90) mouse retinas. Gel analysis revealed PCR
products at the appropriate size of 174 bp. The same transcript
was amplified in kidney tissue, known to express Trpv4 (Strot-
mann et al., 2000, Liedtke et al., 2000; Gu¨ler et al., 2002) (Fig. 1A).
We next compared TRPV4 protein expression in tissues de-
rived from wild-type and TRPV4-null mice (see Materials and
Methods). Consistent with RT-PCR, immunoblots from wild-
type mouse retinas showed a primary band of 85 kDa and a sec-
ondary band at 105 kDa, which probably correspond to
unglycosylated andN-glycosylated forms of TRPV4, respectively,
which is in keeping with previous reports (Fig. 1B) (Liedtke and
Friedman, 2003; Benfenati et al., 2007; Hartmannsgruber et al.,
2007). Both bands were absent in retinal tissue derived from
TRPV4-null mice (Fig. 1B). The TRPV4 antibody was validated
in Western blots from HEK293 cells transfected with Trpv4
cDNA (Fig. 1C) and in trigeminal ganglion tissue known to ro-
bustly express Trpv4 (Liedtke et al., 2000; Liedtke and Friedman,
2003). As an additional test of the TRPV4 antibody, we immuno-
stained the kidney, choroid plexus, and nodose ganglion tissues
in which TRPV4 is expressed (Liedtke et al., 2000; Strotmann et
al., 2000; Brierley et al., 2008). The patterns of TRPV4 expression
in these tissues were identical to those identified in previous re-
ports (data not shown). For example, the somata of neurons
within the nodose ganglion (Fig. 1Di) were strongly TRPV4 im-
munoreactive, whereas the nodose tissue from a TRPV4-null
mouse was unlabeled by the TRPV4 antibody (Fig. 1Dii).
TRPV4 immunoreactivity in the mouse retina
TRPV4-IR in retinal ganglion cells
In wild-type mouse retinas, TRPV4-IR was punctate and distrib-
uted throughout the inner retina (Fig. 2A). A dense array of
TRPV4-IR puncta was seen within cell bodies located in the gan-
glion cell layer (gcl). TRPV4-IRwas distributed at a lower density
throughout the inner plexiform layer (ipl), but only very sparse
TRPV4-IR was located within the inner nuclear layer (inl). This
immunostaining pattern was absent in retinas of TRPV4-null
mice (Fig. 2B). The apparent immunostaining of the outer plex-
iform layer (opl) is nonspecific since it was identical in wild-type
and TRPV4-null retinas (Fig. 2A,B). Within the outer nuclear
layer (onl) consisting primarily of photoreceptor nuclei,
TRPV4-IR was seen in vertical processes of Mu¨ller glial cells (see
also Fig. 2M for Mu¨ller cell signals in the ipl).
We also analyzed a transgenicmouse inwhichGFPwas driven
by the entire promoter of the mouse Trpv4 gene. The 50 kDa
Trpv4 genewas centeredwithin the 200 kDaGFP insert present in
a BAC (see Materials and Methods). Using an antibody against
GFP, retinal immunostaining was confined to cell bodies within
the ganglion cell layer, although additional staining was noted in
retinal blood vessels, in keeping with well established vascular-
endothelial TRPV4 expression (Hartmannsgruber et al., 2007;
Mendoza et al., 2010). When the retina was stained with anti-
GFP, the marker was detected in cell bodies of the ganglion cell
layer (Fig. 2C). Confirming that reporter gene expression was
faithful to the targeted gene, Trpv4, GFP-IR was absent in wild-
type mouse retina (not illustrated).
To probe whether TRPV4-IR is associated primarily or ex-
clusively with ganglion cells, we immunostained the retina for
Brn3a (also called POU4f1), a transcription factor found al-
most exclusively in developing (Liu et al., 2000) and mature
ganglion cells (Nadal-Nicola´s et al., 2009). We found that
TRPV4-IR colocalized with that of Brn3a in ganglion cell per-
ikarya and dendrites (Fig. 2D, arrow). Prominent additional
TRPV4-IR was found within ganglion cell axon bundles in the
optic fiber layer (ofl) (Fig. 2D), and also was abundant within the
optic nerve head (Fig. 2H) and the laminar region of the optic
nerve (Fig. 2 I). The nearly universal distribution of Brn3a-IR in
mouse retinal ganglion cells, together with the finding that
Brn3a-IR and TRPV4-IR almost invariably colocalize, indicates
that TRPV4 protein is distributed among a large fraction of
mouse retinal ganglion cells.
A second marker for ganglion cells was provided by a construct in
whichGFPwas linked to the promoter of Thy1, a ganglion cell-specific
protein(seeMaterialsandMethods).GFP-IRandTRPV4-IRcolocalize
in perikarya and dendrites of RGCs (Fig. 2E) and in displaced gan-
glion cell perikarya (Fig. 2L). Finally, immunostaining with an
SMI-32 antibody that labels intermediate filaments in somata and
axonal processes of wide-field !RGCs colocalized with TRPV4-IR
processes in the ofl entering the optic nerve head (Fig. 2K).
TRPV4-IR is weak or absent in retinal amacrine cells
Approximately 50% of the cells within the ganglion cell layer in
rodent retinas are displaced amacrine neurons rather than gan-
glion cells, whereas a subset of cells in the proximal inl belong to
displaced RGCs (Perry and Walker, 1980; Jeon et al., 1998). To
probe possible colocalization of TRPV4-IR with amacrine cells,
we immunostained the retina with an antibody against choline
acetyltransferase, amarker for starburst amacrine cells (Fig. 2G), and
with glutamic acid decarboxylase 65 (GAD-65), a marker for
Figure 1. Expression of TRPV4 at themRNA and protein levels inmouse retina.A, PCR amplicons for Trpv4 and glyceraldehyde-
3-phosphate dehydrogenase (Gapdh) isolated from total retinal RNA pool and separated on a 2% agarose gel. B, TRPV4 antibody
recognizes a primary band of 85 kDa and a secondary band at 105 kDa in wild-type adult mouse retina. No signal is detected in
TRPV4#/# retinas. C, TRPV4 antibody recognized amajor 105 kDa band in TRPV4-expressing HEK293 cell cultures and trigeminal
ganglion tissue; no signal was apparent in a TRPV4 nonexpressor line.D, Nodose ganglion. TRPV4-IR is observed in wild-type (Di)
but not TRPV4#/# (Dii) tissue.
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GABAergic amacrine cells (Figs. 2F, 3A) that constitute a substantial
fraction of displaced amacrine cells in the RGC layer (May et al.,
2007). These tests revealed no colocalization of TRPV4-IR with
ChAT-IR cells. Moreover, no colocalization with the dopaminergic
amacrine cell marker tyrosine hydroxylase was observed (data not
shown).A totalof4.6%ofcells that labeledwith theGABAergicmarker
GAD-65 stainedwith the TRPV4 antibody; however, the intensity of
TRPV4-IR signals in this subset of cells was
always significantly weaker compared with
Brn3a-IR cells. Occasionally, a Brn3a-IR or
SMI-32-IR cell bodywas detected in the inl.
These perikaryawere alwaysTRPV4 immu-
nopositive (Fig. 2L). Collectively, these data
indicate that TRPV4-IR is associated with
mouse retinal ganglion cells andmay be lo-
calized to a small subset ofGABAergic ama-
crine cells. Within the mouse ganglion cell,
TRPV4-IR is associated principally with the
perikaryon and the axon, but at least some
ganglion cell dendrites also express TRPV4
(Fig. 2D,F, arrow).
TRPV4-IR in retinal glial cells
Detailed inspection of TRPV4-IR in the in-
ner and outer retina revealed radial immu-
nopositive processes that correspond to
Mu¨ller macroglia (Fig. 2M). To assess
TRPV4 expression in astrocytes, sections
from the retina and at the glial lamina at the
optic nerve head were colabeled with the
glial fibrillar acidic protein (GFAP) anti-
body. No colocalization was observed, as
TRPV4 and GFAP signals in the retina and
the glial lamina appeared to label two dis-
tinct populations (Fig. 2I,J). Likewise,
costaining with the microglia-specific Mac-
1/CD11b antibody showed no overlap with
TRPV4(Fig.2M)but showedstaining in the
radial processes emanating from the inner
limiting membrane that may correspond to
Mu¨ller macroglia. These data indicate that in
thewild-typemouseretinaTRPV4isexcluded
fromastrocytes andmicrogliabut is expressed
inMu¨ller cells.
Physiological tests of TRPV4 function
in mouse retina
Identification of RGCs in short-term
culture
In retinal neurons isolated into short-
term culture (see Materials and Meth-
ods) GABAergic neurons, identified by
GAD65-IR, were invariably distinct from
cells showing TRPV4-IR (Fig. 3Ai–iii). It
was also apparent that TRPV4-IR cells
were larger than those immunostained by
GAD-65 (Fig. 3Aiii,B). Another test of
ganglion cell identity in cultured neurons
was immunoreactivity to an anti-Brn3a
antibody (Fig. 4Ai). Brn3a-IR cells were
invariably immunopositive for TRPV4,
whereas photoreceptor and presumed
amacrine perikarya were not (Figs. 2–4).
We extended measures of cell diame-
ters to Brna3a-IR and Thy1:CFP neurons in culture and com-
pared their dimensions to those of Brna3a-IR neurons in retinal
slices; the data are summarized in Figure 3B. Diameters of disso-
ciated Brn3a-IR cells were 9.1! 1.5 !m (N" 74; mean! SD),
not significantly different from 10.2 ! 1.8 !m (N " 58) in dis-
sociated Thy1:CFP cells and 10.3 ! 2.0 !m in Brn3a-IR cells in
Figure 2. TRPV4 immunoreactivity in the mouse retina. A, Vertical section of mouse retina. TRPV4-IR is expressed in ganglion cell
somataand throughout the ipl. TRPV-IR in theonl is expressed invertical fibers ofMu¨ller glial cellswhich run through this layer. Scalebars:
(inA)A–C, I–M, 20!m; (inA)D–G, 15!m; (inA)H, 40!m.B, Absenceof specific TRPV4 immunostaining in the retinaof a TRPV4-null
mouse. C, Transgenic retina produced by recombineering with copGFP sequence inserted cis- to the Trpv4 promoter (see Materials and
Methods). GFP (red) is localized to cytosol of retinal ganglion cells. D, Colocalization of TRPV4-IR (green) and Brn3a-IR (red), a ganglion
cell-specific protein in ganglion cell somata. Additional TRPV4-IR is seen in a ganglion cell dendrite (arrow) and in the ofl, which contains
ganglion cell axons en route to the optic nerve. E, Colocalization of TRPV4-IR (green) and GFP-IR (red) in a mouse line in which CFP was
coupled to the promoter of Thy-1, a ganglion cell specific protein. Colocalization is seen both in the ganglion cell bodies (yellow) and in a
ganglion cell dendrite (arrow). F, TRPV4-IR in ganglion cell bodies (green) does not colocalizewith GAD-65-IR (red).G, TRPV4-IR (green)
does not colocalizewith ChAT-IR (red) seen in cell bodies of starburst amacrine cells (red) and in twodiscrete horizontal bands in the ipl. A
labeledganglioncellbodyis indicatedbyanasterisk.H,Montageoftheopticnerve(on)showingimmunolabelingofopticnervefiberswith
TRPV4 (green). Cell nuclei are stained with Sytox Orange. bv, Blood vessel; ret, retina. I, Higher-magnification view of the optic nerve,
illustrating thatTRPV4-IR (green) is confined toopticnerveaxons,whereasastrocytes labeledwithaGFAPantibody (red)donot colocalize
withTRPV4-IR. J, Vertical sectionof retina illustratingganglioncells labeledwith theTRPV4antibody.GFAP-IR-labeledastrocytes in theofl
(red) do not colocalizewith TRPV4.K, Vertical section of retina illustrating boundary between ofl and on. TRPV4-IR (green) is seenwithin
these layers, and it colocalizeswith intermediate filament immunoreactivity (SMI-32; red). Themergedportions appear yellow. L, Vertical
sectionof retina illustratingadisplacedganglioncell (asterisk)at the inl/iplborder that colocalizeswithTRPV4-ir (green)andGFP-IRinmice
inwhichGFPiscoupledtotheThy-1promoter.Amacrinecellbodiesatthissameinterfacedonot labelwitheitherantibody.Alabeledganglioncell
(yellowprofile) inthegcl isseenatbottom.M,Vertical sectionofretina labeledwithantibodiesagainstTRPV4(red)andAlexaFluor-conjugatedrat
anti-mouseCD11B(green),amicroglial-specificantibody.TRPV4-IRisseeninganglioncellbodiesandMu¨llerglialcellprocesses.Twolabeledmicro-
glialcellsdonotcolocalizewithTRPV4-IR.
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retinal sections (N ! 201) (p " 0.05, Dunn’s multiple-
comparisons test) (Fig. 3B). The distribution of cell diameters
confirms that the vast majority of ganglion cells have diameters
!8"m, whereas GABAergic amacrines are almost invariably#8
"m. Moreover, the size distributions of ganglion cell diameters
based on the different criteria illustrated in Figure 3B are coex-
tensive. Thus, our selection of a neuron for physiological study
initially was made on the basis of cell diameter. In a few cases, we
recorded Ca2$ signals from cyan fluorescent protein (CFP)-
positive RGCs isolated from Thy1:CFP retinas, and in other experi-
mentswe confirmed the identity of TRPV4 agonist-responding cells
by immunostaining the test cells for TRPV4-IR and Brn3a-IR fol-
lowing drug exposure.
TRPV4 agonists induce an increase in [Ca2$]RGC
Once a putative RGC was selected for experimentation, we first
tested the ability of glutamate to evoke an increase in [Ca2$]i.
RGCs have ionotropic glutamate receptors that result in ganglion
cell depolarization and calcium entry, so a vigorous response to
glutamate is a good initial test of RGC viability. To evaluate func-
tional expression of TRPV4 channels in the retina, we measured
calcium concentrations in dissociated RGCs before and after
TRPV4 agonist application, using ratiometric Ca2$ imaging of
RGCs loaded with Fura-2 AM.
On average, glutamate (100"M) evoked a [Ca2$]RGC increase
of 490% 25 nM (mean% SE) over a baseline of 45% 2 nM (N!
216; p# 0.0001, Wilcoxonmatched-pairs signed ranks test). En-
dogenous TRPV4 channels in dissociated neurons were activated
with the following two selective TRPV4 activators: the synthetic
phorbol ester 4#-phorbol 12-myristate13-acetate (didecanoate;
4#-PDD), which directly binds to the transmembrane region of
the protein (Watanabe et al., 2002; Vriens et al., 2007; Loukin et
al., 2010a); and the recently characterized high-affinity agonist
GSK1016790A (hereafter GSK; EC50 &1–10 nM) (Thorneloe et
al., 2008; Willette et al., 2008). Figure 4B illustrates a simultane-
ous recording from two putative RGCs that responded to gluta-
mate and the twoTRPV4 agonists (GSK, 25 nM; 4#-PDD, 30"M).
At 25 and 100 nM, GSK elicited robust [Ca2$]i increases in 40.5
and 47.2% of glutamate-responding cells (N! 10 and 4 experi-
ments), respectively (Figs. 4, 5, 6). In the continued presence of
TRPV4 activators, [Ca2$]i levels typically exhibited a decline,
consistent with desensitization of the channel (Fig. 4B).
Mean [Ca2$]RGC elevation induced by 25 nM GSK was 381%
41 nMover the [Ca2$]RGC baseline (Fig. 4G) (N! 23; p# 0.0001,
Wilcoxon matched-pairs signed-ranks test), whereas 100 nM
GSK elevated [Ca2$]i by 600 % 210 nM (N ! 9; p # 0.004,
Wilcoxon matched-pairs signed-ranks test). In 15 putative
RGCs, 4#-PDD (30 "M) increased the 340/380 ratio from
0.464 % 0.029 to 1.430 % 0.097 (p # 0.0001, paired t test) (Fig.
4B,E). When cells that had been stimulated with TRPV4 activa-
tors were subsequently immunostained for TRPV4 and Brn3a,
the two markers labeled responding cells (Fig. 4D, arrowhead)
but not GSK-insensitive cells. The average diameter of cells that
responded to TRPV4 agonists was 8.9% 1.0"m, not significantly
different from diameters of Thy1:CFP and Brn3a-IR dissoci-
ated cells (p" 0.05) (Figs. 3B, 4H). The very substantial over-
lap of these two populations, responders and immunoreactive
cells, provides more evidence that at least the great majority
of cells selected for physiological study were retinal ganglion
cells. Our data would also suggest that a subset of large-
diameter RGCs may not express TRPV4 (Fig. 3B) or respond
to TRPV4 agonists (Fig. 4G).
Ruthenium Red and lanthanides are nonselective TRP chan-
nel blockers that also antagonize activation of TRPV4 channels
(Liedtke et al., 2000; Strotmann et al., 2000; Watanabe et al.,
2002). [Ca2$]i responses to GSK and 4#-PDD were suppressed
by Ruthenium Red (10 "M; N! 85) (Fig. 4D,E,G). The antago-
nist decreased the amplitude of GSK-evoked [Ca2$]i responses
from 341% 41 nM (N! 23) to 139% 22 nM (Fig. 4G) (N! 16;
p! 0.0001, Mann–Whitney test) and reduced the percentage of
cells responding toGSK from40.5% 6.7 (N! 10) to 16.9% 4.2%
(N ! 4; p ! 0.026, unpaired t test). In the phorbol ester-
Figure 3. TRPV4 is not expressed in amacrine cells. A, Double labeling for GAD-65-IR (Ai;
blue), TRPV-IR (Aii; green), and superimposed transmitted image (Aiii) shows that TRPV4
signals are expressed in apopulationof cells that is distinct fromGABAergic amacrine cells. Scale
bar, 10"m. B, The distribution of cell diameters from dissociated RGCs that were (Brn3a) or
werenot (Thy1:CFP$) fixed, overlapswithBrn3a-IR somata fromretinal sections. Little overlap
in diameter distributions is seen between the RGC cohorts and GABAergic cells.
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insensitive cell depicted in Figure 4E, Ruthenium Red by itself
lowered baseline [Ca2!]i (arrowhead), indicating suppression of
tonic Ca2! influx through TRP-like channels. On average, Ru-
theniumRed decreased baseline [Ca2!]i from 50" 3 nM to 47"
4 nM (N # 133; p # 0.0003, Wilcoxon matched-pairs signed-
ranks test).
The rise in intracellular Ca 2! induced by exposure to GSK
depends on extracellular Ca2!. Figure 4F illustrates that a test
cell shows normal increases in [Ca2!]i in responses to GSK in
2 mM [Ca2!]o, but this increase was abolished in zero extra-
cellular [Ca 2!]o (N # 8; p # 0.78, paired t test). The mean
fluorescence changes induced by glutamate or GSK in normal
versus zero extracellular Ca2! are summarized in the inset to
Figure 4F.
Ligand-evoked [Ca2!]i increases in mouse RGCs can be aug-
mented by secondary contributions from voltage-operated Ca2!
channels (Hartwick et al., 2008). We therefore investigated
whether the response to 25 nM GSK was affected by suppression
of voltage-operated Ca2! entry. In the presence of the nonselec-
tive voltage-gated calcium channel antagonist cadmium (Cd2!;
100 !M), high KCl (30 mM)-evoked [Ca2!]i increases were
blocked (N # 5; data not shown). Nonetheless, GSK elevated
[Ca2!]i to 355 " 110 nM in Cd
2!-containing saline (N # 6), a
value not significantly different from responses to the agonist
alone (p $ 0.89, Mann–Whitney test). Cd2! had no significant
effect on the percentage of GSK-responding cells (31.3 " 5.2%;
p$ 0.36, unpaired t test).
A representation of glutamate- and GSK-evoked [Ca2!]i ele-
vations in a presumedRGC is represented graphically in Figure 5.
This cell was proximal to a perikaryon from a presumed rod
photoreceptor (Fig. 5A). A 60 s exposure to a saturating concen-
tration of the neurotransmitter (100 !M) and sustained (5 min)
exposure to GSK (25 nM) evoked an increase in global free
[Ca2!]i across the RGC cytosol, with superimposed local [Ca
2!]i
elevations. The response to the TRPV4 agonist desensitized dur-
ing continued exposure (Fig. 5 J,K) in contrast to responses to
sustained [Ca2!]i elevations that were observed during 3–5 min
exposures to glutamate. No changes in [Ca2!]i were observed in
the simultaneously recorded rod perikaryon.
Figure 4. TRPV4 agonists selectively elevate [Ca 2!]i inmouse RGCs.A, Brn3a-IR (Ai) and TRPV4 (Aii) colocalize in two RGCs (Aiii). TRPV4-IR is absent fromputative amacrine somata (asterisks).
Scale bar, 5!m. B, Application of GSK1016790A or 4"-PDD induces Ca 2! influx into two simultaneously recorded RGCs. C, Four retinal cells immunostained for Brn3a and TRPV4. The cell that
responded toGSKwith [Ca 2!]i increase, butnotnonresponders, exhibited colocalizationofBrn3a (i) andTRPV4 (ii) immunoreactivity after fixationand immunolabeling. iii, Transmitted imagewith
superimposed TRPV4 and Brn3a signals. Scale bar, 5!m.D, GSK-induced [Ca 2!]i responses are antagonized by RutheniumRed (RR). E, Simultaneous recording from a putative RGC (red trace) and
a putative amacrine cell (black trace) stimulated with 4"-PDD. Ruthenium Red antagonizes TRPV4 agonist responses evoked in the RGC. The amacrine cell is unresponsive to 4"-PDD; however,
Ruthenium Red slightly reduced baseline [Ca 2!]i in this cell (arrowhead). F, Putative RGC, stimulated with GSK in the presence and absence of extracellular Ca
2!. Extracellular calcium is required
for agonist-evoked [Ca 2!]i elevations. Inset, Comparison of [Ca
2!]i for glutamate, GSK, baseline levels in Ca
2!-free saline and in 0 Ca 2!! 25 nM GSK. G, Cumulative [Ca 2!]i for calibrated RGC
baseline and responses to glutamate (100!M), GSK (25 and 100 nM), GSK (25 nM)! Ruthenium Red (10!M) and Ruthenium Red alone. *p% 0.05; **p% 0.001; ***p% 0.0001.H, Distribution
of cell diameters for dissociated RGCs (Thy1:CFP and Brn3-IR cells; black trace) and putative RGCs that responded to TRPV4 agonists (green trace).
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Hypotonic stimuli evoke changes in cytosolic [Ca2!]i
TRPV4 was originally identified as a plasma membrane channel
activated by hypotonic cell swelling (Liedtke et al., 2000; Strot-
mann et al., 2000; Watanabe et al., 2002; Vriens et al., 2004;
Loukin et al., 2010a). A decrease in extracellular osmolarity in-
duces Ca2! influx through TRPV4 channels (Gu¨ler et al., 2002;
Liedtke andFriedman, 2003; Raoux et al., 2007; Phan et al., 2009).
To determine whether hypotonicity modulates [Ca2!]RGCs, cells
were exposed to saline solutions with osmolarity reduced from
280 to 190 mOsm. As illustrated in Figure 6A for an RGC loaded
with the Ca2!-insensitive cell-volume indicator dye calcein AM,
a reduction in osmolarity of the superfusing saline from 280 to
192 mOsm saline evoked sustained swelling of the cell. The re-
sulting increase in cell volume was detected as a decrease in the
intensity of calcein fluorescence (Fig. 6A, green trace). In contrast
to hypotonic stimuli, no change in intracellular volume was ob-
served during exposure to 100 !M glutamate.
Cell swelling was accompanied by tonicity-dependent eleva-
tions in [Ca2!]i. The 190–195 mOsm saline evoked an average
[Ca2!]i increase of 439" 59 nM (N# 48; p$ 0.0001) (Fig. 6) in
72 " 7% of putative RGCs. During continued stretch, [Ca2!]i
levels gradually returned to control levels, indicating desensitiza-
tion of themechanosensingmechanism (Fig. 6). The diameters of
cells that responded to hypotonic stimulation with [Ca2!]i in-
creases (8.7 " 1 !m; N # 126) were not significantly different
from diameters of dissociated Brn3a-immunopositive cells
(9.1 " 1.5 !m; p % 0.05; N # 74) (Fig. 6E). Swelling-mediated
[Ca2!]i signals alsoweremeasured in the presence of gadolinium
(Gd3!), a universal antagonist of Ca2!-permeable TRP channels
(includingTRPV4) (Gustin et al., 1988; Becker et al., 2005).Gd3!
(100 !M) reduced, from 72.1 " 6.7% (N # 10) to 26.0 " 9.5%
(N# 3 slides), the percentage of RGCs that responded to hypo-
tonic stimulation with a [Ca2!]i increase (p $ 0.02, unpaired t
test, Welch corrected) but had no effect on cell swelling, as indi-
cated by unchanged calcein responses (Fig. 6A). Overall, the am-
plitude of hypotonic stretch-induced [Ca2!]i increases was
reduced by Gd3! to 261 " 42 nM (N # 17; p $ 0.05, Mann–
Whitney test). Hypotonicity-induced [Ca2!]i responses were
suppressed by Ruthenium Red to 206 " 21 nM (N # 22; p $
0.0001, Mann–Whitney test) (Fig. 6C,D), and the percentage of
RGCs responding to hypotonic stimulation in the presence of the
antagonist decreased from 72.1" 6.7% (N# 10) to 16.9" 4.2%
(N# 3 slides; p$ 0.005, unpaired t test, Welch corrected).
We asked whether hypotonically induced [Ca2!]i elevations
are mediated by TRPV4. [Ca2!]i increases induced by TRPV4
agonists andmembrane stretch typically desensitized with a time
constant of several tens of seconds. Stimulation with GSK at the
asymptotic end of the desensitized response elicited little or no
change in [Ca2!]i (169.9" 66.2 nM), whereas significant [Ca
2!]i
increases (524.0 " 63.8 nM) were measured following washout
with isotonic saline (Fig. 6G) (N # 14; p $ 0.002, Wilcoxon
matched-pairs signed-ranks test). Of 84.4" 4.6% putative RGCs
that responded to hypotonic stimuli in this experiment, 2.0" 0.7%
exhibited a response toGSK duringmembrane stretch, significantly
less than the 51.7" 7% that responded to GSK alone (N# 3 slides,
14 cells; p $ 0.05, paired t test). To confirm that hypotonic cell
swelling evoked Ca2! influx from the extracellular space, cells were
challenged with Ca2!-free saline. RGCs responding to hypotonic
stimulation in 2mMCa2!-containing salinewith [Ca2!]i elevations
displayed no change in [Ca2!]i in Ca
2!-free hypotonic saline (N#
0/14) (Fig. 6D). Thus, stretch-induced [Ca2!]i elevations in RGCs
primarily depend on entry of extracellular Ca2! rather than on re-
lease from intracellular stores. Together, these data indicate that
RGCs express anosmosensitive channel that exhibits thepharmaco-
logical profile of TRPV4.
GSK-responding RGCs constituted a subset of the total
hypotonicity-sensitive cell cohort, possibly indicating the expres-
sion of other volume increase-sensitive channels within RGCs.
We therefore tested for functional expression of TRPV1, another
vanilloid TRP channel that has been associated with pressure-
sensitive [Ca2!]i responses in RGCs (Sappington et al., 2009).
Under our experimental conditions, the TRPV1 agonist capsai-
Figure 5. GSK-induced [Ca 2!]i dynamics in an RGC. A, Transmitted image of a putative RGC and rod photoreceptor. Scale bar, 5 !m. The temporal progression of upper and lower image
sequences is illustrated by the adjacent traces.B,G, Unstimulated cells perfused with control saline. C,D, The RGC responds to the bath application of glutamate with a large increase in [Ca 2!]i. E,
F,Washout. Scale bar:F, 340/380 ratio level.H–K, ApplicationofGSK transiently elevates [Ca 2!]i in theRGCbutnot the rod. J,K, [Ca
2!]i levels decline in the continuedpresenceofGSK. L,Washout.
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cin (5–100!M) did not induce a rise in [Ca2!]i in acutely isolated
mouse RGCs (N" 110). Moreover, the selective TRPV1 antago-
nist capsazepine (5 !M) had no effect on the amplitude of hypo-
tonic stretch-evoked increases (487# 59 nM in controls;N$ 48
vs 429 # 48 in the presence of capsazepine; N $ 29; p $ 0.39,
Mann–Whitney test) (Fig. 6C) or the percentage of cells respond-
ing to hypotonic stimulation (N $ 2;
62.0 # 14.9%; p $ 0.62, unpaired t test).
These results argue against a significant
role for TRPV1 signals in stretch-evoked
Ca2! signaling in mouse RGCs.
TRPV4 agonists modulate RGC firing
Given that TRPV4 activation elevates
[Ca2!] in RGCs, we asked whether the
depolarizing cation influx through the
TRPV4 channel modulates RGC excit-
ability. Intact retinas were isolated from
the eye and positioned on MEAs, which
allow recording of spontaneous spikes
from many RGCs simultaneously (Rent-
ería et al., 2006). Perfusion with the
TRPV4 agonists 4"-PDD (5 !M) or GSK
(100 or 300 nM) evoked a transient in-
crease in the frequency of spontaneous
firing in a subset of recorded RGCs. The
spike rates of three RGCs, in which typical
increases in spiking after GSK application
occurred, are shown in Figure 7A. For all
recorded cells, the average firing rate dur-
ing the first 3 min after drug application
was compared with the preapplication
frequency (4"-PDD:N$ 160 RGCs from
three retinas; GSK:N$ 115 RGCs from 4
retinas). Figure 7, B and C, shows the
changes in cell firing evoked by each
TRPV4 agonist as a percentage of the pre-
application firing frequency. Each agonist
evoked increased spike rates of twofold or
more in a large percentage of the recorded
RGCs (Fig. 7B,C, arrows) (p % 0.00001
for 4"-PDD; p% 0.02 for GSK; Wilcoxon
signed-rank test). The increase in spike
rate during drug application was tran-
sient, exhibiting significant adaptation in
the continued presence of drug (Fig. 7A).
Displaced amacrine cells either do not
spike (Zhou and Fain, 1996) or express
few action potentials in response to depo-
larizing current injection (Ozaita et al.,
2004). This suggests that the majority of
cells responding to TRPV4 agonists were
RGCs, although some nonresponders (5–
10%/retina) may have been displaced
amacrine cells. These experiments indi-
cate that TRPV4 activation transiently in-
creased RGC excitability and augmented
RGC output from the retina.
Sustained activation of TRPV4 channels
is cytotoxic for RGCs
Wenext consideredwhether extendedstim-
ulation with a TRPV4 agonist impacts the
survival of acutely isolated RGCs. As shown previously (Otori et al.,
1998; Hartwick et al., 2008), 1 h incubation with the AMPA/KA
receptor agonist kainate (10!M) increased the number of TUNEL-
positive cells by 68# 7% (N$ 305; p% 0.0001, Mann–Whitney)
(Fig. 8B,D), whereas RGCs exposed only to control saline supple-
mentedwith L15 showed little TUNEL signal (Fig. 8A,D). Exposure
Figure 6. Cell stretch elevates [Ca 2!]RGC. A, Simultaneous recording of RGC volume (calcein, green trace), 340 nm (red trace),
380nm(blue trace) intensities, and [Ca 2!]i (fura-2 ratio, black trace). An increase in RGC volumewas indicatedby adrop in calcein
fluorescence intensity during hypotonic stimulation (decreased osmolarity in superfusing saline from 280 to 192 mOsm). Gluta-
mate stimulation increased [Ca 2!]i but evoked no change in the calcein signal. The increase in [Ca
2!]i induced by hypotonic
stimulation was antagonized by Gd 3!. B, Hypotonically induced [Ca 2!]i elevations are antagonized by Ruthenium Red. C,
Cumulative total for calibrated RGC [Ca 2!]i responses to glutamate (100!M), hypotonic stimulation (192mOsm), and hypotonic
stimulation in the presence of capsazepine, Ruthenium Red (10!M) or Gd 3! (100!M). NS, p" 0.05; *p% 0.05; **p% 0.001;
***p% 0.0001.D, [Ca 2!]i trace from a GSK-sensitive RGC. Hypotonically evoked [Ca
2!]i increase requires Ca
2! influx from the
extracellular space. Inset, Relative [Ca 2!]i totals for control and hypotonically stimulated RGCs with and without the presence of
extracellular calcium. E, Distribution of cell diameters from dissociated RGCs (Thy1:CFP and Brn3-IR cells; black trace) and the
hypotonicity-responding cohort (green trace). F, Hypotonicity-responding cell, labeled with TRPV4 and Brn3a antibodies. Scale
bar, 10!m. G, Hypotonicity-induced membrane stretch occludes the response to GSK. The volume decrease following the hypo-
tonic step was associated with a transient increase in [Ca 2!]i. H, Cumulative calibrated responses to glutamate (100 !M),
hypotonic stimulation (190–195 mOsm), GSK (25 nM) and GSK in the presence of hypotonic stretch shows a marked reduction in
the amplitude of the TRPV4 agonist-evoked response during mechanical stimulation.
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to GSK1016790A induced significant cell
death,whichwas confined to cellswith large
somata (!6 !m, arrowheads). The 25 nM
GSK induced TUNEL-positive signals in
33" 7% (N# 1523; p# 0.0002), and 100
nM GSK induced TUNEL labeling in 67 "
13% of presumed RGCs (N # 917; p $
0.0005). GSK had relatively little effect on
signals in presumed photoreceptor per-
ikarya (cell diameters, 3–5!m; arrows).
Discussion
This study provides anatomical, molecular,
and physiological evidence that the poly-
modal pressure-sensitive TRPV4 ion chan-
nel participates in the transduction of
hypotonic stimuli and contributes toCa2%-
dependent intracellular signaling andmem-
brane excitability of mammalian RGCs.
First, we have shown that the wild-type
mouse retina expresses TRPV4 mRNA and
protein. Second, we show that the TRPV4
protein is localized primarily in RGC so-
mata and axons. Third, usingCa2% imaging
and MEA recording, we directly demon-
strate that TRPV4 channels contribute to
transmembrane Ca2% flux and spike firing
rates of RGCs. Finally, we show that phar-
macological characteristics of hypotonicity-
induced [Ca2%]i increases in RGCs match
the known pharmacology of TRPV4 and
that sustained activation of this subtype of
TRPVchannels initiates cell death pathways
in RGCs.
In the mouse retina, almost every cell
identified with RGC-specific markers
(Thy1:CFP; Thy1:GFP; Brn3a; SMI-32)
was immunopositive for TRPV4, indicat-
ing that all identified RGC perikarya ex-
press TRPV4. TRPV4-IR was particularly
prominent within RGC axons in the nerve
fiber layer and the optic nerve head, both
of which represent initial targets for dele-
terious effects of increased IOP. TRPV4 staining was excluded
from amacrine, astrocytic, and microglial processes in the retina
but was apparent in Mu¨ller cell processes. Our demonstration of
the localization of the channels to RGCs suggests that retinal
output neurons are capable of transducing mechanical, thermal,
and/or osmotic stimuli.
Functional role for TRPV4 in the retina
Cell stretch induced by hypotonic swelling caused a marked in-
crease in [Ca2%]i of RGCs. Because the restingmembrane poten-
tial of RGCs is within the operational range for inactivating and
persistent Na% conductances (& '60 mV) (Kim and Rieke,
2003; Hayashida and Ishida, 2004; Margolis et al., 2010), we pos-
tulate that sustained depolarization through stretch-sensitive
cation-permeable channels will contribute to the excitability and
dynamic range of RGC responses (Shibasaki et al., 2007) by coun-
tering, in a significant subset of RGCs, the tonic inhibitionmedi-
ated by GABAergic and glycinergic amacrines. Consistent with
this hypothesis, TRPV4 activators 4"-PDD and GSK1016790A
elevated [Ca2%]i and caused a !100-fold increase in the fre-
quency of spontaneous RGC spiking. While TRPV4 activation
may also have influenced the increase in spiking through recip-
rocal neuroglial interactions (Newman, 2001), the comparable
time courses of agonist-evoked [Ca2%]i signals and spike firing
argues for a predominant action on RGCs themselves. This find-
ingmay be relevant to entoptic physiology as it implicates TRPV4
channels in the perception of “pressure phosphenes” believed to
originate in RGCs (Gru¨sser et al., 1989).
The effects of pharmacological and hypotonic stimulation ob-
served in RGCs are consistent with properties of heterologously
expressed and endogenous TRPV4 channels (Liedtke et al., 2000;
Strotmann et al., 2000; Becker et al., 2005; Hartmannsgruber et
al., 2007). Plasma membrane ion channels activated by an in-
crease in cell volume were reported to be identical to TRPV4
agonist-sensitive channels with respect to Ca2% permeability,
rectification behavior, and permeability sequence of monovalent
cations (Watanabe et al., 2002; Phan et al., 2009). While all
Brn3a-IR and Thy1:CFP-positive cells labeled with TRPV4 anti-
bodies, only a subset of dissociated putative RGCs was activated
by hypotonic stimulation (&72%) or TRPV4 agonists (&16.7–
Figure 7. TRPV4 agonists transiently increase spontaneous firing rate of RGCs. A, The spontaneous firing rates of three RGCs
recordedonamultielectrode array are shownduring the application of GSK at time0 (300nM; black bar). The rate increased for 2–3
min before returning to the initial baseline level during the continued presence of the drug for nearly all responsive cells. B, A
histogram of the change in firing rates of individual RGCs during the 3 min after 4"-PDD (5!M) application compared with the
pretreatment firing rate is shown for all cells recorded from three treated retinas. Cells with a rate double or higher in drug are
combined in the rightmost bin (!100; arrow); nearly half of the cellswere in this category, andmost cells increased their firing. As
with GSK, the increasewas transient (not illustrated). C, Histogramas inB, but here the applied drugwas GSK (100 or 300 nM;N#
4 retinas). As inB, cells with a spike rate double or higher during the initial period of drug exposure are combined in the rightmost
bin (!100; arrow), constituting!12% of the recorded cells. The bias in the distribution to positive values reveals that most cells
increased firing in response to GSK application.
Figure8. Exposure to TRPV4agonist induces RGCapoptosis.A, TUNEL (FITC)% transmitted image in control dissociatedmouse
retinal cells. No TUNEL staining is observed under control conditions.B, TUNEL staining% transmitted image. Cells were exposed
to kainate (KA; 10!M) for 1h.Ci,Cii, Transmitted imageandTUNEL staining in cells exposed for 1h to25nMGSK.Arrowheadspoint
at putative RGCs; arrows point at putative photoreceptors. Scale bars, 10!m.D, Cumulative data for putative photoreceptors (cell
diameters 3–5!m)andputative RGCs (cell diameters!6!m) in L15medium, 25nMGSK, 100nMGSK, andKA in all experiments.
**p$0.001; ***p$ 0.0001.
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95.8%). We attribute the variability in stretch- and agonist-
induced responses to the mechanical trauma associated with the
dissociation protocol, which may have compromised a necessary
step in TRPV4 activation. It is possible that, as suggested for other
tissues (Raoux et al., 2007; Sharif-Naeini et al., 2008; Alessandri-
Haber et al., 2009), RGC plasma membranes have other volume
increase-sensitive channels such as TRPC1, TRPV1, TRPV2,
TREK-1, 2, or TRAAK (TWIK-related arachidonic acid-stimulated
potassium channel) (Maingret et al., 1999; Reyes et al., 2000;
Križaj, 2005; Leonelli et al., 2009). In particular, TRPV1 was re-
cently implicated in mediating [Ca2!]i increases and pressure-
induced apoptotic cell death in cultured rat RGCs (Sappington et
al., 2009). While no isoforms of TRPV1 are known to be affected
by hypotonic stimulation (Liedtke et al., 2000; Strotmann et al.,
2000; Loukin et al., 2009) and stimulation with specific TRPV1
agonists/antagonists failed to induce changes in [Ca2!]i in
acutely dissociated mouse RGCs under isotonic or hypotonic
conditions, the difference between our study and that of Sapping-
ton et al. (2009) can be attributed in part to the dramatic upregu-
lation of Trpv1 gene expression in cultured RGCs. We propose
that TRPV4 is a necessary sensing/transducer protein that partic-
ipates in the RGC response to volume increase, whereas TRPV1
may contribute to RGC excitability as well, once upregulated
under certain culture conditions.
Consistent with a role in sensory transduction, TRPV4 is
expressed in sensory neurons of dorsal root ganglia, in the
trigeminal ganglion, and in hair cells (Liedtke et al., 2000;
Alessandri-Haber et al., 2009). A major TRPV4 role in healthy
RGCs may be to function as an osmoreceptor (Liedtke et al.,
2003; Liedtke and Kim, 2005). The RGC cytosolic volume
should be susceptible to local changes in tonicity that occur dur-
ing the light response or retinal waves (Huang and Karwoski,
1992; Dmitriev et al., 1999). Swelling-induced increases in
[Ca2!]i, but not swelling itself, were suppressed by Gd
3! and
Ruthenium Red, two compounds that inhibit osmosensory
transduction (Liedtke et al., 2003; Bourque, 2008). Activation of
endogenous TRPV4 channels has been implicated in other
mechanotransduction events including shear stress in vascular
endothelia (Hartmannsgruber et al., 2007), stretch-induced in-
tegrin signaling (Thodeti et al., 2009), shear stress-mediated re-
laxation of endothelial cells (Mendoza et al., 2010), and viscous
load-coupled ciliary activity in epithelial cells (Andrade et al.,
2005).
Implications for glaucoma
TRPV4 localization to the NFL, ONH and the proximal optic
nerve together with proapoptotic effects of sustained TRPV4
channel stimulation appear to implicate this channel in the initi-
ation and progression of glaucomatous remodeling. The
pressure-induced activation range of TRPV4 (10–30 mmHg)
(Loukin et al., 2010b) matches the sustained IOP elevations in
chronic glaucoma that can span a range of 10 to several tens of
mmHg over the control value of 10–15 mmHg (Bonomi et al.,
2001; Quigley, 2005; Whitmore et al., 2005). Increases in hydro-
static or intraocular pressure are correlated with RGC death in
cell cultures (Tezel and Wax, 2000; Agar et al., 2006), isolated
retinas (Resta et al., 2007), the acute rat glaucoma model (Mor-
rison et al., 1997), the chronic DBA/2J mouse model (John et al.,
1998; Libby et al., 2005b), and human glaucoma patients (Bo-
nomi et al., 2001; Gordon et al., 2002), whereas lowering of the
IOP slows the progression of axonal loss at all stages of glauco-
matous degeneration (Quigley, 2005). Rapid and severe IOP rises
(such as occur in acute angle closure glaucoma) (Saw et al., 2003)
may cause RGC loss within hours (Naskar et al., 2002) by com-
promising RGC function at their axons (Quigley, 1983) and their
cell bodies (Libby et al., 2005a; Agar et al., 2006; Liu et al., 2007).
Our calcium imaging and immunolocalization experiments
suggest that RGC perikarya and axons could be targeted by
changes in mechanical and osmotic pressure. At the level of the
perikaryon, [Ca2!]RGC increases induced by membrane stretch
and TRPV4 agonists hadmaximal amplitudes comparable to lev-
els evoked by intense stimulation of ionotropic glutamate recep-
tors. Consistent with the hypothesis that RGCs represent the first
responder to an acute increase in IOP is the finding that the
cornea-positive arm of the scotopic threshold response, the com-
ponent of the visual ERG response that is the most sensitive to
increased IOP, has a significant contribution from RGCs (Bui
and Fortune, 2004; Kong et al., 2009). While retinal astrocytes
and microglia were not immunolabeled by the TRPV4 antibody,
it remains to be determined whether retinal glial TRPV4 expres-
sion is affected by sustained IOP increases, a possibility based on
TRPV4 expression in cortical astrocytes (Benfenati et al., 2007)
and the sensitivity of astrocyte Ca2! homeostasis to increases in
hydrostatic pressure (Mandal et al., 2010).
While the Trpv4 gene plays a critical function in regulation of
systemic tonicity in mammals (Liedtke et al., 2000; Bourque,
2008; McHugh et al., 2010), inappropriate activation of TRPV4
in rodents and canines produces an acute circulatory collapse
associated with edema, pulmonary hypertension, endothelial in-
jury, ischemia, and/or cell death (Willette et al., 2008).We report
that sustained exposure to TRPV4 agonists compromises the vi-
ability of mouse RGCs by triggering the apoptotic process, con-
sistent with the observation that even low levels of elevated
[Ca2!]i are toxic for RGCs if sustained over an extended period
of time (Hartwick et al., 2008). RGCs express the PAR-2 receptor
that has been implicated in sensitization of TRPV4 to mechanical
stimuli (Luo et al., 2005; Grant et al., 2007). Moreover, gain-of-
function TRPV4 mutations cause a range of cellular problems that
include axonal neuropathy and suppression of growth (Camacho et
al., 2010; Loukin et al., 2010b; Zimon´ et al., 2010). Thus, antagoniz-
ing excessive TRPV4 activationmay be protective against apoptosis
in RGCs stressed by sustained mechanical and/or osmotic
stimulation.
Together, our data indicate the presence, in mammalian
RGCs, of a novel background cation-permeable channel that
confers mechanical/pressure sensitivity to cells that convey light-
evoked signals to visual centers in the brain. The TRPV4 mecha-
nism in RGCs represents a prime molecular target for severe
blinding diseases such as diabetic retinopathy and glaucoma.
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CHAPTER 6 
 
SWELLING AND EICOSANOID METABOLITES 
DIFFERENTIALLY GATE TRPV4 CHANNELS 
IN RETINAL NEURONS AND GLIA 
 
Daniel A. Ryskamp, Nanna MacAulay, Andrew O. Jo, Amber Frye, Felix Vazquez-
Chona, Wallace B. Thoreson and David Krizaj contributed to experiments, analysis 




Dramatic shifts in ions and water accompany neuronal and glial activity and can 
generate osmotic forces that have biological consequences for brain physiology. Active 
regulation of osmotic gradients and cellular volume requires coordinated operation of 
aquaporin water channels and volume-sensitive ion channels. In the vertebrate retina, 
Müller astroglia provide critical support to retinal neurons by regulating the transport of 
ions, metabolites and water, but the identity of their osmosensor is unknown. Here, we 
identify TRPV4 channels as necessary and sufficient to transduce increases in mouse 
Müller cell volume into physiological responses. Hypotonic stimuli induced sustained 
[Ca2+]i elevations that were inhibited by TRPV4 antagonists and absent in TRPV4-/- 
Müller cells. Glial TRPV4 signals were phospholipase A2 (PLA2)-dependent, 
characterized by slow-onset and Ca2+ waves, and, in excess, were sufficient to induce 
reactive gliosis. In contrast, neurons responded to TRPV4 agonists and swelling with fast, 
inactivating Ca2+ signals that were independent of PLA2, suggesting that neuronal 
TRPV4 is either direct gated by membrane stretch or by a novel force-transduction 
pathway. PLA2 and arachidonic acid signaling was previously implicated in pathological 
glial swelling. Here, we demonstrate that Ca2+ influx via TRPV4 is required for PLA2-
mediated glial swelling. TRPV4 signals in Müller glia and heterologously expressing 
Xenopus oocytes were amplified by water fluxes and swelling mediated by glial-specific 
aquaporin-4 (AQP4). Our results support a model whereby swelling and proinflammatory 
signals differentially gate TRPV4 in retinal neurons and glia with potentially significant 





The ability to sense increases in cell volume represents a primal sensory modality 
employed by cells and organisms as they detect and adapt to activity-dependent changes 
in their physical environment. Within the central nervous system (CNS), swelling induces 
compensatory relocation of ions/water and long-term changes in enzyme activation/gene 
expression in neurons and glia, but can also result in excitotoxicity, cytotoxic/vasogenic 
edema and irreversible loss of neural function (Hoffmann et al., 2009; Pasantes-Morales 
& Cruz-Rangel, 2010). Astroglial swelling results in increased intracellular calcium 
concentration [Ca2+]i, PLA2 activation,  release of arachidonic acid (all-cis-5,8,11,14-
eicosatetraenoic acid; AA) and production of oxygen-derived free radicals (Staub et al., 
1994; Hoffmann et al., 2009; Thrane et al., 2011); however, the detailed molecular 
mechanisms that underlie transduction of cellular swelling within the brain into the 
physiological response remain to be elucidated.  
Müller cells mediate bidirectional ion and water transport between retinal neurons 
and vascular endothelial cells in part through strategically placed ion channels and 
aquaporin 4 (AQP4) water channels. Under pathological conditions, AQP4-mediated 
water fluxes drive glial swelling and AA/eicosanoid release and may contribute to 
excitotoxic edema and ischemic damage (Da & Verkman, 2004; Reichenbach & 
Bringman, 2006; Verkman et al., 2008). Still, the relationship between glial 
osmotransduction and arachidonic signaling in the retina or the brain is not well 
understood (Reichenbach & Bringman, 2006). Here, we provide evidence that the 
TRPV4 (transient receptor potential vanilloid type 4) channel mediates Müller cell 
osmosensing, define its link to PLA2 and its downstream metabolite 5’6’-
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epoxyeicosatrienoic acid (5’6’-EET), and formulate a mechanistic framework for 
TRPV4-AQP4 interactions in astroglial volume regulation.  
Gain/loss of TRPV4 function has been related to deficient osmoregulation, force 
transduction and numerous neurological and musculoskeletal phenotypes (Liedtke & 
Friedman, 2003; Tian et al., 2009; Loukin et al., 2010; Nilius & Voets, 2013). 
Nonetheless, the gating mechanism of this ubiquitous channel (Strotmann et al., 2000; 
Nilius et al., 2004; Kunnert-Keil et al., 2006; Ryskamp et al., 2011) remains unclear. The 
canonical view, that TRPV4 activation requires the involvement of PLA2 and 
epoxygenase (Watanabe et al. 2003a; Nilius et al., 2004; Vreins et al., 2004), has been 
challenged by studies in heterologously transfected yeast, oocytes and sensory neurons 
(Loukin et al., 2009; 2010; Lechner et al., 2011).  Here, we show that activation of 
astroglial, but not neuronal, TRPV4 channels requires AA and/or its metabolite 5’6’-EET 
and is potentiated by water influx through AQP4. Moreover, TRPV4-dependent Ca2+ 
influx enables further swelling in a hypoosmotic gradient and is sufficient to trigger glial 
reactivity. This provides a cellular and molecular framework with mechanistic insight 
into known relationships among glial swelling, mechanical stress, proinflammatory 
signaling and edema (Pannicke, et al., 2006; Reichenbach & Bringmann, 2006; Pinar-
Sueiro et al., 2011; Krizaj et al., 2014), and thus, a potential novel target for therapeutic 







6.3 Materials and Methods 
6.3.1 Animals 
All experiments adhered to the NIH Guide for the Care and Use of Laboratory 
Animals and the Association for Research in Vision and Ophthalmology Statement for 
the Use of Animals in Ophthalmic and Vision Research and were approved by the 
Institutional Animal Care and Use Committees at the University of Utah and the 
University of Nebraska Medical Center. Mouse strains C57BL/6J, B6.Cg-Tg(Thy1-
CFP)23Jrs/J and pan-null TRPV4-/- with excised exon-encoding transmembrane domains 
5 and 6 (Liedtke & Friedman et al., 2003) were maintained in a 12-hour light/dark cycle 
with free access to food and water. Data from male and female mice were pooled. No sex 
differences were noted.  
 
6.3.2 Acutely Dissociated Retina Preparation 
Mice were euthanized, eyes removed and retinas isolated in cold Leibovitz 15 (L15) 
medium (Life Technologies) containing 11 mg/ml L15 powder, 20 mM D-glucose, 10 
mM Na-HEPES, 2 mM Na-pyruvate, 0.3 mM Na-ascorbate, and 1 mM glutathione. To 
digest the extracellular matrix, retinas were incubated in L-15 containing papain (7 U/ml; 
Worthington) for 1 hour at room temperature (RT). Retinas were rinsed, placed on ice 
and cut into 500 µm pieces. One to two of these pieces were triturated and plated on 
concanavalin A (1 mg/ml) -coated coverslips. Dissociated cells were loaded with Fura-2 
AM or Fura-5F AM (5-10 µM; Life Technologies) for 30-40 minutes and washed for 10-
20 minutes. Under our experimental conditions, most plated cells maintained homeostasis 
for several hours at 25°C without substantial shifts in baseline [Ca2+]i or the amplitude of 
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[Ca2+]i responses to agonists or depolarization (Molnar et al., 2012; Ryskamp et al., 2011; 
Szikra et al., 2009). 
 
6.3.3 Retinal Slice Preparation 
Eye cups were loaded for 70 minutes with Oregon Green BAPTA-1 AM (Life 
Technologies; 200 µM in L-15 with 7 mg/ml Pluronic acid) to load the dye in Müller 
glia. The isolated retina was flat-mounted (RGC side down) on filter paper using vacuum 
suction. Retinas were sliced at 200 µm and rotated 90 degrees before mounting by lines 
of vacuum grease on a BD Cell-Tak-treated coverslip (BD Biosciences). 
 
6.3.4 Superfusion of Retinal Tissue and Cell Swelling Assays 
During imaging experiments, Ringer’s solution (133 mM NaCl, 2.5 mM KCl, 1.5 
mM NaH2PO4, 1.5 mM MgCl2 (6H20), 2 mM CaCl2, 10 mM glucose, 10 mM HEPES 
hemisodium salt, 1 mM pyruvic acid, 1 mM lactic acid, 0.5 mM L-glutamine, 0.5 mM 
glutathione, and 0.3 mM Na-ascorbate, pH 7.4, 300 mOsm) was perfused at a rate of 1-
2.5 ml/minute. Extracellular osmolarity was set by addition or removal of mannitol, a 
procedure that minimally disrupts ionic strength of the extracellular solution but also 
reduces the secondary effects of RVD in Müller glia (VRD; Fernández et al., 2013). 
Following hypotonic stimulation (HTS), the x-y cross-sectional area of calcein-loaded 
cells was determined offline using NIS-Elements AR 3.2 (Ryskamp et al., 2011). To 
examine the geometric properties of swelling more closely, dissociated retinal cells were 
labeled with 100 µM Sulforhodamine 101. Cell volume is proportional to √area3 when 
swelling occurs uniformly in all directions, which we confirmed with confocal z-stacks 
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over time (data not shown). Confocal imaging with a Zeiss LSM 510 was used to acquire 
Z-stacks before and during swelling. 3D volume was analyzed in ImageJ. 
 
6.3.5 Optical Imaging 
Ratiometric Ca2+ fluorescence imaging was performed on an inverted Nikon Ti, or an 
upright Nikon E600 FN microscope using 20x (0.75 N.A. oil), 40x (1.3 N.A. oil & 0.8 
N.A. water) and 60x (1.0 N.A. water) objectives. Excitation was provided by the Lambda 
DG-4 illumination system (Sutter Instruments, Novato, CA). Images were captured with 
a 14-bit CoolSNAP HQ2 camera and processed using NIS-Elements AR 3.2 and Excel. 
[Ca2+]i was measured as described previously (Molnar et al., 2012; Ryskamp et al., 2011; 
Szikra et al., 2009), accounting for the Ca2+ dissociation constant of Fura-2 (224 nM) and 
Fura-5F (400 nM) at RT. We followed the conventional Tsien protocol to calibrate 
[Ca2+]i. Ten µM ionomycin permeabilized cell membranes to Ca2+, driving Ca2+ out of 
cells with 0 Ca2+/0.8 mM EGTA Ringer, giving (Rmin and 380max), and into cells with 10 
mM Ca2+ Ringer, giving (Rmax and 380min). If Ca2+ elevations saturated the Ca2+ indicator 
or exposure to calibrating solutions induced dye leakage, ΔR/R (Peak ratio – 
baseline/baseline) was used. Results represent averages of RGC or Müller cell responses 
from a minimum of three animals. 
 
6.3.6 Electrophysiology 
Retina pieces were incubated in Hibernate A medium with papain (30 U/ml) plus 
cysteine (0.2 mg/ml) for 25-30 minutes at RT. Tissue was washed in ice-cold, Hibernate 
A supplemented with 1% BSA and DNAse (1 mg/ml) followed by two additional washes 
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in ice-cold Hibernate A alone. Retinal cells were dissociated and plated as before. After 
10-15 minutes of plating, cells were superfused with oxygenated Ames’ medium. Upon 
obtaining a whole cell recording, the superfusate was switched to Ames’ medium 
containing 5 mM CsCl and 10 mM TEA (minimizes inward and outward K+ currents). 
Recording electrodes were pulled using a PP-830 vertical puller (Narishige, Tokyo, 
Japan) from borosilicate glass pipettes (1.2 mm O.D., 0.9 mm I.D.) to obtain tips that 
were 2 µm in diameter and with resistance values between 8-10 MΩ. Müller cells were 
voltage-clamped at –70 mV using a Multiclamp 700A patch clamp amplifier. Voltage 
steps and ramps were applied and membrane currents acquired using pClamp 9.2 
software with a Digidata 1322 interface. The pipette solution contained (in mM): 125 
CsGluconate, 10 TEACl, 10 HEPES, 3 EGTA, 1 ATP, 0.5 GTP, 3 MgCl2, 1 CaCl2 (pH 
7.2). Simultaneous ratiometric intracellular Ca2+ measurements were made as before with 
0.2 mM Fura-2 pentapotassium salt in the pipette. 
 
6.3.7 Heterologous Expression in Xenopus Oocytes 
Xenopus laevis frogs were obtained from Nasco (Fort Atkinson, WI) or National 
Center for Scientific Research (France). Oocytes were surgically removed from 
anesthetized frogs and prepared as previously described (Fenton et al. 2010). cDNA, 
encoding rat TRPV4 and AQP4.M23 in the oocyte expression vector pXOOM, were 
linearized downstream from the poly-A segment and in vitro transcribed using T7 
mMessage Machine (Ambion, Austin, TX). cRNA was extracted with MEGAclear 
(Ambion, Austin, TX) and micro-injected into defolliculated Xenopus laevis oocytes (4 
ng TRPV4 and/or 10 ng AQP4 RNA/oocyte). Oocytes were kept at 19˚C in Kulori 
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medium (in mM: 90 NaCl, 1 KCl, 1 CaCl2, 1 MgCl2, 5 HEPES, pH 7.4) for 3-4 days 
prior to experiments. Due to basal activity of TRPV4 and associated cell lysis, the 
oocytes were kept in 1 µM ruthenium red (Sigma) but rinsed prior to experiments 
(Loukin et al., 2011).  
 
6.3.8 Electrophysiology and Volume Measurements on Oocytes 
Conventional two-electrode voltage clamp studies were performed with a Dagan CA-
1B High Performance oocyte clamp (DAGAN, Minneapolis, MN) with Digidata 1322A 
interface controlled by pCLAMP software, version 9.2 (Axon Instruments, Burlingame, 
CA). The oocyte membrane potential was clamped at −30 mV and the current-voltage (I-
V) relationship was determined by stepping the clamp potential to test potentials ranging 
from +60 mV to −140 mV in 20-mV increments (100-ms pulses). The experimental setup 
for measuring water permeability of oocytes has been described in detail previously 
(Zeuthen et al., 2006). Briefly, the oocyte was placed in a small chamber with a glass 
bottom and perfused with a control solution (40 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 
mM MgCl2, 125 mM mannitol, 10 mM HEPES, pH 7.4). Oocyte images were captured 
continuously from below at a rate of 25 images/s. To induce cell swelling, the oocytes 
were challenged with a hypotonic solution (composition as in control solution although 
with removal of 125 or 15 mM mannitol) and cell swelling determined as the percentage 
increase in cross-sectional area of the oocyte. Data were acquired from three different 






Eyes were removed after euthanasia, punctured with a needle at the ora serrata and 
placed in 4% paraformaldehyde in 1X phosphate buffered saline (PBS) for 10 minutes In 
PBS, the anterior eye was cut away and the posterior eye was fixed for another 50 
minutes After 3 x 10 minutes washes with PBS, eyecups were soaked in 15% sucrose for 
45 minutes at RT and then 30% sucrose overnight at 4oC. Cryoprotected eyecups were 
embedded in OCT (Ted Pella), frozen at -80oC, sliced at 16 µm with a cryostat and 
mounted onto Superfrost Plus slides. Slides were warmed at 40oC for 10 minutes and 
circled with a PAP pen. After washing with PBS, tissue was blocked for 30 minutes (10 
ml PBS, 30 µl of Triton X-100, 100 mg BSA, 200 µl 5% w/v Na azide solution). Primary 
antibodies in PBS were incubated with the tissue overnight at 4oC. Retinas were rinsed 
with PBS and secondary antibodies in PBS were applied at 1:1000 for 1 hour at RT. After 
rinsing, labeled slices were protected with Fluoromount-G (Southern Biotech), 
coverslipped and imaged. Dissociated cells were fixed in 95% methanol and 5% acetone 
at -20oC for 10 minutes, washed 3 x 10 minutes in PBS and immunostained as before. 
The following primary antibodies were used in this study: anti-TRPV4 (Lifespan 
Biosciences), 1:100-1:1000; anti-GS (BD Biosciences), 1:2000; anti-GFAP (Dako), 
1:500, 1:500; anti-AGB (Signature Immunologics), 1:100. The secondary antibodies were 
goat antimouse or goat antirabbit IgG (H+L) conjugated to fluorophores (Alexa 488 and 
Alexa 594; Life Technologies). Negative controls without a primary antibody showed no 
staining. For the AGB loading experiment, retinas were incubated in 5 mM AGB  
(agmatine) for 10 minutes at 37oC, fixed and cryoprotected. Immunofluorescence and 
differential interference contrast (DIC) images were acquired on a confocal microscope 
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(Zeiss LSM 510 or Olympus FX1000) using 488 nm Ar (10%) and 543 nm He/Ne 
(100%) lines for fluorophore excitation, suitable filters for emission detection and 
40x/1.2 NA oil objectives. 
 
6.3.10 Reagents 
Salts and reagents were purchased from Sigma, except where noted otherwise. AA 
and its metabolites were from Cayman Pharmaceuticals. Given the instability of AA and 
5’6’-EET due to auto-hydrolyzation, the compounds were aliquoted, gassed with liquid 
nitrogen and stored at -80oC until use. 
 
6.3.11 Statistics 
GraphPad Prism 6.0 was used to analyze statistics. Means are shown ± SEM. Unless 
specified, an unpaired t-test was used to compare two means and a one-way ANOVA 
along with the Holm-Šídák test was used to compare three or more means. p > 0.05 = NS, 
p < 0.05 = *, p < 0.01 = **, p < 0.001 = *** and p < 0.0001 = ****. 
 
6.4 Results 
6.4.1 TRPV4 is Functional in RGCs and Müller Glia 
To map the pattern of functional TRPV4 expression in the retina, we incubated intact 
mouse retinas with AGB+, which permeates most nonselective cation channels (Marc, 
1999). Control light-adapted retinas probed with an anti-AGB antibody displayed little 
endogenous signal (Fig. 6.1A). AGB incubation (10 minutes at 37º C) revealed cation 
accumulation in RGCs and photoreceptors (Fig. 6.1B,E). Stimulation with the selective 
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TRPV4 agonist GSK1016790A (hereafter, GSK101; 100 nM) increased AGB-
immunoreactivity (ir) in large somata within the ganglion cell layer (GCL; arrowheads in 
Fig. 6.1C) and in radial processes of Müller glia (Fig. 6.1C,F) marked by glutamine 
synthetase (GS) staining. Consistent with preferential Müller glia and RGC cation 
loading, GSK101 increased AGB-ir by 14.2 ± 5.3 fold between the outer edge of the 
GCL and the outer limiting membrane (OLM) together with a 4.1 ± 1.3 fold increase in 
the GCL (p < 0.05 for both; Fig. 6.1G,H). Demonstrating agonist specificity, AGB-ir was 
blocked by co-incubation with the selective TRPV4 antagonist HC-067047 (hereafter, 
HC-06; 1 µM; Fig. 6.1D,G-H). Thus, RGCs and Müller glia represent predominant 
transducers of TRPV4 signals in the mouse retina. 
A TRPV4 antibody prominently labeled RGCs and Müller cell processes (GS-ir; Fig. 
6.1I). The specificity of the staining was confirmed by omitting the primary antibody and 
in sections from TRPV4-/- retinas (Ryskamp et al., 2011). TRPV4-ir was strongest in the 
perivascular endfoot region (Fig. 6.1I), suggesting a role for the channel in negotiating 
ion/water fluxes between the inner retina and blood vessels. Localization to glial endfeet 
was similarly observed in the human retina (Fig. 6.1K).  
 
6.4.2 TRPV4 Agonists Induce Sustained Elevations in 
Müller Cell [Ca2+]i 
We next investigated the properties of TRPV4 signals in Müller glia. In acutely 
dissociated cells, GSK101 elicited robust, reversible and dose-dependent increases in 
intracellular Ca2+ ([Ca2+]MC; Fig. 6.2A-C) with an EC50 of ~16 nM (Fig. 6.2D). Twenty-
five nM GSK101 elevated [Ca2+]MC from a baseline of 225 ± 31 nM to 2547 ± 269 nM (p 
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< 0.0001; Tukey test; Fig. 6.2B). The amplitude of GSK101 responses markedly 
exceeded [Ca2+]MC signals evoked by other known [Ca2+]MC modulators including: 
depolarization (32.5 mM KCl), release from internal stores (20 µM carbachol) and 
saturating activation of purinergic (100 µM ATP) and glutamate receptors (100 µM 
glutamate; p < 0.0001, Tukey test; Fig. 6.2C).  
To examine the mechanism underlying the GSK101 response, we recorded the 
transmembrane current in voltage-clamped Müller cells. GSK101 (25 nM) induced an 
increase in conductance (p < 0.0212), averaging 1378 ± 522 pS (n = 9/10 cells). 
Consistent with imaging data, ITRPV4 showed little inactivation during 3-10 minutes 
stimulation with the agonist, showing a current-voltage relation typical of nonselective 
cation channels with a reversal at -4.5 ± 5.5 mV (Fig. 6.2E,F). This observation was 
reinforced by concurrent [Ca2+]i and whole-cell recordings that indicated substantial 
overlap between [Ca2+]i and ITRPV4 (Fig. 6.S2F). GSK101-induced [Ca2+]MC increases 
were abolished in Ca2+-free saline (p < 0.0001, Fig. 6.3AB), insensitive to the voltage-
operated Ca2+ channel blocker Cd2+ (100 µM; p < 0.01; Fig. 6.3CD) and inhibited by the 
nonselective TRP channel blocker Ruthenium Red (10 µM; p < 0.0001; Fig. 6.3EF) and 
the selective TRPV4 antagonist HC-06 (p < 0.0001, Tukey test; Fig. 6.3GH). The TRPV1 
antagonist capsazepine (10 µM) had no effect on GSK101-induced [Ca2+]i elevations in 
Müller cells (data not shown). 
 
6.4.3 The Kinetics of TRPV4 Activation Differ in Neurons and Glia 
In contrast to the pronounced inactivation of agonist-induced [Ca2+]i responses in 
RGCs, signals in Müller cells declined to stable plateaus (Fig. 6.4A,B). GSK101 elevated 
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[Ca2+]i to a peak 215 ± 15% and 217 ± 16% greater than the baseline in Müller glia and 
RGCs, respectively (Fig. 6.4B). Four minutes after the peak, these [Ca2+]i levels declined 
to 179 ± 11% and 116 ± 5% of the baseline (p < 0.05 for Müller glia and p < 0.0001 for 
RGCs; two-way repeated measures ANOVA). Müller cells exhibited a slower response 
onset (95.3 ± 18.4 seconds vs. 26.9 ± 3.6 seconds; p < 0.001, two-way ANOVA; Fig. 
6.4C) and time-to-peak [Ca2+]i elevations (236.9 ± 17.7 seconds vs. 93.0 ± 4.4 seconds; p 
< 0.0001, two-way ANOVA). The slope of the GSK101 response diverged for Müller 
glia (0.0132 ± 0.0027 Ratio/second) and RGCs (0.0319 ± 0.0052 Ratio/second; p < 0.01; 
Fig. 6.4D). The time constant of inactivation following the peak was larger in Müller glia 
than RGCs (τ = 346.2 ± 31.6 seconds vs. 123.0 ± 12.3 seconds; p < 0.0001; Fig. 6.4E). 
Thus, glial TRPV4 is characterized by distinct modulation and/or gating compared to its 
neuronal counterparts.  
 
6.4.4 Spatiotemporal TRPV4 Activation in Müller Cells Involves 
Transcellular Ca2+ Waves 
Müller glial Ca2+ signals evoked by agonists or membrane stretch typically took the 
form of Ca2+ waves propagating from the endfoot or the distal end towards the perikaryon 
(Fig. 6.5A-H). Ca2+ store depletion by cyclopiazonic acid (CPA), a reversible antagonist 
of sarco/endoplasmic Ca2+-ATPases (SERCAs), combined with stimulation of Ca2+ 
release by carbachol, reduced the amplitude of the GSK101 response by 34.5 ± 11.6% (p 
< 0.05; Fig. 6.5I). CPA also suppressed Ca2+ wave propagation (Fig. 6.5K-Q), suggesting 
that Ca2+-induced Ca2+ release (CICR) amplifies the TRPV4 response.  
To follow glial TRPV4 activation in the retinal slice (Fig. 6.5R), glia were loaded 
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with Oregon Green 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA)-
1 (OGB-1; Kurth-Nelson et al., 2009). GSK101 induced Ca2+ waves that originated 
within focal points in the distal end of Müller glia and/or the endfoot. The agonist 
elevated [Ca2+]i in 12/14 (86%) distal stalks, 26/30 (87%) somata, 21/26 (81%) proximal 
stalks and 20/28 (71%) endfeet. Peak response amplitudes for these regions in ΔF/F were: 
distal stalk 0.4005 ± 0.0662, soma 0.3707 ± 0.0643, proximal stalk 0.1980 ± 0.0551 and 
endfoot 0.2988 ± 0.0642 (Fig. 6.5S). Somatic Ca2+ signals remained elevated after [Ca2+]i 
levels within apical and distal regions returned to the baseline. The response amplitudes 
for all Müller cell domains were greater than Ro (p < 0.01 in all cases; Dunnett’s test). 
Response latencies were (in seconds): distal stalk 214.8 ± 15.2, soma 246.2 ± 18.1, 
proximal stalk 353.0 ± 14.3 and endfoot 262.6 ± 14.9 (p < 0.001-0.0001; Bonferroni test; 
Fig. 6.5T). Thus, TRPV4 channels can initiate and contribute to propagation of 
transretinal Ca2+ waves, representing a plausible candidate trigger mechanism for the 
regenerative phenomena reported previously (Newman & Zahs, 1998).  
 
6.4.5 Differential TRPV4 Channel Activation Mediates Neuronal and 
 Glial Responses to Swelling 
Astroglial swelling can compromise neuronal function through edema and 
excitotoxicity (Reichenbach & Bringmann, 2006; Pasantes-Morales & Cruz-Rangel, 
2010; Thrane et al., 2011). Given that TRPV4 is activated by swelling (Strotmann et al., 
2000; Becker et al., 2005; Benfenati et al., 2011), we examined the relationship between 
hypotonicity and volume regulation in Müller cells. HTS dose-dependently and 
reversibly increased the cell area and volume of Müller glia (Fig. 6.6). Müller cells were 
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able to withstand larger hypotonic challenges than concomitantly recorded RGCs (Fig. 
6.6B) that are also known to express TRPV4 (Ryskamp et al., 2011), possibly because of 
the greater elasticity of the glial membrane (Lu et al., 2006). As depicted in Figure 6.6, 
cell swelling was associated with increases in [Ca2+]i of concurrently recorded Müller 
cells with an EC50 of 34.15 ± 3.31 % HTS, (Fig. 6.6C,D). The [Ca2+]i response in Müller 
cells and RGCs was abolished by the removal of extracellular Ca2+ (Fig. 6.6E) and was 
inhibited by HC-06 (1 µM; p < 0.05; Fig. 6.6F,G). Consistent with optical imaging data, 
50% HTS stimuli elicited inward currents (91.34 ± 17.66 pA) that were antagonized by 
HC-06 and were absent from TRPV4-/- cells (Fig. 6.6H,I). Thus, TRPV4 channels play a 
central role in the hypotonicity-induced Ca2+ signals of Müller glia and RGCs.  
TRPV4 activation might be secondary to stretch-induced stimulation of PLA2 
(Watanabe et al., 2003a). Consistent with this, PLA2 inhibition with 4-bromophenacyl 
bromide (pBPB; 100 µM) blocked HTS-induced glial TRPV4 signals (p < 0.001; Fig. 
6.6F). pBPB (n = 39) did not affect GSK101 responses (n = 23; p > 0.05), suggesting that 
cell swelling and GSK101 activate Müller TRPV4 through different mechanisms. 
Surprisingly, swelling-induced [Ca2+]i increases in RGCs were unaffected by pBPB (p > 
0.05; Fig. 6.6G). Thus, the Müller glial TRPV4 response to swelling requires the 
“canonical” PLA2 signaling pathway, whereas in neurons TRPV4 may either be directly 
force sensitive (Loukin et al., 2010) or reliant on a novel, indirect force transduction 
cascade.  
Ruthenium Red reduced the percentage of Müller glia responding to 35% HTS with 
[Ca2+]i elevations from 59 ± 7% to 17 ± 5% (p < 0.01, Dunnett’s test; Fig. 6.6J). HC-06 
also reduced the percentage of HTS-responding Müller glia to 29 ± 8% (p < 0.05), 
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whereas capsazepine (5 µM), a competitive inhibitor of TRPV1 channels, had no effect 
(p > 0.05). Likewise, HTS-evoked [Ca2+]i responses of RGCs were diminished by 
Ruthenium Red and HC-06, but not capsazepine (Dunnett’s test; Fig. 6.6K). The 
comparable efficacy of Ruthenium Red and HC-06 suggests that TRPV4 is the primary 
TRP channel contributing to volume sensing in Müller glia and RGCs. Although the 
residual responsiveness in the presence of TRPV4 blockers suggests that additional Ca2+-
permeable ion channels may contribute to the HTS-induced Ca2+ response, neuronal and 
glial responses to HTS and GSK101 were almost completely absent in TRPV4-/- cells 
(Fig. 6.7A-D). 
 
6.4.6 TRPV4 Gating in Müller Cells but not RGCs Requires  
Activation of Phospholipase A2 
The prevailing model of TRPV4 gating involves PLA2 activation and biosynthesis of 
epoxyeicosatrienoic acids, which act as endogenous activators of TRPV4 (Watanabe et 
al., 2003a; Nilius et al., 2004; Jang et al., 2012; Fig. 6.8A). To test the function of this 
canonical transduction pathway, we stimulated retinal cells with AA and its downstream 
metabolite 5’6’-epoxyeicosatrienoic acid (5,6-EET). AA (100 µM) elevated [Ca2+]i 
(ΔR/R = 0.39 ± 0.3; Fig. 6.8B,C) above spontaneous activity (noise; ΔR/R = 0.16 ± 0.03; 
p < 0.0001). HC-06 abolished these responses (p < 0.001), suggesting that AA-induced 
[Ca2+]MC responses were mediated by TRPV4. AA (10 µM) induced [Ca2+]i elevations in 
all RGCs (Fig. 6.8D,E), but these were not antagonized by HC-06 (p > 0.05), even 
though HC-06 effectively blocked the GSK101 response (p < 0.05). 5’6’-EET, a major 
astroglial metabolite of AA, was proposed as the final activator of TRPV4 (Nilius et al., 
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2004). 5,6-EET (5 µM) induced [Ca2+]i increases (ΔR/R = 0.83 ± 0.2 in Müller glia and 
0.47 ± 0.08 in RGCs) that were inhibited by HC-06 (ΔR/R = 0.40 ± 0.07 in Müller glia 
and 0.28 ± 0.03 in RGCs; p < 0.05; Fig. 6.8F-H). We conclude that glial, but not 
neuronal, TRPV4 activation in the retina involves an intermediary PLA2 step.  
 
6.4.7 Calcium Influx via TRPV4 Exacerbates Swelling in  
Müller Glia and RGCs 
Astroglial swelling is a major problem in traumatic brain injury and retinal diseases 
such as diabetic retinopathy and glaucoma (Staub et al., 1994; Pasantes-Morales & Cruz-
Rangel, 2010; Pannicke et al., 2006; Sofroniew, 2009; Pinar-Sueiro, et al., 2011). We 
exposed HTS-stimulated cells to HC-06 and analyzed the swelling response in TRPV4-/- 
Müller cells. As shown in Figure 6.9A, HTS-induced increases in cross-sectional area 
were counteracted by HC-06 (reduced by 46.9 ± 9.4%; p < 0.01; two-way ANOVA; 
Dunnett’s test) and markedly reduced in TRPV4-/- cells (reduced by 47.3 ± 6.1%; p < 
0.01), indicating that swelling is facilitated by TRPV4 activation itself. HC-06 did not 
cause a further reduction in HTS-stimulated swelling in TRPV4-/- Müller glia, consistent 
with the central role for TRPV4 in the swelling response. Moreover, HTS-induced 
swelling was more pronounced in heterologously expressing HEK293:TRPV4 
overexpressors compared to control cells (p < 0.001 in 35% HTS at each time, two-way 
ANOVA, Fig. 6.9B). While the mechanism through which TRPV4 channels contribute to 
the HTS-induced swelling in recombinant cells, neurons and glia remains to be 
determined, the effect is likely to be mediated by Ca2+ influx. This is indicated by the 
suppression of HTS-induced increase retinal cell area by BAPTA-AM (200 µM; reduced 
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by 45.7 ± 7.2% for RGCs; p < 0.0001; reduced by 33.2 ± 6.3% for Müller cells; p < 0.05; 
Fig. 6.9A).  
Given that Müller glial swelling was proposed to involve PLA2 (Pannicke et al., 
2006; Reichenbach & Bringmann, 2006), we exposed wild type and TRPV4-/- Müller 
cells to hypotonic saline in the presence of pBPB to test the hypothesis that this proposed 
obligatory activator of TRPV4 (Watanabe et al., 2003a; Nilius et al., 2004) is involved in 
the swelling response via its role in TRPV4 activation. The PLA2 antagonist reduced cell 
swelling in wild type Müller cells (reduced by 66.5 ± 12.2%; p < 0.001), but was not 
effective in TRPV4-/- Müller glia (Figure 6.9A). Moreover, pBPB did not suppress HTS-
induced swelling in RGCs (reduced by 2.9 ± 9.2%; p < 0.05). Thus, hypotonicity-induced 
increases in cell volume are likely augmented by reciprocal stimulation between TRPV4-
mediated Ca2+ influx and PLA2 activation in retinal glial cells but not neurons.  
 
6.4.8 Aquaporin 4 Channels Amplify Stretch-Induced  
TRPV4 Activation 
TRPV4 channels in astrocyte-derived cultures may form a complex with aquaporin 4 
(AQP4), the dominant aquaporin in the brain (Benfenti et al., 2011; Verkman et al., 
2008). TRPV4-ir and AQP4 –ir showed prominent colocalization within Müller endfeet, 
in Müller processes surrounding RGC layer (RGCL) somata and in radial processes 
extending towards the INL (Fig. 6.10A, arrowheads). Arguing against an obligatory 
interaction, TRPV4 immunolocalization in AQP4-/- retinas was indistinguishable from 
wild type retinas and AQP4 localization in TRPV4-/- retinas was likewise qualitatively 
similar to controls (Fig. 6.10B,C). Nevertheless, it is possible that the two channels 
  
120 
interact functionally through changes in swelling and/or [Ca2+]MC. AQP4-/- cells 
continued to respond to GSK101 with robust [Ca2+]i elevations (Fig. 6.10D), suggesting 
that AQP4 is not required for TRPV4 function in Müller glia. However, analysis of HTS 
responses in AQP4-/- Müller glia revealed both a prolonged latency-to-peak of the 
swelling response and a decrease in the amplitude of HTS-induced [Ca2+]i responses from 
ΔR/R of 0.74 ± 0.051 to 0.34 ±0.025 (p <0.0001; two-way ANOVA; Fig. 6.10E). This 
suggests that AQP4-mediated water influx facilitates TRPV4 activation and subsequent 
modulation of intracellular Ca2+ homeostasis. 
To test the functional interaction between TRPV4 and AQP4 in an isolated setting, 
both channels were expressed in Xenopus oocytes either alone or in combination. The cell 
volume and membrane currents were simultaneously determined following 60 seconds 
stimulation with HTS or GSK101. As expected, exposure to GSK101 induced inward 
currents in TRPV4 -expressing oocytes (at Vm = 60 mV; 2.4 ± 0.6 µA for TRPV4-
expressing oocytes and 3.6 ± 1.1 µA for TRPV4/AQP4-expressing oocytes). The GSK-
induced currents were of similar magnitude whether AQP4 was co-expressed or not (p = 
0.9), whereas no current was observed in AQP4-expressing controls (0.08 ± 0.01 µA; 
Fig. 6.11A-C). Hypotonic cell swelling was more prominent in AQP4 expressors (5.76 ± 
0.37% for AQP4-expressing oocytes, 4.25 ± 0.24% for TRPV4/AQP4-expressing oocytes 
vs. 0.33 ± 0.04% in TRPV4-expressing oocytes, p < 0.001, Dunnett’s test). The I-V 
relationship measured 60 seconds after imposition of HTS (Δ125 mOsm) yielded 
markedly larger currents in TRPV4/AQP4-expressing oocytes than oocytes expressing 
only TRPV4 (at Vm = 60 mV; 6.3 ± 1.5 µA vs. 1.7 ± 0.4 µA, p < 0.05; Fig. 6.11B,D-E). 
The increased HTS-induced current in oocytes co-expressing TRPV4 and AQP4 could be 
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due to a required presence of AQP4 for full TRPV4 activity or due to the increased 
AQP4-dependent oocyte swelling. We thus determined HTS-induced TRPV4-mediated 
current in TRPV4-expressing oocytes and TRPV4/AQP4-expressing oocytes exposed to 
different osmotic gradients in order to obtain a similar degree of cell swelling (Δ125 
mOsm for TRPV4-expressing oocytes; 0.33 ± 0.04% cell swelling after 60 seconds, and 
Δ15 mOsm for TRPV4+AQP4-expressing oocytes; 0.27 ± 0.03% cell swelling after 60 
seconds, p = 0.2, t test). The I-V curves showed distinct overlap (p = 0.4; Fig. 6.11F). 
This suggests that water entry through AQP4 stimulates TRPV4-activation primarily by 
facilitating the rate of swelling-induced membrane stretch. 
 
6.4.9 TRPV4 Activation or Deletion is Sufficient to  
Trigger Reactive Gliosis 
Reactive astrogliosis is an early indicator of CNS stress induced by mechanical stress 
and neuroinflammation (Tezel et al., 2003; Reichenbach & Bringmann, 2006; Inman & 
Horner, 2007; Sofroniew, 2009; Lindqvist et al., 2010). In control retinas, the gliotic 
marker glial fibrillary acidic protein (GFAP) was confined to astrocytes within the inner 
limiting membrane (ILM), whereas TRPV4-/- retinas exhibited a moderate level of 
GFAP-ir (Fig. 6.12A,B). Following intravitreal injection of GSK101, a marked 
upregulation in GFAP-ir was observed especially at the endfeet and proximal processes 







This study provides new insights into retinal physiology by identifying the Müller 
glial osmosensor and demonstrating a mechanistic framework that governs the 
relationship between glial osmosensing, Ca2+ homeostasis, AQP4-mediated water fluxes, 
arachidonic acid metabolism and swelling. The differential modulation of neuronal and 
glial TRPV4 channels has broader implications for our understanding of volume 
(dys)regulation and inflammatory signaling in the healthy and diseased CNS.  
At EC50, GSK101-evoked [Ca2+]i signals far surpassed Müller responses to other 
known effectors of Ca2+ signaling, including depolarization, purinergic signaling and 
Ca2+-induced Ca2+ release. The close match between TRPV4-mediated currents and 
[Ca2+]i suggests that the peak and plateau phases of the TRPV4 response are mainly 
mediated by plasma membrane influx. Interestingly, the I-V relationship underlying glial 
ITRPV4 did not exhibit the outward rectification typical of homomeric TRPV4 (Watanabe 
et al., 2003b; Loukin et al., 2010), but rather resembled the stretch-sensitive voltage-
independent cation current observed in cultured Müller cells (Puro, 1991). It is possible 
that the conductance is linearized by heteromerization of TRPV4 with auxiliary TRPC1 
or TRPP2 subunits (Köttgen et al., 2008; DaSilva et al., 2008; Ma et al., 2011) and/or 
modulatory influence of AQP (Becker et al., 2005; Liu et al., 2006; Benfenati et al., 
2011). Release from internal stores provided a minor contribution to the overall [Ca2+]i; 
however, as in brain astrocytes (Butenko et al., 2012; Dunn et al., 2013) and possibly 
mechanically stimulated retinal glia (Newman & Zahs, 1998), it fostered the propagation 
of TRPV4-initiated Ca2+ waves from the endfoot towards the distal retina. 
The mechanism of TRPV4 gating has been controversial. The obligatory role of 
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PLA2 has been questioned because TRPV4 is stretch-activated in excised patches of 
membrane, which are devoid of eicosanoids (Loukin et al., 2010; Loukin et al., 2011), 
and the channel is force-sensitive in yeast, which do not express PLA2 (Loukin et al., 
2009). Our conclusion, that TRPV4 function in Müller glia requires AA and/or its 
metabolite 5’6’-EET, is based on the following observations: (1) AA and 5’6’-EET-
induced [Ca2+]MC elevations are sensitive to TRPV4 antagonists; (2) AA potentiates 
Müller cell swelling, whereas PLA2 antagonists suppress TRPV4-evoked and HTS-
induced [Ca2+]MC elevations; (3) PLA2 antagonists did not further suppress HTS-evoked 
swelling in TRPV4-/- Müller cells; (4) The lengthy activation lag time in Müller cells is 
consistent with activation of intermediary steps; and (5) HTS-evoked inward current and 
[Ca2+]i increases were not observed in TRPV4-/- Müller cells or in the presence of the 
selective TRPV4 antagonist HC-06. These findings therefore provide a molecular context 
for the reported effects of AA on glial swelling in cellular and tissue models of ischemia, 
TBI and diabetic edema (Pannicke et al., 2006; Sofroniew, 2009; Nedergaard et al., 2010; 
Pasantes-Morales and Cruz-Rangel, 2010; Reichenbach & Bringmann, 2006). The 
simplest model to account for our results is that cell swelling, generated by hypotonic 
shock and therefore partly mediated by AQP4, induces TRPV4-dependent cation influx 
into Müller glia. This ionic flux is subsequently augmented by PLA2 activation and 
results in further glial swelling. 
Data from TRPV4-/- and HC-06-exposed retinal cells and HEK293 overexpressors 
show that TRPV4 activation contributes to cell swelling. This is in contrast to 
observations in salivary gland cells and keratinocytes where TRPV4/Ca2+ contributed to 
RVD (Becker et al., 2005; Liu et al., 2006), and cultured astrocytes in which RVD 
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required AQP4, whereas hypotonic sensing was mediated by TRPV4 (Benfenati et al., 
2011). Arguing against an obligatory TRPV4-AQP4 complex (Benfenati et al., 2011), our 
data from AQP4-/- and TRPV4-/- retinas show that the distribution of TRPV4 is largely 
independent of AQP4, whereas the additional AQP4 contribution to the swelling-induced 
TRPV4 current is largely eliminated when TRPV4 and TRPV4/AQP4-expressing oocytes 
are exposed to the same extent of swelling. Nonetheless, it seems clear that functional 
coupling between the osmosensor and water transport has potentially significant 
consequences for Ca2+ homeostasis and downstream signaling pathways in glia, as 
suggested by in vivo experiments (Thrane et al., 2011). Exposure to GSK101 was 
sufficient to evoke reactive Müller gliosis either as a result of direct Ca2+ influx or as a 
secondary response to excitotoxic degeneration of RGCs (Ryskamp et al., 2011; Krizaj et 
al., 2014). However, as indicated by the mild gliosis observed in unstimulated TRPV4-/- 
retinas, basal TRPV4 activity in healthy retinas is likely to restrain glial reactivity.  
Excitation mapping and HTS confirmed previous evidence of functional TRPV4 
expression in RGCs (Ryskamp et al., 2011); however, the fast, inactivating [Ca2+]i 
responses in RGCs were easily distinguishable from lagging, sustained glial signals. 
Given the relative insensitivity of [Ca2+]RGC to 5’6’-EET and the inability of pBPB to 
block HTS-induced [Ca2+]i elevations, we conclude that, as reported for gastrointestinal 
neurons (Lechner et al., 2011), RGC responses are largely independent of the canonical 
transduction mechanism. Thus, TRPV4 might differentially contribute to volume sensing 
and AA-mediated proinflammatory signaling in retinal neurons vs. glia.  
In summary, we report that TRPV4 is expressed in every Müller cell and that its 
activation is essential for the normal glial [Ca2+] response to hypotonic stress, whereas 
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both its absence and overactivation are associated with reactive gliosis. Given that Müller 
glia perform key housekeeping, osmoregulatory and mechanosensory functions in the 
retina, our findings implicate TRPV4 in both normal visual function and injury responses 
caused by excessive swelling and/or release of proinflammatory metabolites. While 
Müller cells are not classically excitable, Ca2+ waves induced by endfoot TRPV4 
channels might translate the effects of mechanical stress into interglial, gliovascular and 
neuroglial signals (Newman & Zahs, 1998; Kurth-Nelson et al., 2009; Butenko et al., 
2012; Dunn et al., 2013). In addition to offering a new mechanistic context for previous 
studies that have yielded contradictory results regarding TRPV4 activation, our findings 
provide novel insights into differential neuronal and astroglial Ca2+ responses to swelling 
and inflammation. Our data suggest that targeting TRPV4 channels might offer a rational 
new tool for mitigating swelling-mediated neuronal damage and gliosis in patients with 
traumatic ocular/brain injury, edema, ischemia and glaucoma. 
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Figure 6.1 TRPV4 mediates cation influx in Müller glia and RGCs. A-D. Vertical 
cryosections of mouse retinas immunolabeled for Müller glia marker GS (red) and AGB 
(green). Freshly isolated retinas were incubated for 10 minutes at 37°C with the indicated 
conditions. A. Negative control (L15 media alone; n = 2). B. Retinas incubated with AGB 
(N = 3). Basal cation (AGB+) influx takes place in RGCs and photoreceptors. C. GSK101 
(100 nM) induces cation influx in RGCs and a subset of Müller glia (n = 3). D. Agonist-
induced cation entry is suppressed by HC-06 (1 µM; n = 3). E-F. Additional examples of 
cation influx in the absence (E) and presence (F) of GSK101. G-H. AGB influx between 
the outer edge of the GCL and the outer limiting membrane (OLM; G) or within the GCL 
(H) was quantified by measuring the mean value (optical density) of AGB-ir. Ii-Iiii. 
Vertical cryosection of mouse retina immunolabeled for the Müller cell marker glutamine 
synthetase (GS; red) and TRPV4 (green; Ii). TRPV4 is preferentially localized to Müller 
cell endfeet (arrows) and RGCs (blue *). Müller cell somata (white *) lack TRPV4 in 
intact retinas. An example distal stalk/distal end is indicated with a bracket. Iii-Iiii. Close 
up of Ii (dashed rectangle) showing TRPV4 (Iii) and the merge (Iiii). J. TRPV4-ir is 
present throughout acutely dissociated Müller cells and a presumed RGC soma. Proximal 
stalk indicated by arrowhead. K. In a human retina section TRPV4 similarly localizes to 
endfeet and proximal stalks of Müller glia as well as RGC somata and axon bundles (#). 
Scale bars = 10 µm. I = Inner, O = Outer, S = Segments, N = Nuclear, P = Plexiform, L = 
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Figure 6.2 TRPV4 activation massively elevates Müller cell calcium levels. A. GSK101 
dose-dependently increases calcium above spontaneous calcium spikes. B. The amplitude 
of Müller cell responses to GSK101 was quantified using Fura-5F. n = 14, 12 and 4, 
respectively. C. Twenty-five nM GSK101 increased calcium levels far more than other 
known modulators of Müller cell calcium homeostasis. n = 33, 26, 25, 19 and 19, 
respectively. D. According to the sigmoidal fit, the EC50 of GSK101 was ~16 nM. n = 12. 
E. GSK101 induced a current with an IV plot characteristic of heteromeric TRPV4. n = 
10. F. TRPV4 opening by GSK101 resulted in a large inward conductance that coincided 
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Figure 6.3 TRPV4 mediates responses to GSK101 in Müller cells. A-B. External calcium 
is required for GSK101-induced calcium elevations, n = 16. C-D. Responses to GSK101 
persist in the presence of the voltage-gated channel blocker Cadmium (Cd2+), n = 4. E-F. 
The nonselective TRP channel antagonist Ruthenium Red (RuR) blocks responses to 
GSK101, n = 21 for GSK101 and 15 for GSK101 + RuR. G-H. GSK101 responses are 
also blocked by the selective TRPV4 antagonist HC-06. This inhibition is reversible 
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Figure 6.4 TRPV4 response kinetics differ in RGCs and Müller glia. A. RGC responses 
to GSK101 are fast and transient, whereas Müller cells exhibit delayed and sustained 
TRPV4 activation. B. GSK101 significantly increased calcium in both cell types (n = 25 
Müller glia and 51 RGCs); however, RGC calcium returned closer to baseline levels 4 
minutes after the response peak in the continued presence of GSK101. C. The latency to 
the base (n = 17 Müller glia and 19 RGCs), 50% amplitude and peak response (n = 21 
Müller glia and 24 RGCs) was longer in Müller cells. D-E. The rate of TRPV4 activation 







































































































































Figure 6.5 TRPV4 activation triggers Ca2+-induced Ca2+ release and calcium waves. A-
H. Upon applying 25 nM GSK101 (B-G), calcium typically first flows into Müller glial 
endfeet (bottom) or their apical process (top). Calcium then elevates as a wave, filling the 
cytosol globally. Scale bar = 10 µm. The timing of the images (A-G) is indicated in the 
corresponding calcium trace (H). The rainbow scale specifies the 340/380 ratio level. I. 
TRPV4 stimulation by GSK101 further elevates Ca2+ via Ca2+ release (stores depleted by 
bathing cells with 5 µM CPA while stimulating release with applications of 20 µM 
carbachol), n = 19. J-Q. (J) A brightfield image of the Müller cell. (K-P) Store depletion 
by CPA attenuates the response to GSK101 (L-P) and the resulting wave. The 
corresponding trace (Q) indicates timing of images (K-L). R. OBG-1 selectively loaded 
Müller glia in a retina slice. Four of the main Müller cell compartments are labeled for 
one cell. This image is the median composite of 10 temporally adjacent images separated 
by 3 seconds in time during the response to GSK101. The contrast between the Müller 
cells and the background was enhanced with the application of the rolling ball 
background subtraction function in ImageJ (10.0 pixel radius). Outer nuclear layer 
(ONL), outer plexiform layer (OPL), inner nuclear layer (INL), inner plexiform layer 
(IPL), ganglion cell layer (GCL). Scale bar 10 µm. S. Responses to 10 µM GSK were 
significantly above the baseline for all cellular compartments. T. The distal stalks and 
endfeet were the primary transduction sites, as indicated by shorter response latencies 
(time to ½ peak). n = 13 for distal stalk, 23 for somata, 16 for proximal stalk and 13 for 
endfeet. 
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Figure 6.6 Differential TRPV4 channel activation mediates neuronal and glial responses 
to swelling. A. Changes in the volume of calcein-loaded Müller cells were apparent when 
switching from isotonic (Ai) to hypotonic saline (Aii). Aiii. The volume changes were 
approximated by measuring cell area. Isotonicity = black. Hypotonicity = gray. Scale bar 
= 10 µm. B. Müller glia and RGCs swelled and shrunk as a function of tonicity. C. HTS 
elevated Müller cell calcium as they swelled in a representative experiment. D. Swelling-
evoked calcium elevations were dose-dependent (95% confidence band around the 
sigmoidal fit), n = 13-20. E. Swelling-evoked [Ca2+]MC elevations required external 
calcium. F. PLA2 and TRPV4 contribute substantially to the hypoosmotic response of 
Müller glia, n = 10, 13 and 11, respectively. G. The PLA2 antagonist pBPB has no effect 
on RGC responses to cell swelling, even though these responses are mediated largely by 
TRPV4, n = 23, 16 and 9, respectively. H-I. Fifty percent HTS evoked inward currents in 
Müller glia (n = 7) that were absent in the presence of HC-06 (n = 8) or in TRPV4-/- cells 
(n = 7). J. Müller glia responsiveness to 35% HTS (n = 10 experiments) is reduced by the 
TRP channel antagonist Ruthenium Red (RuR 10 µM; n = 5) or 1 µM HC-06 (n = 6), but 
not the TRPV1 antagonist capsazepine (CPZ 10 µM; n = 3). K. RGC responsiveness to 
HTS (n = 6) is impaired by Ruthenium Red (n = 6) and HC-06 (n = 6), but not TRPV1 







Figure 6.7 TRPV4 mediates RGC and Müller cells responses to HTS and GSK101. A. 
The percentage of RGCs responding to 50% HTS and 25 nM GSK101 is reduced by 
TRPV4 ablation (n = 4-9 experiments, two-way ANOVA). B. Calcium elevations 
induced by HTS and GSK are smaller in TRPV1-/- RGCs  (N = 12-74 cells, two-way 
ANOVA). C. The percentage of Müller cells responding to 50% HTS and 25 nM 
GSK101 is reduced by TRPV4 ablation (n = 3-8 experiments, two-way ANOVA). D. 
Calcium elevations induced by HTS and GSK are smaller in TRPV1-/- Müller glia (n = 










































































Figure 6.8 TRPV4 gating in Müller cells but not RGCs requires activation of 
phospholipase A2. A. Working model for TRPV4 activation by cell swelling. In 
hypotonicity, both RGCs and Müller glia swell. This stretches the membrane and 
activates PLA2, at least in Müller cells. PLA2 then synthesizes AA, which is metabolized 
by a cytochrome P450 into 5,6-EET, an endogenous agonist for TRPV4. 5,6-EET can 
activate TRPV4 in both cell types, but its potency is greater in Müller cells. Although 
required in Müller cells, this indirect force transduction pathway does not contribute to 
swelling responses in RGCs. Thus, RGCs either utilize a novel force transduction 
pathway (indicated by the solid blue arrow) or direct gating of TRPV4 by membrane 
stretch (red arrows). B-C. AA elevates [Ca2+]MC by activating TRPV4, n = 34, 19 and 15, 
respectively. D-E. Although HC-06 (n = 16) can completely inhibit TRPV4 activation by 
GSK101 (n = 10), HC-06 has no effect on AA responses (n = 46), suggesting that AA 
does not elevate RGC calcium through the activation of TRPV4. F. Average traces from 
a representative experiment show that the 5,6-EET response is larger in Müller cells (red) 
than RGCs (blue). G-H. 5,6-EET activates TRPV4 in both Müller glia (G, n = 14) and 
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Figure 6.9 TRPV4 contributes to HTS-induced swelling. A. The maximal extent of 
Müller cell (red) and RGC (blue) swelling in 35% HTS was reduced by chelating 
intracellular calcium with BAPTA-AM or by inhibiting TRPV4 and thereby limiting 
calcium entry. TRPV4-mediated swelling was PLA2-dependent in Müller glia, but not 
RGCs. Swelling was reduced in cells from TRPV4-/- mice. HC-06 and pBPB had no 
additional effect on the reduction of swelling. For Müller glia, n = 96, 14, 11, 8, 13, 18 
and 14. For RGCs, n = 145, 31, 36, 24, 21, 9 and 22. B. Thirty-five percent HTS 
increased the cross-sectional area of calcein-loaded, WT (n = 51) and TRPV4-
overexpressing HEK293 cells (n = 64); however, the extent of swelling was increased by 
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Figure 6.10 AQP4 expression is independent of TRPV4, yet it contributes to the swelling 
response of Müller glia. A. Colocalization between TRPV4 and AQP4 within the glial 
endfeet and transverse processes in the inner retina (arrowheads). B. TRPV4 expression 
in RGCs and the endfeet of Müller glia is normal in the AQP4-/- retina. C. AQP4 is 
similarly expressed in the endfeet of Müller glia in retinal cryosections from both WT 
and TRPV4-/- mice. D. Responses to GSK101 were slightly reduced, but still robust in 
AQP4-/- Müller glia. E. Responses to 50% HTS (n = 20) were reduced in AQP4-/- Müller 
glia (n = 13). Scale bars = 20 µm. I = Inner, N = Nuclear, P = Plexiform, L = Layer, GC 
= Ganglion Cell, LM = Limiting Membrane.  
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Figure 6.11 Aquaporin 4 channels amplify stretch-induced TRPV4 activation. A. 
Oocytes expressing TRPV4 and AQP4 alone or in combination were voltage clamped at 
Vm= -30 mV and exposed to 100 nM GSK101 (indicated by black bar). After 60 seconds 
GSK exposure, an I-V curve was obtained by jumping the clamp potential to potentials 
ranging from +60 mV to -140 mV at 20 mV intervals (seen as the vertical lines in the 
current trace). B. Representative I-V relations from oocytes expressing either 
TRPV4+AQP4 (n = 8), TRPV4 (n = 7), or AQP4 (n = 5) in control solution, in GSK 
solutions or when exposed to 125 mOsm HTS. C. Summarized I-V relations obtained 
with GSK (as in B, middle panel), n = 5-8. D. Representative current (black lines) and 
volume traces (grey lines) recorded simultaneously from oocytes expressing TRPV4 and 
AQP4 alone or in combination upon exposure to a 125 mOsm hypotonic stimulus 
(indicated by the black bar), summarized in (E), n = 5-9. F. Oocytes expressing TRPV4 
alone or in combination with AQP4 were exposed to hypotonic challenges of different 
magnitudes in order to observe similar degree of cell swelling (125 mOsm for TRPV4-
expressing oocytes and 15 mOsm for TRPV4/AQP4-expressing oocytes) and I-V 
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Figure 6.12 Role of TRPV4 in Müller glia reactivity. A. Two weeks after a single 
intravitreal injection of a vehicle or 2 µl of 75 µM GSK101, mouse eyes were harvested 
and processed for immunohistochemistry. Only astrocytes on the vitreal surface 
expressed GFAP in control eyes, whereas Müller glia also expressed GFAP in the 
GSK101-injected eyes of wild type (WT) mice. TRPV4-/- Müller glia were reactive in 
both conditions, but GSK101 did not further increase gliosis. B. The GFAP optical 
density was significantly greater in the GSK101-injected eyes, n = 3 for each. Scale bar = 
20 µm. OLM = outer limiting membrane, ONL = outer nuclear layer, OPL = outer 
plexiform layer, INL = inner nuclear layer, IPL = inner plexiform layer, ILM = inner 








































TRPV4 SIGNALS GENERATE AND TRANSDUCE 
INTRAOCULAR PRESSURE IN GLAUCOMA 
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Glaucoma treatment has faced two intractable challenges: to identify new 
pharmacological approaches to lower intraocular pressure (IOP) and to protect retinal 
ganglion cells (RGCs) from the effects of IOP (Chang & Goldberg, 2012). Here, we 
report that pharmacological or genetic inhibition of TRPV4, a mechano- and 
osmosensitive channel (Liedtke & Friedman, 2003), simultaneously addresses both key 
aspects of glaucoma therapy. Biochemical and functional analyses revealed TRPV4 
expression in mouse and human trabecular meshwork (TM), a cellular network that 
permits aqueous humor outflow when its morphology and cytoskeletal organization are 
normal (Clark et al., 1994; Mitchell et al., 2002; Zhang et al., 2008). However, TRPV4-
mediated Ca2+ influx into TM cells augmented hypoosmotic swelling, whereas 
suppression of TRPV4 activity decreased IOP in rodent and nonhuman primate models of 
glaucoma. TRPV4 inhibition additionally protected RGCs from apoptosis caused by 
glaucomatous mechanical strain, suggesting that the channel transduces elevated IOP into 
an excitotoxic calcium signal. The pathological effect of TRPV4 stimulation was 
reproduced by in vivo agonist stimulation of retinal TRPV4 channels and was sufficient 
to enable excitotoxic NMDA receptor currents. In support of these results, inhibition of 
TRPV4 prevented RGC loss in a rodent glaucoma model. These findings reveal a 
multifaceted role for TRPV4 in the regulation of conventional outflow and the sensitivity 
of RGCs to mechanical strain and suggest a potential first-in-kind comprehensive 






Elevation of intraocular pressure (IOP), a major risk factor for glaucoma (Bonomi et 
al., 2001; Leske et al., 2007), most commonly results from impediment of aqueous humor 
drainage through the trabecular meshwork (TM; Clark et al., 1994; Mitchell et al., 2002; 
Zhang et al., 2008). The hydraulic conductivity of the iridocorneal angle and steady-state 
IOP are dynamically adjusted by TM cell volume regulation (Mitchell et al., 2002), actin 
reorganization (Clark et al., 1994; Zhang et al., 2008) and their capacity to transduce 
mechanical strain of the interwoven extracellular matrix (ECM) into a compensatory 
fluid transport response (Johnstone, 2004). If excessive, TM swelling and/or actin 
remodeling obstructs the conventional outflow pathway, which can pathologically elevate 
IOP (Brubaker 1975; Epstein & Rohen, 1991) and induce pressure-dependent 
degeneration of RGCs (Anderson et al., 2006; Della Santina et al., 2013). Thus, a better 
understanding of TM cell volume regulation and actin remodeling promises new 
molecular targets for IOP management; however, the mechanism by which TM cells 
respond to IOP, cell swelling and/or aqueous outflow remains poorly understood. Here, 
we identify the TM osmosensor/mechanosensor as TRPV4, a nonselective cation channel 
associated with polymodal transduction of warm temperature, cell swelling, shear stress 
and proinflammatory metabolites (Liedtke & Friedman, 2003; Watanabe et al., 2003). 
Real-time polymerase chain reaction (RT-PCR), western blotting and antibody staining 
showed TRPV4 expression in cultured human TM (hTM) cells (Fig. 7.1A,B), mouse TM 
cells (Fig. 7.1C), TM cells from glaucoma patient trabeculectomies (Fig. 7.1D) and 
HEK293 TRPV4 overexpressors (TRPV4:HEK293 cells), but not in naive HEK293 cells 
(Ryskamp et al., 2011). Both the selective TRPV4 agonist GSK10167901A (hereafter, 
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GSK101; 25 nM) and hypotonic swelling (220 mOsm) elevated the intracellular calcium 
concentration [Ca2+]i in Fura-2 AM-loaded hTM cells (Fig. 7.1E,F,H,I). Similar to 
cultured cells (Fig. 7.1E,F), trabeculectomized human tissue responded to GSK101 with 
[Ca2+]i elevations that were sensitive to the selective TRPV4 antagonist HC067047 (HC-
06; 1 µM; Fig. 7.1G). GSK101- and swelling-induced [Ca2+]TM elevations were 
prominently inhibited by HC-06 (Fig. 7.1H,I), suggesting that TRPV4 channels are 
necessary and sufficient for the transduction of swelling into [Ca2+]i elevations in human 
TM cells. Inhibition of TRPV4 in hTM cells also reduced the extent of hypoosmotic 
swelling (Fig. 7.1J), indicating a potential pathogenic role for TRPV4 in human TM cell 
remodeling-induced IOP elevations.  
To assess the potential involvement of TRPV4 in in vivo TM function, we studied the 
effect of the antagonist in mice with experimental glaucoma. As shown previously 
(Huang et al., 2011; Della Santina et al., 2013), injection of polystyrene microbeads 
rather than phosphate buffered saline (PBS; control) into the anterior chamber caused 
sustained IOP elevations (20.04 ± 1.24 (N = 13) vs. 9.8 ± 0.26 (N = 15) mm Hg; p < 
0.0001; Fig. 7.2A). Animals were assigned to control or treatment groups while matching 
for the initial IOP elevation in the bead-injected eye before daily intraperitoneal (IP) 
injections commenced. Compared to MB/vehicle-injected controls (N = 9), daily 
MB/HC-06-treated animals (10 mg/kg) showed a rapid drop in IOP (N = 4; p < 0.0001; 
Fig. 7.2B), which showed no desensitization in the continued presence of the antagonist 
(Fig. 7.2A). We tested whether the effectiveness of HC-06 was derived from direct 
targeting of the eye by injecting it (1.862 mM, 2 µl) directly into the anterior chamber 
(Fig. 7.2C,D). Single intraocular HC-06 injections rapidly reduced IOP and the effect 
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lasted for days, presumably by maximizing the local bioavailability of the antagonist. 
Further indicating that TRPV4 channels are required to maintain elevated IOP within the 
anterior eye, microbead injections never elevated pressure in TRPV4-/- eyes (N = 4; Fig. 
7.2E). To test whether topical eye drops could lower IOP, we generated a prodrug 
(isopropyl ester; YX-02) version of the antagonist. Daily administration of the prodrug 
likewise decreased the IOP to baseline levels (Fig. 7.2F; N = 4; p < 0.01 to p < 0.0001; 
Holm-Šídák test). Given the functional expression of TRPV4 in hTM cells and 
trabeculectomized human TM (Fig. 7.1), we surmised that TRPV4 channels might 
regulate IOP in nonhuman primates. IOP was elevated in two macaque eyes by laser 
treatment of the TM. Microinjection of HC-06 (1.862 mM) into the anterior chamber 
elicited a long-lasting reduction of IOP (e.g., 25.6 ± 0.1 vs. 29.8 ± 0.1 mm Hg at 80 
hours). These data suggest that TRPV4 channels, expressed within the conventional 
outflow pathway, contribute to the maintenance of elevated IOP in rodent and primate 
glaucoma.  
We previously discovered that neuronal TRPV4 expression in the retina is restricted 
to most, if not all, RGCs where it contributes to their intrinsic mechanosensitivity and its 
activation increases RGC [Ca2+]i, spiking and apoptosis (Ryskamp et al., 2011). Given 
theses findings and the importance of calcium dysregulation in the pathogenesis of IOP-
dependent RGC neurodegeneration (Crish & Calkins, 2011), we hypothesized retinal 
TRPV4 transduces glaucomatous forces into activation of IOP-dependent biochemical 
cascades associated with dendritic/synaptic remodeling, axon transport deficiencies and 
RGC apoptosis.  
IOP mechanically strains the retina (Krizaj et al., 2014) and, during glaucoma 
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progression, RGCs are additionally subjected to osmotic pressures within the peripheral 
retina associated with swelling (Pinar-Sueiro et al., 2011) and apoptotic shrinking (Weber 
et al., 1998). To investigate the potential role of TRPV4 activation in glaucomatous 
force-induced RGC death, isolated mouse retinas were incubated in control L-15 media 
or hypoosmotic media for 2.5 hours and dead cells were labeled with ethidium 
homodimer. Thirty-five percent hypotonic stimulation (HTS) was sufficient to cause cell 
death in the ganglion cell layer (GCL; Fig. 7.3A,B). This required cytosolic calcium 
because death was suppressed by 200 µM BAPTA-AM. HC-06 (1 µM) also prevented 
HTS-induced death, indicating that TRPV4 is required for mechanical excitotoxicity of 
RGCs. TRPV4 overactivation by GSK101 (1 µM) was sufficient to drive RGC loss and 
this also required elevation of [Ca2+]RGC. Moreover, genetic ablation of TRPV4, but not 
TRPV1, another mechanosensitive channel expressed in RGCs (Sappington et al., 2009), 
prevented RGC death. These results indicate a role for TRPV4 in osmotic pressure-
induced RGC death. 
To examine whether TRPV4 overstimulation causes RGC death in vivo, GSK101 was 
injected into the intravitreal space of anesthetized mice. After 4 weeks, a profound loss of 
RGC nuclei was observed in GSK101-treated eyes compared to vehicle-treated eyes 
(2465.6 ± 92.5 vs. 5884.4 ± 166.3 NeuN+ cells in the GCL / mm2; N = 6; p < 0.0001; Fig. 
7.3C,D). GSK101-induced RGC loss was blocked by a prior intraperitoneal injection of 
HC-06 (Fig. 7.3D). This further indicates that excessive TRPV4 activity can drive RGC 
pathology.  
Although the precise coupling mechanism that underlies the transduction of 
mechanical (IOP-induced) stress within the retinal tissue and that leads to RGC pathology 
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is not known, one possibility entails the direct sensitivity of the output neurons to 
mechanical strain (local deformation induced by applied stress) produced by increased 
IOP (Burgoyne, 2011). Glaucomatous IOP elevations generate biomechanical strain 
through a pressure gradient that causes the volume of the eye to expand, stretching the 
retina (Krizaj et al., 2014). IOP fluctuations during saccades and head movements are 
superimposed on static IOP elevations (Downs et al., 2011) and thus contribute to 
dynamic retinal strain. To model this and to assess the RGC response to biomechanical 
strain, acutely dissociated mouse retinal cells were stimulated with biaxial substrate 
stretch (5 ± 1.5%; 2 Hz; 90 min). As shown in Fig. 7.3E,F, continuous cyclic strain 
increased RGC apoptosis as indicated by the percentage of Annexin V+/propidium 
iodide+ RGCs (10.55 ± 2.0 % vs. 31.47 ± 5.6 %; N = 6; p < 0.01). Stretch-elicited RGC 
loss was blocked by concurrent-treatment with HC-06 (Fig. 7.3F). Likewise, TRPV4-/- 
RGCs, but not TRPV1-/- RGCs, were protected from stretch-induced RGC apoptosis (Fig. 
7.3F). Thus, TRPV4 represents an endogenous RGC sensor of mechanical strain that, 
when overactivated, is sufficient to compromise the viability of RGCs.  
NMDA-mediated excitotoxicity and Ca2+ overload have been amongst the main 
mechanisms proposed to damage glaucomatous RGCs (Hare et al., 2001; Crish & 
Calkins, 2010). We investigated the possibility that TRPV4 activation induces Ca2+ 
overloads in part by augmenting NMDA receptor function. Thy1:CFP RGCs were 
stimulated with GSK101 (25 nM) and NMDA/glycine (100 µM/10 µM) in control (3 mM 
Mg2+-containing) and Mg2+-free saline. NMDA alone had no effect on [Ca2+]RGC in 
control saline, but evoked marked [Ca2+]i responses in 0 Mg2+ (Fig. 7.3G). Suggesting 
that TRPV4 activation is sufficient to override the effects of the Mg2+ block, concurrent 
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application of the GSK101 and NMDA (100 µM) in 3 mM Mg2+ exceeded the effects of 
each compound alone (p < 0.001; N = 16; repeated measures ANOVA; Fig. 7.3G).  
Finally, to determine whether TRPV4 suppression or elimination treatment is 
neuroprotective, we analyzed RGC survival in the mouse glaucoma model treated daily 
with the antagonist. Eight weeks after IOP elevation, RGC counts in eyes with elevated 
IOP were decreased to 2370.1 ± 72.8 TuJ-1+ cells in the GCL / mm2 (N = 6) compared to 
3425.1 ± 251.3 in control eyes from vehicle-treated animals (N = 7). Consistent with the 
requirement for TRPV4 channels to support IOP elevation (Fig. 7.2), no RGC loss was 
observed in microbead-treated eyes of mice treated with HC-06 (Fig. 7.3H,I).  
Glaucoma is a multifactorial disease involving multiple IOP-generating mechanisms 
within the anterior eye and several target cell populations within the retina (Clark et al., 
1994; Mitchell et al., 2002; Johnstone et al., 2004; Zhang et al., 2008; Burgoyne, 2011; 
Crish & Calkins, 2011; Chang & Goldberg, 2012; Della Santina et al., 2013; Krizaj et al., 
2014). As additional alleles that confer genetic susceptibility are discovered (van 
Koolwijk et al., 2012), it will be important to determine whether and how they contribute 
to IOP generation and/or retinal vulnerability. For example, a common variant near 
caveolin1/caveolin2 (CAV1/CAV2) was associated with primary open-angle glaucoma 
(Thorleifsson et al., 2010; Wiggs et al., 2011); however, despite the expression of 
CAV1/CAV2 in TM cells and RGCs, the mechanism by which changes in caveolin 
expression and/or function contributes to glaucoma remains unknown. CAV1/CAV2 
form caveolae within membranes, which are important signaling domains for TRPV4 
(Saliez et al. 2008). Thus, changes in their tissue-specific expression and/or function 
could potentially enhance or suppress TRPV4 function, which might explain the role of 
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CAV1/CAV2 variants in IOP generation and/or RGC susceptibility in open-angle 
glaucoma.  
Given the vast number of studies that sought an effective modulator of elevated IOP 
within the conventional outflow pathway and the notable absence of successful 
neuroprotective approaches, it is remarkable that inhibition of the stretch- and swelling-
sensitive TRPV4 channel simultaneously lowers IOP (Fig. 7.2) and protects RGCs from 
the effects of excessive mechanical stimulation (Fig. 7.3). Thus, TRPV4 blockers might 




All experiments followed recommendations of the NIH Guide for Care and Use of 
Laboratory Animals and the Association for Research in Vision and Ophthalmology 
Statement for the Use of Animals in Ophthalmic and Vision Research and were approved 
by the University of Utah and University of Nebraska Medical Center Animal Care and 
Use Committees. Experiments involved C57BL/6J, B6.Cg-Tg(Thy1-CFP)23Jrs/J, 
TRPV4-/- (Liedtke & Friedman, 2003) and TRPV1-/- mice (JAX) and cynomolgus 
monkeys.  
 
7.3.2 hTM Cell Culturing 
hTM cells (ScienCell Research Laboratories) were grown in Dulbecco’s modified 
eagles medium (DMEM), penicillin (100 U/ml), streptomycin (0.1 mg/ml) and 10% fetal 
bovine serum at 37˚C and 5% CO2. 
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7.3.3 mRNA and Protein Analysis 
Semiquantitative RT-PCR and western blotting of hTM cells were performed as 
described previously (Ryskamp et al., 2011).  
 
7.3.4 Cryosection Immunohistochemistry 
Mice were deeply anesthetized with isoflurane and transcardially perfused with PBS, 
followed by 4% PFA in PBS. Eyes were postfixed for 2 hours at 4°C and rinsed with 
PBS. Fresh TM tissue explants were fixed in 4% PFA and PBS for 1 hour at room 
temperature (RT). Tissue was cryoprotected in 15% (1 hour RT) and 30% sucrose (4˚C 
overnight) and embedded in OCT (Tissue-Tek). Twelve to sixteen µm slices were cut 
with a cryostat and mounted on Superfrost plus slides (Fisher Scientific). Slides were 
dried and frozen at -80˚C until use. Slices were rinsed in PBS and incubated in blocking 
solution (10 ml PBS, 30 µl Triton X-100, 100 mg BSA, 100 µl 10% w/v Na+ azide 
solution) for 30-60 minutes at RT. Primary (rabbit anti-TRPV4, 1:100; Lifespan) and 
secondary (goat antirabbit Alexa Fluor 488: 1:1000) antibodies were diluted in blocking 
solution and applied for 12 hours (4°C) and 1 hour (RT), respectively. Nuclei were 
counterstained with propidium iodide (PI). Sections were mounted in VectaShield 
(Vector Laboratories) and coverslipped.  
 
7.3.5 Calcium Imaging 
Cultured hTM cells were loaded with 5 µM Fura-2 AM 30 minutes and were perfused 
with isotonic saline (pH 7.4) containing the following (in mM): 98.5 NaCl, 5 KCl, 3 
MgCl2, 2 CaCl2, 10 HEPES, 10 Glucose, 93 Mannitol. Mannitol was removed to make 
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30% hypotonic saline (HTS). To obtain primary retina cells, mice were euthanized with 
isoflurane, followed by cervical dislocation. Eyes were removed and retinas were isolated 
by dissection in cold L-15 media. Retina incubation in 7 U/ml papain (Worthington)/L-15 
for 1 hour at RT digested the extracellular matrix to facilitate cellular dissociation by 
gentle mechanical trituration. Retinal cells were plated on a concanavalin A-coated 
coverslip and incubated with Fura-2-AM (5 µM) for 30-40 minutes. Human TM explants 
were loaded with 10 µM Fura-2 for 1 hour at RT and were perfused with recording buffer 
containing (in mM): 120 NaCl, 6 KCl, 1.4 CaCl2, 1 MgSO4, 20 HEPES, 5.6 glucose and 
9 sodium pyruvate (pH 7.4). Calcium imaging was performed as described (Ryskamp et 
al., 2011). Cells from experiments summarized in Fig. 7.3G were exposed to verapamil 
(100 µM) to reduce spontaneous activity and to study more direct synergy between 
TRPV4 and NMDA receptors without depolarization/Ca2+ from L-type Ca2+ channels.  
 
7.3.6 Volume Imaging 
hTM cells were loaded with 10-15 µM calcein-AM during Fura-2 loading. Cell area, 
which was crisply delineated by calcein fluorescence, was measured with NIS-Elements 
(Nikon) to approximate cell volume. Percent change in cell area reflects the difference in 
volume after 5 minutes of exposure to 30% HTS compared to volume preceding HTS. 
 
7.3.7 Microbead Occlusion Glaucoma Model 
Mice were anesthetized with an intraperitoneal (IP) injection of ketamine/xylazine 
(90 mg/10 mg / kg of body weight) and eye drops were used to numb the eyes (0.5% 
proparacaine hydrochloride) and dilate the pupils (1% tropicamide ophthalmic solution 
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USP; Bausch & Lomb). IOP was elevated unilaterally by injecting 2 µl of polystyrene 
microbeads (10 µm FluoSpheres) with a blunt tip, Hamilton syringe (Hamilton 
Company) into the anterior chamber after making a guide hole using a 30.5 gauge needle, 
gently depressing the cornea to displace aqueous humor and drying the eye. Microbeads 
were injected over 60 seconds and the needle remained for an additional 60 seconds 
before injecting a small bubble to seal the cornea and prevent microbead outflow. The 
contralateral eye was injected with PBS. Erythromycin ophthalmic ointment USP 0.5% 
(Bausch & Lomb) was applied after the procedure.  
 
7.3.8 Mouse IOP Measurements 
We used a Tonolab rebound tonometer to measure IOP of Avertin-treated (Figure 
7.2A,B; Huang et al., 2011) and awake mice (Figure 7.2C-F; Ding et al. 2011) between 
10 AM and noon. For awake mice, 0.5% proparacaine hydrochloride was applied prior to 
measurements. IOP was determined from the mean of 15 to 20 tonometer readings.  
 
7.3.9 Systemic TRPV4 Inhibition 
HC-067047 (Sigma Aldrich, St. Louis, MO) was dissolved in 1.85% DMSO and 
PBS, then it or the vehicle was administered via a 10mg/kg intraperitoneal injection (IP) 
once daily for 8 weeks.  
 
7.3.10 Topical TRPV4 Inhibition 
The prodrug used for eye drops was identical to HC-06 except an isopropyl ester 
group replaced the trifluoromethyl group. To make the prodrug, 2-methyl-1-(3-
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morpholinopropyl)-5-phenyl-1H-pyrrole-3-carboxylic acid (200 mg; 0.610 mmol) in 5 
mL dichloromethane (DCM) was added to thionyl chloride (220 µL; 3.05 mmol) and 
dimethylformamide (20 µl). After stirring for 3 hours at RT, the reaction mixture was 
evaporated and dried under vacuum pressure. To the residue was added DCM (5 ml), 
isopropyl 3-aminobenzoate (218 mg; 1.20 mmol) and N,N-Diisopropylethylamine (0.42 
ml), and the reaction mixture was stirred overnight. Water was added and the mixture 
was extracted with DCM. The organic phase was washed with water, brine, dried by 
anhydrous sodium sulfate, concentrated and purified by chromatography to provide the 
prodrug YX-02 (290 mg; 0.592 mmol, 97% yield). H-NMR (CD3OD/400 MHz):  δ 8.32 
(s, 1H); 7.89 (d, 1H); 7.71 (d, 1H); 7.42 (m, 6H); 6.65 (s, 1H); 5.21 (m, 1H); 4.07 (m, 
2H); 3.54 (m, 4H); 2.64 (s, 3H); 2.15 (m, 6H); 1.64 (m, 2H); 1.38 (d, 6H).  MS (ES+, 
m/z): 490.1 (M++1, 100.0). One drop of a 1.862 mM prodrug solution (1.85% DMSO and 
PBS) was applied unilaterally to each mouse eye. The vehicle was applied contralaterally 
as a control. 
 
7.3.11 Primate Glaucoma Model and IOP Measurements 
Two female cynomolgus monkeys between the ages of 6 and 14 years were included 
in the study. Both had laser treatment to the trabecular meshwork of the left eye to 
elevate IOP. Lasering had been done between 3 and 10 years earlier. HC-06 solution 
(1.862 mM) or the vehicle (1.85% DMSO and PBS) was injected into the anterior 
chamber, but the solution contents were masked until the study was completed. IOP was 
measured by tonometry, as in Toris et al. (2005), while animals were conscious and 
seated in specially designed chairs.  
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7.3.12 RGC Death/Neuroprotection Assays 
To study acute RGC excitotoxicity, mouse retinas were isolated and incubated in L-
15 media or specified conditions for 2.5 hours at RT in darkness. Membrane breakdown 
was indicated by ethidium homodimer (8 µM) labeling of RNA and DNA (15 minutes at 
RT). After rinsing, retinas were flatmounted and imaged on an Olympus FV1200 upright 
confocal (40X water objective, NA 0.8) or a Zeiss LSM 510 confocal (40X oil objective, 
NA 1.3) microscope. Five images were taken and the dead cell count in the GCL was 
averaged for each retina. Image acquisition parameters remained constant across samples. 
To quantify GSK101- and IOP-induced RGC loss in vivo, retinas were fixed as before, 
isolated in PBS, flatmounted and immunostained. To reduce autofluorescence, retinas 
were treated for 5 minutes with 50 mM NH4Cl in PBS (Bosco et al., 2011). After rinsing 
with PBS, retinas were incubated for 1.5 hours at RT in 0.2% Triton X-100, 1% bovine 
serum albumin (BSA), and 5% normal goat serum (NGS) and PBS. Primary antibodies 
were diluted in 1% BSA, 5% NGS and PBS (1:500) and incubated with the retina for 1 
hour at RT while rocking, then for 3 days at 4°C. Retinas were rinsed with PBS and 
secondary antibodies (1:500 in 1% BSA and PBS) were applied for 2 hours at RT. 
Retinas were rinsed in PBS, 0.2% Triton X-100 and then PBS again. Retinas were 
mounted in VectaShield and imaged with confocal microscopes. Neurons in the GCL 
were labeled by staining β-III-Tubulin (anti-Tuj1; Millipore) or NeuN (anti-NeuN Alexa 
Fluor 488; Millipore). Four images per quadrant were quantified manually for each retina 
while blinded to treatment. To examine the effects of sustained mechanical strain on 
RGC apoptosis, acutely isolated mouse retinal cells were plated on collagen type IV-
coated silicone membranes. These membranes were then radially stretched using a 
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StageFlexer FX5000 system (Flexcell International Corporation) statically by 5% and 
sinusoidally ± 1.5% at 2 Hz for 90 minutes. RGCs were identified as before (Ryskamp et 
al., 2011) and the percentage of apoptotic RGCs was quantified using an Alexa Fluor 488 
Annexin V/Dead Cell Apoptosis Kit. 
 
7.3.13 Materials 
Salts and reagents were purchase from Sigma or Life Technologies unless specified 
otherwise.  
 
7.3.14 Statistical Analysis 
GraphPad Prism 6.0 was used for statistics. Means are shown ± SEM. Unless 
specified, an unpaired t-test was used to compare two means and an ANOVA along with 
Tukey’s multiple comparisons test was used to compare three or more means. p > 0.05 = 
NS, p < 0.05 = *, p < 0.01 = **, p < 0.001 = *** and p < 0.0001 = ****. 
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Figure 7.1 TRPV4 is functionally expressed in mouse and human TM and contributes to 
TM swelling. A. Trpv4 mRNA is expressed in hTM tissue (202 bp amplicon). B. TRPV4 
protein was detected in hTM cells at the appropriate molecular weight. C. TRPV4 is 
expressed in the mouse TM (arrow) preceding Schlemm’s canal (#) and in corneal 
epithelial cells (*). D. Trabeculectomized human TM tissue immunolabels for TRPV4. 
Nuclei were counter-stained with propidium iodide (PI). E-H. GSK101- and hypotonic 
swelling (220 mOsm) -induced [Ca2+]i increases in hTM cells are inhibited by HC-06. I. 
Trabeculectomized human TM tissue cells respond to 100 nM GSK101 with elevations in 
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Figure 7.2 TRPV4 is required for IOP elevation in mouse and primate glaucoma models. 
A. Intravitreal injection of MBs (black trace), but not PBS (dashed grey trace), caused a 
sustained elevation in IOP. Subsequent systemic injection of HC-06 (blue trace) lowered 
IOP to the baseline, whereas vehicle injection had no effect (dashed light blue trace). B. 
TRPV4 is required for MB-induced IOP elevations. C-D. Long-lasting IOP decreases 
were achieved by intravitreal injection of HC-06 into MB-treated eyes. E. MB injection 
into TRPV4-/- eyes elicited little IOP elevation. F. Application of the HC-06 prodrug eye 
drops was sufficient to decrease IOP. G. HC-06 injection into two glaucomatous macaque 




































































































































































































Figure 7.3 TRPV4 overactivity is necessary and sufficient for mechanical excitotoxicity 
of RGCs. A-B. Isolated mouse retinas were incubated in the indicated conditions for 2.5 
hours, stained with ethidium homodimer (EthHd) and dead cells in the GCL were imaged 
and counted. Thirty-five percent HTS increased RGC death and this required cytosolic 
Ca2+ and TRPV4. GSK101 (1 µM) overstimulated TRPV4, which was sufficient to kill 
RGCs. This required [Ca2+]i. Genetic TRPV4 ablation, but not deletion of TRPV1, 
rescued RGCs from swelling-induced excitotoxicity. C. A 4-week prior intravitreal 
injection of GSK101 (75 µM, 2 µl) induces massive NeuN+ neuron loss in the GCL of 
retinal wholemounts. D. Intraperitoneal pretreatment of HC-06 rescues RGCs from 
TRPV4 overactivation. E-F. RGC apoptosis induced by cyclic stretching for 90 minutes 
is inhibited by HC-06 and by genetic ablation of TRPV4, but not by elimination of 
TRPV1. Stretching did not increase apoptosis in other cell types such as bipolar cells (left 
of each image), consistent with a selective vulnerability of RGCs to mechanical strain. G. 
Submaximal stimulation of TRPV4 facilitates removal of the Mg2+ block of the NMDA 
receptor. H. IOP was raised by microbead (MB) injections or maintained at normal levels 
following PBS injections for 8-weeks. Mice were treated with daily IP injections of HC-
06 or PBS. RGC loss was quantified by measuring the density of TuJ1+ cells in the GCL 
of in retinal wholemounts. RGC density was diminished by sustained exposure to high 
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We identified activation of the mechanosensitive ion channel TRPV4 as a primary 
mechanism by which RGCs, Müller glia and TM cells transduce biomechanical strain. In 
excess, this can activate calcium-dependent biochemical cascades, resulting in glial 
reactivity, increased hypoosmotic swelling and neuronal excitotoxicity. Because calcium 
dysregulation is implicated in the pathogenesis of glaucoma, TRPV4 may represent an 
elegant link between IOP elevation and RGC degeneration. Although glaucoma lacks 
neuroprotective treatments, we have identified TRPV4 as a promising therapeutic target 
to reduce the mechanosensitivity of retinal neurons and glia and to maintain IOP within a 
safe range. These findings thus provide important insights into the pathogenesis of 
glaucoma and may explain a potential mechanism for the generation of pressure 
phosphenes, a sensory phenomenon that may serve as a warning of impending retinal 
damage and blindness.  
 
8.2 Future Directions 
8.2.1 Vision Loss Caused by Ocular/Brain Trauma 
Suppression of TRPV4 activity may additionally provide neuroprotection from the 
effects of traumatic impacts on the retina and the brain. Among the most common and 
debilitating consequences of traumatic ocular injuries (TOIs) and traumatic brain injuries 
(TBIs) in surviving patients is vision loss, resulting from damage to eyes or the brain 
network dedicated to vision, afflicting 57-66% of TBI patients (Lew et al., 2009). For 
example, combat-related blast exposure is the primary cause of TOI and TBI in U.S. 
soldiers (Okie, 2005; Owens et al., 2008). Developments in armor have reduced fatalities 
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and eye/brain injuries from shrapnel; however, wearing ballistic eyewear and Kevlar 
helmets does little to spare the eyes and brain from exposure to high blast overpressure, 
making it necessary to study the effects of primary blast waves on ocular and brain tissue 
(Okie, 2005; Mader et al., 2006; Thomas et al., 2009). While visual problems depend on 
the severity and type of injury, visual deficits in TBI patients can include diminished 
visual acuity, visual fields and/or oculomotor control (Glenn et al., 2009). Surgical 
interventions are available to correct corneal and lens damage as well as some 
oculomotor problems; however, retina and brain damage remains refractory to current 
medical interventions (Celesia et al., 1991; Ahmed et al., 2011; Nashed et al., 2011; 
Fasolo et al., 2012; Yu-Wai-Man & Griffiths, 2013; Gonzalez et al., 2013; Eiber et al., 
2013; Shepherd et al., 2013; Xiong et al., 2013). Protective gear alone is not enough to 
effectively avert TOIs and TBIs; we need to both better understand the biological 
mechanisms that contribute to visual system dysfunction and develop neuroprotective 
pharmaceuticals that can readily prevent immediate and secondary injury mechanisms 
(e.g., mechanotransduction and inflammation, respectively) to preserve the sight and 
cognitive function of the wounded. 
 
8.2.2 Increased Mechanosensitivity and/or Mechanical Strain 
 Could Explain Age-Dependent Risk in Glaucoma 
Along with elevated IOP, advanced age is a major risk factor for glaucoma; however, 
it is unclear how aging increases the likelihood of developing glaucoma. IOP stays fairly 
constant with age (Klein et al., 1992); thus, an age-dependent increase in IOP is probably 
not a major factor in the increased prevalence of glaucoma with aging. As mouse RGCs 
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are intrinsically sensitive to glaucomatous forces, an aging-dependent increase in their 
responsiveness to biomechanical strain could account for progressive vulnerability. 
Alternatively, age-dependent structural alterations within the tissues that contribute to 
RGC strain could magnify the IOP-related forces that normally impinge upon RGCs. To 
distinguish between these possibilities, it will be important to characterize the effect of 
aging on RGC sensitivity to mechanical forces and TRPV4 activation. 
 
8.2.3 Cell-Type Specific Contributions of TRPV4  
to the Pathogenesis of Glaucoma 
We were unable to use TRPV4-/- mice or systemic TRPV4 inhibition to test the role 
of retinal TRPV4 in the pathogenesis of glaucoma in vivo because these manipulations 
serendipitously prevented pathological elevations in IOP. This, however, was exciting 
from a therapeutic standpoint, especially because TRPV4 inhibition may interfere with 
glaucoma pathogenesis at two key steps, which is a suggested and presently unmet 
requirement for the successful advancement of neuroprotective glaucoma treatments 
through late-stage clinical trials (Baltmr et al., 2010).   
Although the present findings convincingly indicate that glaucomatous forces 
impinging upon the retina activate TRPV4 and damage RGCs, the functional expression 
of TRPV4 in RGCs, Müller glia and microglia (data not shown), in addition to possible 
expression in vascular endothelial cells, complicates the relative cellular involvement of 
TRPV4-signals in the initiation and progression of RGC degeneration. We are creating 
floxed TRPV4 mice to conditionally knockout TRPV4 using cell type-specific Cre 
expression to resolve this question and to definitively test our hypothesis that TRPV4 
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expression in RGCs is necessary for high-IOP to kill RGCs in glaucoma. Nevertheless, 
our data to date strongly support this possibility. Most notably we found that: 1) TRPV4 
overactivation is sufficient to trigger apoptosis of dissociated RGCs and in vivo RGCs; 2) 
dissociated RGCs respond to tensile forces comparable to those experienced during 
glaucomatous IOP elevations with a Ca2+ elevation that is sensitive to TRPV4 inhibition; 
3) TRPV4 is required for apoptosis induced by sustained mechanical strain (osmotic 
pressure or cyclic stretching); 4) TRPV4-mediated Ca2+ influx exacerbates osmotic 
swelling of RGCs; and 5) TRPV4 activation in RGCs is sufficient to potentiate other 
excitotoxic mechanisms such as NMDA receptor activation. 
 
8.2.4 Mechanisms of Compartmentalized Calcium Dysregulation 
Although we focused on Ca2+ regulation within RGC somata, an important site of 
excitotoxicity (Hare et al., 2001) during glaucoma progression, Ca2+ dysregulation also 
occurs within RGC dendrites and axons, contributing to their compartmentalized 
neurodegeneration (Crish & Calkins, 2010). IOP-dependent inner retina dysfunction 
occurs early (Kong et al., 2009; Kong et al., 2012; Frankfort et al., 2013) and is 
associated with dendritic arbor remodeling and/or electrophysiological changes (Della 
Santina et al., 2013). Given the important roles of Ca2+ in synaptic maintenance (Sun et 
al., 2014) and TRPV4 expression within proximal RGC dendrites (Chapter 5), it seems 
likely that TRPV4-dependent transduction of IOP-related forces will directly allow Ca2+ 
influx into RGC dendrites and/or trigger a Ca2+ influx in somata that spreads to RGC 




High IOP also mechanically strains RGC axons within the complex physical 
environment of the optic nerve head laminar region, subjecting them to tensile, 
compressive and distortional forces as well as structural remodeling (another process 
thought to involve mechanosensation (Downs et al., 2008). Anterograde axonal transport 
from retina to the axon terminals in the brain is lost before retrograde transport (Crish & 
Calkins, 2010). This means that axonal transport is not physically obstructed (e.g., by the 
pinching of axons); otherwise, transport in both directions would be affected similarly. 
This finding and other evidence (e.g., Huang et al., 2008) implicate Ca2+ dysregulation 
within the axonal compartment in the axonal transport deficits and the ensuing 
consequences (e.g., impaired BDNF delivery to the soma (Quigley et al., 2000) and 
accelerated axonal degeneration; Knöferle, 2010). We observed TRPV4 expression 
within mouse and human RGC axon bundles (Chapters 5, 6), which might reflect its 
transport or functional expression within the membrane. Although the source of excessive 
axonal calcium is unknown, TRPV4 might confer mechanosensitivity to RGC axons or 
generate signals within the somata that spread into the axon. In support of this possibility, 
strain-induced Ca2+ elevations have been observed in the axons of other neurons in the 
absence of mechanically produced pores (Wolf et al., 2001). Alternatively, Ca2+ 
diffusion/waves, voltage-gated Ca2+ channels (Wolf et al., 2001) and/or reversal of the 
sodium-calcium exchanger could all be sources of axonal Ca2+ (Stys et al., 1992). Future 
experiments testing this will refine our understanding of a basic disease mechanism, 
which is important because it is necessary to protect all RGC compartments to maintain a 




8.2.5 TRP Channels in the Retina 
Although findings within this dissertation expand knowledge of TRP channel 
physiology and function in the retina, the retina-specific roles of most TRP channels 
remain unknown. This deficit is surprising given that the retina expresses most, if not all, 
mammalian TRP channels (Gilliam & Wensel et al., 2011) and that their expression is 
evolutionarily conserved (Montell & Ruben, 1989; Hardie & Minke, 1992; Niemeyer et 
al., 1996; Zimov &Yazulla, 2004; Szikra et al., 2008; Morgans et al., 2009; Shen et al., 
2009; Sapington et al., 2009; Ryskamp et al., 2011; Kaur & Nawy, 2012; Molnar et al., 
2012; Sánchez Ramos et al., 2012; Niederhäusern et al., 2013; Ward et al., 2014). 
Progress in this frontier has been hampered by an inadequate assortment of tools that can 
accurately characterize the expression and function of specific TRP channel subunits. For 
instance, many antibodies directed toward TRP channels are nonselective (Chapter 2) and 
most of the published immunohistochemical data regarding retinal TRP channel 
localization (Crousillac et al., 2003; Sekaran et al., 2007; Sappington et al., 2008; 
Leonelli et al., 2009; Sappington et al., 2009; Leonelli et al., 2010; Wang et al., 2010; 
Gilliam & Wensel et al., 2011) has not been validated by the absence of antibody staining 
in the retina of knockout animals. Furthermore, many TRP channels lack selective 
agonists and antagonists (Wu et al., 2010), making it difficult to examine their functional 
expression and physiological roles. We have begun collaborations with Drs. Christopher 
Reilly, Glenn Prestwich and Yong Xu to identify and/or create new modulators of TRPV 
channels. In addition to developing a prodrug version of a TRPV4 antagonist for topical 
delivery to the eye (Chapter 7) and novel TRPV4 antagonists (Krizaj et al., 2013), we 
identified a TRPV3 agonist with greater selectivity for the TRPV3 channel than other 
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known agonists (Appendix). As we have preliminary data indicating TRPV3 mRNA 
expression in mouse retinas and RGC [Ca2+]i elevations in responses to camphor 
(nonselective TRPV3 agonist), this new agonist will help us to further examine the 
functional distribution of TRPV3 in the retina. Because body temperature potentiates 
TRPV3 activity (Smith et al., 2002; Xu et al., 2002), its thermosensitivity, like that of 
TRPV4 (Shibasaki et al., 2007), may contribute the resting excitability of RGCs. Thus, 
the repertoire of TRP channel expression, combined with their sensitivities to diverse 
stimuli, distinctive channel properties and subcellular localizations, will culminate in the 
emergent, polymodal properties of the mammalian retina. Future studies of these 
properties will not only teach us more about how the visual system functions normally, 
but also how the visual system behaves in disease. This information would further allow 
us to promote retinal homeostasis and orchestrate retinal output. 
 
8.2.6 Polymodal Sensation in the Visual System  
as a Potential Tool for Visual Prostheses 
Finally, the polymodal behavior of TRPV4 and other gene products may eventually 
allow us to hack the retina to provide useful visual information to RGCs that lack input 
from photoreceptors. Albert et al. (2012) discovered that RGCs are excited by infrared 
laser-based heating via the activation of TRPV4. Thus, expression of TRPV4 in RGCs, 
although potentially problematic in the presence of sustained, pathological forces, might 
allow us to interface with the retina to provide high spatial and temporal frequency 
information to the brain in otherwise blind patients. Optimization of this approach 
requires a clear understanding of the temperature parameters that gate TRPV4 as well as 
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molecular and genetic tools that may allow us to target relevant, specialized information 
to RGCs that normally represent preprocessed and integrated visual information. Thus, a 
rich understanding of polymodal sensation in the retina could lead to highly refined 
visual prostheses (Eiber et al., 2013; Shepherd et al., 2013), in addition to therapies that 
reduce neuronal vulnerability to biomechanical strain, a culprit implicated in many 
blinding and neurodegenerative diseases. 
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Transient receptor potential vanilloid-3 (TRPV3) is a member of the TRPV
subfamily of TRP ion channels. The physiological functions of TRPV3 are not
fully understood, in part, due to a lack of selective agonists and antagonists that
could both facilitate the elucidation of roles for TRPV3 in mammalian physiol-
ogy as well as potentially serve as therapeutic agents to modulate conditions for
which altered TRPV3 function has been implicated. In this study, the Micro-
source Spectrum Collection was screened for TRPV3 agonists and antagonists
using alterations in calcium flux in TRPV3 overexpressing human embryonic
kidney-293 (HEK-293) cells. The antispasmodic agent drofenine was identified
as a new TRPV3 agonist. Drofenine exhibited similar potency to the known
TRPV3 agonists 2-aminoethoxydiphenylboronate (2-APB) and carvacrol in
HEK-293 cells, but greater selectivity for TRPV3 based on a lack of activation
of TRPA1, V1, V2, V4, or M8. Multiple inhibitors were also identified, but all
of the compounds were either inactive or not specific. Drofenine activated
TRPV3 via interactions with the residue, H426, which is required for TRPV3
activation by 2-APB. Drofenine was a more potent agonist of TRPV3 and more
cytotoxic than either carvacrol or 2-APB in human keratinocytes and its effect
on TRPV3 in HaCaT cells was further demonstrated using the antagonist icilin.
Due to the lack of specificity of existing TRPV3 modulators and the expression
of multiple TRP channels in cells/tissue, drofenine may be a valuable probe
for elucidating TRPV3 functions in complex biological systems. Identification
of TRPV3 as a target for drofenine may also suggest a mechanism by which
drofenine acts as a therapeutic agent.
Abbreviations
2-APB, 2-aminoethoxydiphenylboronate; HEK-293, human embryonic kidney-293
cells; TRPA1, transient receptor potential ankyrin-1; TRPV1, transient receptor
potential vanilloid-1; TRPV3, transient receptor potential vanilloid-3.
Introduction
The transient receptor potential vanilloid (TRPV) subfam-
ily of TRP channels consists of six structurally similar, but
functionally unique proteins (TRPV1-V6). Mammalian
TRPV and other TRP family proteins (i.e., TRPA, TRPC,
and TRPM) are differentially expressed in neurons and
non-neuronal cells of animals and humans. Unlike many
other TRP channels, TRPV3 expression in sensory neurons
appears low, and it may exist in some cells as a hetero-
multimer with TRPV1 resulting in a functionally unique
ion channel (Cheng et al. 2012). TRPV3 is abundantly
expressed by keratinocytes, particularly intrafollicular
keratinocytes (Peier et al. 2002; Chung et al. 2003, 2004b)
as well as cells of the tongue, palate, testes, cornea, nasal
epithelium, distal colon, and inner ear (Xu et al. 2006).
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TRPV3 is currently being investigated for its role in
cutaneous physiology, specifically its role in thermal per-
ception, inflammation, irritation and pain, wound heal-
ing, maintenance of skin barrier integrity, and hair
growth (Nilius and B!ır!o 2013; Nilius et al. 2013; Kaneko
and Szallasi 2014). Known TRPV3 agonists include natu-
ral products such as thymol, carvacrol, camphor, 6-tert-
butyl-m-cresol, menthol, eugenol, farnesyl pyrophosphate,
incensole acetate, as well as synthetic 2-aminoethoxydi-
phenylboronate (2-APB), and a-hydroxy acids which are
widely used in the cosmetic industry as skin peeling
agents (Chung et al. 2004a; Xu et al. 2006; Vogt-Eisele
et al. 2007; Moussaieff et al. 2008; Bang et al. 2010; Earley
et al. 2010; Cao et al. 2012). These agents exhibit EC50
values between ~130 nmol/L (farnesyl pyrophosphate),
~34 to ~500 lmol/L (carvacrol), and up to >6 mmol/L
(cresol), depending on the model used. The fact that essen-
tially all known agonists of TRPV3 are skin sensitizing
agents and irritants suggests that aberrant activation of
TRPV3 may play key roles in regulating skin homeostasis
and dermatopathologies, a notion supported by the identifi-
cation of a constitutively active TRPV3 variant as a cause of
Olmsted Syndrome (Lin et al. 2012). However, conflicting
evidence has been obtained regarding the role of TRPV3 in
skin using both transgenic mice and known TRPV3 agon-
ists, essentially all of which also modulate the activity of
other TRP channels including TRPA1 and TRPM8.
Known TRPV3 antagonists include 17(R and S)-resolvin
D1, naturally occurring anti-inflammatory/proresolving
x-3 lipid derivatives (Bang et al. 2012), the TRPM8 ago-
nist icilin (Sherkheli et al. 2012), 2,2-diphenyltetrahydrofu-
ran (a 2-APB analog) (Chung et al. 2005), and isopentenyl
pyrophosphate (Bang et al. 2011). However, much like the
known TRPV3 agonists, these antagonists are not selective
for TRPV3. Numerous TRPV3 modulators are currently
under development as possible therapeutic agents (e.g.,
GRC15300 by Glenmark Pharmaceuticals and others by
Hydra Biosciences), with potential utility in conditions such
as itch, psoriasis, hirsutism, dermatitis, pain, etc. Thus, there
is not only a need to identify selective agonists and antago-
nists of TRPV3 that can be used to understand its role in
mammalian physiology but there is also an ongoing effort
to target TRPV3 for treating human disorders and diseases.
The purpose of this study was to identify new commer-
cially available agonists and antagonists with increased
selectivity for TRPV3. Here we report that drofenine
(CAS#: 0001679-76-1), a 2-APB analog, is an agonist of
human TRPV3, with greater selectivity for TRPV3 versus
other TRP channels than both 2-APB and carvacrol. As
such, drofenine may be a valuable chemical probe to
more specifically ascertain the complex physiological and
pathophysiological roles of TRPV3. Furthermore, one
might speculate that TRPV3 may have some role in the
purported antispasmodic activity of drofenine (Spasmo-
Cibalgin; Novartis, Muscat, Oman).
Materials and Methods
Chemicals
All chemicals used in this study were purchased from
Sigma-Aldrich (St. Louis, MO), unless otherwise stated.
2-(5-trifluoromethyl-pyridine-2ylsulfanyl)-1-(8-methyl-3,4-
dihydro-2H-quinolin-1-yl)-ethanone (TRPV3 antagonist)
was synthesized as previously described (Chong et al.
2010) and the purified product verified by 1H-NMR.
Screening library
The Microsource Spectrum Collection was obtained from
the Drug Screening Resource at The University of Utah.
This library consisted of 2320 compounds including drug
components (60%), natural products (25%), and other
bioactive compounds (15%). The compound library was
prepared for screening as 39 (300 lmol/L) stock solutions
in calcium assay buffer (19 HBSS [Hank’s Balanced Salt
Solution], 20 mmol/L HEPES [4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid], pH 7.3) in 384-well plates.
Cell culture
Human embryonic kidney-293 (HEK-293) cells (ATCC,
Rockville, MD) were engineered to stably overexpress
human TRPV3 (in pcDNA3.1 D V5/His-TOPO) and other
human TRP channels (TRPA1, TRPM8, TRPV1, TRPV2,
and TRPV4) as previously described (Deering-Rice et al.
2011). HEK-293 cells were grown in DMEM:F12 (Invitro-
gen, Carlsbad, CA) containing 5% fetal bovine serum (FBS)
and 19 penicillin/streptomycin (Invitrogen). HEK-293 cells
stably overexpressing the various TRP channels were main-
tained in DMEM:F12 supplemented with 5% FBS, 19 peni-
cillin/streptomycin, and 350 lg/mL Geneticin (Invitrogen).
Cells were subcultured using trypsin and plated into 1% gel-
atin-coated 96- or 384-well plates for calcium imaging exper-
iments. Human immortalized keratinocytes, HaCaT cells,
were provided by Dr. Douglas Grossman, M.D., Ph.D., of
the Department of Dermatology, University of Utah. HaCaT
cells were cultured in DMEM containing 5% FBS and 19
penicillin/streptomycin/glutamine. Cells were subcultured
using trypsin and plated into 96-well plates for experiments.
Site-directed mutagenesis and transient
transfection of TRPV3
The following TRPV3 mutants were constructed using the
QuickChange XL site-directed mutagenesis kit (Stratagene,
2014 | Vol. 2 | Iss. 5 | e00062
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La Jolla, CA): H426N and R696K, residues previously
identified as being critical for activation of TRPV3 by 2-
APB (Hu et al. 2009). The primers were: TRPV3-H426N
(+) 50-CTGGAGCCGCTGAACACGCTGCTGC-30 and (!)
50-GCAGCAGCGTGTTCAGCGGCTCCAG-30; and TRPV3-
R696K (+) 50-CATCTGGCGCCTGCAGAAAGCCAGGAC-
30 and (!) 50-GTCCTGGCTTTCTGCAGGCGCCAGATG-30.
For assays, HEK-293 cells were transfected with mutant or
wild-type constructs using 175 ng purified plasmid DNA
complexed with Lipofectamine 2000 (Invitrogen), at a 2:1
ratio of lipid to DNA. Transiently transfected cells were
assayed 48 h post transfection.
Calcium imaging
Calcium imaging experiments were performed as
described previously (Deering-Rice et al. 2011, 2012;
Shapiro et al. 2013). Briefly, cells were loaded with Fluo-4
AM using the Fluo-4 Direct Kit (Invitrogen) diluted in
LHC-9 (HEK-293 cells) or calcium assay buffer (HaCaT
cells) for 60 min at 37°C (HEK-293) or room tempera-
ture (HaCaT). The loading solution was removed and the
cells were subsequently incubated 30 min at 37°C (HEK-
293) or room temperature (~23°C) (HaCaT) in the dark
with LHC-9 (HEK-293) or calcium buffer (HaCaT) con-
taining 0.5 mmol/L probenecid and 0.75 mmol/L trypan
red (ATT Bioquest, Sunnyvale, CA). Treatment solutions
were prepared in LHC-9 (HEK-293) or calcium assay buf-
fer (HaCaT) at 39 concentration and 10 or 25 lL was
added to 20 or /50 lL of media on the cells in 384- or 96-
well plates. Calcium flux responses were measured using
either a NOVOstar plate reader (BMG LABTECH, Offen-
berg, Germany) or microscopically as described previously
in the references above. Where specified, data were corrected
for nonspecific responses observed with HEK-293 cells, and
normalization to the maximum attainable change in fluores-
cence elicited by ionomycin (10 lmol/L).
Electrophysiology
Whole-cell recordings were made using borosilicate
pipettes (3–5 MΩ). Coverslips were coated with concanav-
alin A as described previously (Ryskamp et al. 2011) and
rinsed with phosphate buffer solution. Suspended TRPV3-
overexpressing HEK-293 cells were plated on these cover-
slips in supplemented DMEM:F12 and used within 24 h.
Throughout experiments, cells were perfused with external
saline containing 145 mmol/L NaCl, 5 mmol/L KCl,
3 mmol/L MgCl2, 10 mmol/L HEPES, 10 mmol/L glucose,
and 2 mmol/L CaCl2 (pH 7.4, 320 mOsm). Drofenine was
bath applied via perfusion (250 and 500 lmol/L) or injec-
tion (1 mmol/L). The internal pipette solution consisted
of 133 mmol/L CsCl, 10 mmol/L HEPES, 5 mmol/L ethy-
lene glycol-bis(2-aminoethylether)-N,N,N0,N0-tetraacetic
acid (EGTA), 1 mmol/L CaCl2, and 1 mmol/L MgCl2 (pH
of 7.3 set with CsOH) (Bae et al. 2011). Pipette and mem-
brane capacitances were automatically compensated and
current recordings were Bessel-filtered at 10 kHz using an
EPC-10 amplifier (Patchmaster; HEKA Instruments Inc.,
Bellmore, NY). Cells were voltage clamped at !60 or
!70 mV to measure inward currents. The holding poten-
tial was adjusted to approximately normalize the baseline
current from cell to cell. For each drofenine concentration,
we only used cells that were recorded at the same holding
potential. Fresh cells were used for each recording to pre-
vent variability due to sensitization or desensitization. Data
were collected at 1.0 kHz and analyzed with IGOR Pro 6
software (WaveMetrics Inc., Lake Oswego, OR). Every
100th data point was plotted in example traces (Fig. 3A).
Cell viability assay
HaCaT cells were subcultured in 96-well plates, grown until
the cells reached 80–90% confluence, and incubated with
increasing concentrations of 2-APB, drofenine, or carvacrol
for 24 h. Cytotoxicity was measured using the Cell Counting
Kit-8 assay (Cell Counting Kit CCK-8, Dojindo Laborato-
ries, Gaithersberg, MD) as per manufacturer’s instructions.
Results
The Microsource Spectrum Collection of compounds was
screened to identify modulators of TRPV3 activity, as rep-
resented graphically in Figure 1. Calcium influx (i.e.,
increased fluorescence upon compound addition; t = ~8–
17 sec) was used as an indicator of TRPV3 activation by
an agonist. Attenuated calcium influx (i.e., reduced fluo-
rescence change) upon addition of the known TRPV3
agonist carvacrol (300 lmol/L; t = ~17–30 sec) was indic-
ative of an antagonist. Initial screening identified 22 of
2320 as possible TRPV3 agonists, and 102 of 2320 as pos-
sible antagonists; 1873 had insignificant effects on TRPV3
function. Upon further analysis of the potential agonists
and antagonists, selected based on the magnitude of the
effect and compound availability, all were either known
agonists (e.g., 2-APB), false-positives (e.g., autofluorescent
such as fluorescein), not reproducible, or nonspecific for
TRPV3; activating or inhibiting other TRP channels
(Tables 1 and 2), and/or causing an equivalent degree of
calcium flux response in native HEK-293 cells (e.g., ace-
tylcholine). A brief summary of the confirmation studies
and selectivity data generated using other TRP channel
overexpressing HEK-293 cell lines and specific agonists
for each receptor, are summarized in Tables 1 and 2.
Drofenine, was selective for TRPV3 in that activation
of TRPA1, M8, V1, V2, and V4, which are known to be
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activated by the TRPV3 agonists 2-APB and/or carvacrol,
was not observed at concentrations up to 1 mmol/L
(Fig. 2A). A detectable change in TRPV3 activity was
observed at concentrations as low as ~30 lmol/L and
increased in a concentration-dependent manner. At con-
centrations greater than 500 lmol/L, calcium flux exhib-
ited some evidence of TRPV3 independence based on
small and comparable responses in both native HEK-293
cells and other TRP channel overexpressing cell lines. The
maximum change in cytosolic calcium (DF) for drofenine
(EC50 = 207 lmol/L) was comparable to the known
TRPV3 agonists 2-APB (EC50 = 78 lmol/L) and carvacrol
(EC50 = 438 lmol/L) (Fig. 2B). A TRPV3 antagonist was
synthesized and used to block calcium flux in TRPV3
overexpressing HEK-293 cells. Equal inhibition of calcium
flux was observed for all three agonists with an IC50 of
1–3 lmol/L.
Consistent with calcium influx across the plasma
membrane, drofenine dose-dependently induced inward
currents in TRPV3-overexpressing HEK-293 cells held at
Table 1. List of potential TRPV3 agonists identified by initial screening and re-evaluated as TRPV3 agonists.
Name CAS # Description/Use Comment(s)
Acetanilide 103-84-4 Analgesic, antipyretic acetaminophen
precursor; toxic
Inactive in confirmation assay
Acetylcholine 60-31-1, 51-84-3 Neurotransmitter Nonselective; HEK-293 response
Acriflavinium HCl 8018-07-3 Topical antiseptic, antifungal; irritant; antitumor Fluorescence interference




524-95-8 Broad-spectrum TRP channel modulator Nonselective for TRPV3; activates HEK-TRPV1
others
Bepradil HCl 74764-40-2 Nonselective voltage-gated calcium channel
blocker for angina
Inactive in confirmation assay
Calcein 1461-15-0 Fluorescent indicator Not evaluated
Carbachol 51-83-2 Cholinomimetic; acetylcholine receptor
agonist
Nonselective; HEK-293 response
Digitonin 11024-24-1 Detergent Not evaluated
Drofenine HCl 1679-76-1 Antispasmodic agent TRPV3-selective agonist
Fluorescein 2321-07-5 Fluorescent indicator Not evaluated
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Figure 1. Schematic representation of the screening protocol. HEK-293 cells overexpressing TRPV3 were plated in a 384-well plate and loaded
with Fluo-4 AM (cell plate). The compound library was prepared in 384-well plates (treatment plate) at a 39 (300 lmol/L) stock in calcium assay
buffer (19 HBSS, 20 mmol/L HEPES, pH 7.3). Using the NOVOstar plate reader, compounds from the treatment plate were transferred to the cell
plate and fluorescence was measured for 8 sec testing for agonist responses, followed by addition of carvacrol (250 lmol/L) to assess antagonist
responses. The graph to the right depicts fluorescence traces representative of an agonist (red), a potent antagonist (purple), a partial antagonist
(blue), and a buffer control (unmodified) response (green).
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negative membrane potentials (Fig. 3A–D). Drofenine
(250 lmol/L) tended to increase the frequency and ampli-
tude of stochastic and transient inward currents, whereas
500 lmol/L and 1 mmol/L drofenine induced higher
amplitude, more sustained responses with faster onset.
Drofenine-induced inward currents were similar to 2-
APB-evoked TRPV3 currents (Chung et al. 2004a). These
data demonstrate that drofenine gates plasmalemmal
cation influx.
The chemical structure of drofenine is similar to the
known nonspecific TRPV3 agonist 2-APB (Fig. 4A). The
contributions of the residues previously shown to deter-
mine 2-APB sensitivity were evaluated as determinants of
drofenine sensitivity by comparing calcium flux elicited
by carvacrol, 2-APB, and drofenine in HEK-293 cells
transiently transfected with wild-type human TRPV3
(TRPV3-WT), TRPV3-H426N, or TRPV3-R696K. The
TRPV3-H426N mutant exhibited reduced activation rela-
tive to TRPV3-WT using both drofenine and 2-APB at a
concentration of 100 lmol/L (Fig. 4B). Mutation of H426
had no effect on calcium flux induced by carvacrol
(100 lmol/L), as has been previously reported for the
structurally similar monoterpenoid agonist camphor (Hu
et al. 2009). At 200 lmol/L drofenine, the H426N muta-
tion did not reduce TRPV3 activation, indicating only a
shift in the binding of drofenine to TRPV3 or that drofenine
may potentially interact with TRPV3 similar to, but not
identically to 2-APB. The TRPV3-R696K mutant dis-
played diminished-to-no-function using all three agonists.
Of significance, based on structural similarity and screen-
ing results, the 2-APB and drofenine analogs dicyclomine
(Bentyl; anticholinergic, antispasmodic), was neither a TRPV3
agonist nor antagonist, while diphenhydramine was a
nonselective TRPV3 inhibitor.
Drofenine also induced calcium flux in HaCaT cells,
which are an immortalized human keratinocyte cell line
that expresses high levels of TRPV3 and other TRP chan-
nels. Drofenine was a more potent agonist of TRPV3 in
HaCaT cells than both 2-APB and carvacrol (Fig. 5A).
The EC50 for drofenine was 605 lmol/L, versus
>1000 lmol/L for carvacrol and 2-APB (Fig. 5A), and the
maximum change in fluorescence achieved by treatment
with drofenine was ~80% that of ionomycin. Fluorescence
images of HaCaT cells 1 min after treatment with
100 lmol/L carvacrol, 100 lmol/L 2-APB, or drofenine
(50 and 100 lmol/L) show the differences in potency for
the three TRPV3 agonists in HaCaT cells (Fig. 5B). Icilin,
a potent TRPM8 agonist, also inhibits TRPV3 at low
micromolar concentrations (Sherkheli et al. 2012). Icilin
ameliorated drofenine-induced calcium flux with an IC50
of 3.3 lmol/L (Fig. 5C). The synthesized TRPV3 antago-
nist could not be used in the HaCaT cells due to apparent
off target effects characterized by increases in calcium flux
at low (<300 nmol/L) and high (>1 lmol/L) concentra-
Table 2. List of potential TRPV3 antagonists identified by initial screening and re-evaluated as TRPV3 antagonists.
Name CAS # Description/Use Comment(s)
Erythromycin 114-07-8 Macrolide antibiotic Not inhibitory on rescreen
Tetracaine HCl 136-47-0, 94-24-6 Anesthetic; antipruritic; ryanodine
receptor antagonist; Ca++-induced
Ca++ release/SOCE inhibitor
Structural similarity with dyclonine, pramoxine,
tamoxifen, and mifepristone; inhibited
TRPA1>V3=V1; apparent TRPV1 agonist <25 lmol/L
Etoposide 33419-42-0 Antineoplastic Cytotoxic, false positive
Diphenhydramine HCl 147-24-0 Antihistaminic Inhibitory at high concentrations.
TRPV1>TRPV3>TRPA1.
Clomipramine HCl 17321-77-6, 303-49-1 Tricyclic antidepressant; nonselective
neurotransmitter reuptake inhibitor
Inhibitory in rescreen; nonselective SOCE inhibitor.
Inhibited TRPV1, V4, M8>V3
Spectinomycin HCl 22189-32-8, 21736-83-4 Aminocyclitol antibiotic Not inhibitory on rescreen
Sulfinpyrazone 57-96-5 Uricosuric diuretic Not inhibitory on rescreen
Chloramphenicol 56-75-7 Bacteriostatic antibiotic Not inhibitory on rescreen
Dyclonine HCl 536-43-6, 586-60-7 Topical anesthetic Not inhibitory on rescreen
Tamoxifen citrate 54965-24-1, 10540-29-1 Estrogen receptor antagonist Structural similarity with dyclonine, pramoxine,
tetracaine, and mifepristone; inhibited
TRPV3>V1>A1 at <50 lmol/L
Warfarin 81-81-2, 2610-86-8 Anticoagulant Nonselective; also inhibited TRPV1
Flufenamic acid 530-78-9 NSAID; voltage-gated Na+ channel
inhibitor
Nonselective; also inhibited TRPV1
Pramoxine HCl 637-58-1, 140-65-8 Topical anesthetic; antipruritic; Na+
channel blocker
Structural similarity with dyclonine, tetracaine,
tamoxifen, and mifepristone; inhibited TRPA1,
V3, and V1
Mifepristone (RU 486) 84371-65-3 Progesterone receptor antagonist;
abortifacient
Structural similarity with dyclonine, pramoxine, and
tamoxifen; inhibited TRPA1>V3>V1
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tions, and apparent inhibition at intermediate concentra-
tions, which was not observed in TRPV3-overexpressing
HEK-293 cells. Drofenine was the most cytotoxic of the
three TRPV3 agonists to HaCaT cells, with an LC50 of
~230 lmol/L versus >300 lmol/L for both 2-APB and
carvacrol (Fig. 5D). This result was consistent with the
relative potencies of these agents as TRPV3 agonists in
HaCaT cells, and implies a potential role for TRPV3 in
mediating the cytotoxic effects of TRPV3 agonists in these
cells.
Discussion
The roles TRPV3 plays in mammalian physiology are not
completely understood. This is due, in part, to the lack of
selective agonists and antagonists. In this study, we
sought to identify new compounds that may be used as
pharmacological tools for the study of TRPV3, as well as
molecules that may have potential for treating pathologies
in which TRPV3 may be involved. The Microsource Spec-
trum Collection, containing 2320 compounds including






































Drofenine EC50 = 207 mol/L























Carvacrol IC50 = 3 mol/L
Drofenine IC50 = 2 mol/L
2-APB IC50 = 1 mol/L
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Figure 2. Characteristics and specificity of TRPV3 activation by
drofenine. (A) Drofenine selectively increased calcium flux in HEK-293
cells overexpressing TRPV3, but not HEK-293 cells overexpressing
TRPA1, M8, V1, V2, or V4 at concentrations up to 1000 lmol/L. (B)
HEK-293 cells overexpressing TRPV3 were exposed to increasing
concentrations of drofenine, carvacrol, and 2-APB. Changes in
fluorescence were monitored. (C) TRPV3 overexpressing HEK-293
cells were preincubated with increasing concentrations of the TRPV3
antagonist for 30 min followed by treatment of drofenine
(200 lmol/L), carvacrol (300 lmol/L), or 2-APB (300 lmol/L),
inhibition of calcium flux was measured and an IC50 value was
calculated. Data were collected using a NOVOstar plate reader, blank
subtracted, and are expressed as the change in the maximal
fluorescence (DFmax) or the initial rate of change in cellular
fluorescence (DF/sec). Antagonist data were normalized to the
agonist response in the absence of antagonist. Data are the mean
and SEM (n ≥ 3) and asterisks indicate a statistical difference
between TRPV3 and the other TRP channels using two-way ANOVA
with Bonferroni multiple comparison posttest. *P < 0.05, **P < 0.01,

























































Figure 3. Drofenine induces inward currents in TRPV3-overexpressing
HEK-293 cells. (A) Example traces of whole-cell recordings at a
negative holding potential. 250 lmol/L, 500 lmol/L, and 1 mmol/L
drofenine increased the change in inward current (DI). (B–D) Dose-
dependent responses were characterized by comparisons between
basal current and the peak response. (B) n = 6, P = 0.197. (C) n = 5,
P = 0.00151. (D) n = 8, P = 0.00574. Data are represented as
mean ! SEM and asterisks indicate a significant difference between
the baseline current and the peak response detected using a one-
tailed, paired t-test.
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Of the 2320 compounds tested, none of them selec-
tively inhibit TRPV3. Tables 1 and 2 list some of the
compounds identified as potential agonists or antagonists.
Potential antagonists (Table 2) included antineoplastic
agents (etoposide and tamoxifen), analgesics/anesthetics
(acetanilide, flufenamic acid, pramoxine, and tetracaine),
an antihistamine (diphenhydramine), a progesterone
antagonist (mifepristone), an antiarrhythmic (procain-
amide), an antibiotic (spectinomycin), a uricosuric diure-
tic (sulfinpyrazone), and an anticoagulant (warfarin).
Several of these compounds appeared to have structural
commonality, yielding potential insights into the struc-
tural requirements for TRPV3 antagonists. Unfortunately,
none of these agents were selective for TRPV3, and based
on structural similarities may act by inhibiting store-oper-
ated calcium release as reported for structurally related
2-APB (Bootman et al. 2002). Regardless, the inhibition
of multiple TRP channels by these agents may illuminate
new, or further explain the known pharmacological effects
for these molecules. For example, recent studies have
identified substance P, resulting from TRPA1 activation
in peripheral C-fibers, as a mediator of pruritus (Liu
et al. 2013). Therefore, inhibition of TRPV3 in conjunc-
tion with other TRP channels such as TRPV1 and TRPA1
by diphenhydramine, tetracaine, or other molecules found
to inhibit multiple TRP channels, in addition to inhibi-
tion histamine H1 receptors or other receptor targets,
may have complimentary effects in treating itch. This
concept is supported by finding that the antitussive prop-
erties of dexbrompheniramine and chlorpheniramine are
attributable to both inhibition of histamine H1 receptors
and TRPV1 (Sadofsky et al. 2008).
Multiple potential TRPV3 agonists were also identified
and evaluated (Table 1). These included 2-APB (previ-
ously known) and drofenine. Here, drofenine was shown
to activate TRPV3 (Figs. 2 and 3), but not other TRP
channels that are known to have overlap in agonist pref-
erence with TRPV3 (Fig. 2A). For example, 2-APB was
also identified in our screen, but 2-APB I known to be
nonselective for TRPV3, based on numerous reports doc-
umenting the activation of other TRP channels including
TRPA1, M6, V1, and V2, and inhibiting TRPC4, C5, C6,
M2, and M8 (Clapham 2007).
Amino acid residues comprising a binding site for drof-
enine on TRPV3 were similar to 2-APB; H426 and R696
(Hu et al. 2009). However, these sites do not appear to
solely explain the activation mechanism for TRPV3 since
inhibition of TRPV3 was not achieved with the H426N
mutant when higher concentrations of drofenine were
used, similar to carvacrol (Fig. 4B). The differences in the
relative potency of the three agonists between TRPV3
overexpressing HEK-293 and HaCaT cells may be due to
differences in cell permeability and activation of different
subcellular pools of TRPV3. Thus, additional studies are
required to more fully elucidate the molecular basis for
TRPV3 activation by drofenine.
In the human keratinocyte (HaCaT) cell line, drofenine
also induced calcium flux (Fig. 5A–C) and caused cyto-
toxicity (Fig. 5D), exhibiting greater potency in both
measures than the known TRPV3 agonists 2-APB and
carvacrol. These results suggested a role for TRPV3 acti-
vation in cell death as has been suggested by others
(Yamada et al. 2010). Pretreatment of HaCaT cells with
icilin completely inhibited TRPV3-induced calcium flux
(Fig. 5C) (Sherkheli et al. 2012), but icilin was also
potently cytotoxic to HaCaT cells (data not shown)
preventing the use of icilin to definitively link drofenine-
induced calcium flux with cell death. The TRPV3 antago-
nist was also evaluated, but was not informative in this
cell line due to apparent off target effects. This empha-
sizes the continued need for new TRPV3 antagonists for
elucidating precisely what roles TRPV3 plays in biological
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Figure 4. Mechanism of TRPV3 activation by drofenine. (A) Chemical
structures of drofenine and 2-APB. (B) Mutation of the 2-APB
“binding site” residue H426 blocks drofenine induced calcium flux at
low concentrations. HEK-293 cells were transiently transfected with
TRPV3-WT, TRPV3-H426N, and TRPV3-R696K and calcium flux was
measured via fluorescence microscopy using 100 lmol/L carvacrol,
100 lmol/L 2-APB, and 100 and 200 lmol/L drofenine. Data are
blank subtracted and expressed as the percentage of maximum
cellular fluorescence elicited by ionomycin (10 lmol/L) and normalized
to TRPV3-WT transfected cells. Data are the mean and SEM (n ≥ 3)
and asterisks indicate a statistical difference between TRPV3-WT and
TRPV3-H426N or R696K using two-way ANOVA with Bonferroni
multiple comparison posttest. *P < 0.05, **P < 0.01, ***P < 0.001.
ANOVA, analysis of variance.
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Drofenine, product name Spasmo-Cibalgin (Novartis,
Oman), is an antispasmodic/anticholinergic agent used
for relaxing smooth muscle, treating dysmenorrhea, and
relieving pain in the gastrointestinal tract, biliary passages,
and urogenital tract. Information regarding the clinical
utility of drofenine is limited, but obscure sources suggest
use for treatment of visceral spasm and urinary retention.
Our results may suggest that TRPV3 could be involved in
regulating these phenomena, if the concentration is high
enough at the site of action, thus potentially providing
new insights into mechanisms by which these events tran-
spire. Additionally, drofenine has also been identified as
an inhibitor of neomycin-induced hair cell loss in a
zebrafish model of ototoxicity (Coffin et al. 2010). Simi-
larly, several of the nonselective TRPV3 inhibitors listed
in Table 2 were also identified as ototoxins (Coffin et al.
2010). Although not investigated, the results presented
herein could indicate a critical role for TRPV3 in hair cell
physiology and ototoxicity, as has been suggested for
TRPA1, V1, and V4 (Mukherjea et al. 2008; Stepanyan
et al. 2011; Lee et al. 2013).
In summary, drofenine has been characterized as a
TRPV3 agonist with improved selectivity for TRPV3 rela-
tive to other TRP channels. The ability to target individ-
ual TRP channels is important not only for identifying
key mediators of physiological and pathological processes
but also in identifying the correct TRP channels for
potential pharmacological interventions. Our results dem-
onstrate that drofenine may be a new and valuable
TRPV3 agonist for further unraveling some of the myste-
rious and occasionally paradoxical properties that have
been attributed to TRPV3 thus far.
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Figure 5. Activation of TRPV3 in keratinocytes by drofenine, 2-APB, and carvacrol. (A) HaCaT cells were exposed to increasing concentrations of
2-APB, drofenine, or carvacrol. The EC50 for drofenine was 605 lmol/L. Data were collected using a NOVOstar plate reader, blank subtracted,
and expressed as the fold change in maximum cellular fluorescence (DFmax) compared to untreated controls. Data are the mean and SEM (n ≥ 3)
and asterisks indicate a statistical difference between drofenine and either 2-APB or carvacrol using two-way ANOVA with Bonferroni multiple
comparison posttest. **P < 0.01, ***P < 0.001. (B) Visual representation of the calcium flux observed in HaCaT cells treated with carvacrol
(100 lmol/L), 2-APB (100 lmol/L), and drofenine (50 or 100 lmol/L). Green represents fluorescent cells where calcium flux was observed. (C)
Specificity of TRPV3 activation in HaCaT cells was assessed by inhibition of calcium flux using icilin, a TRPV3 antagonist. HaCaT cells were
pretreated with increasing concentrations of icilin for 30 min followed by treatment using 600 lmol/L drofenine. Calcium flux was measured as
described above and the IC50 was calculated (IC50 = 3.3 lmol/L). (D) Viability of HaCaT cells treated with increasing concentrations of 2-APB,
drofenine, and carvacrol for 24 h. Data were quantified with the absorbance ratio (k = 450/630). The results were adjusted by subtracting the
blank value, and reported as percent of untreated control. ANOVA, analysis of variance.
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